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Abstract 
Hot flushes are the most commonly reported symptom in postmenopausal 
women, occurring in approximately 73% of women and causing significant 
morbidity in 25%, affecting social life and even the ability to work.  With 
improved healthcare and increased life expectancy (death rates decreased by 
19% in the last 10 years), women spend a considerable proportion of their lives 
(30 years on average) in the menopause.  At present 36% of the women in the UK 
are over 50 years of age.  If left untreated, hot flushes resolve within one year, 
or less, in the majority of postmenopausal women.   A third will report 
symptoms that last up to 5 years after natural menopause, and in 20% hot 
flushes persist for up to 15 years.  This equates to as many as 1.5 million women 
in the UK.  Despite this the mechanism of flushing is still poorly understood. 
A hot flush resembles a heat dissipation response, in that both are characterised 
by sweating and peripheral vasodilation.  It follows that the underlying 
mechanism may involve some dysfunction in thermoregulation, which in humans 
is controlled by the medial preoptic area of the hypothalamus (MPOA), and 
effectors include cutaneous vessels for vasodilation and vasoconstriction. 
Therefore a dysfunction in thermoregulation may lie within the control centre 
(MPOA), its messengers (adrenergic neurones controlling vasoconstriction and 
cholinergic neurones controlling vasodilation) or the effectors (cutaneous 
vessels). 
Studies by Freedman et al, using an ultrasensitive temperature probe, suggest 
that hot flushes are triggered by small elevations in core body temperature (Tc) 
acting within a narrowed thermoneutral zone, mainly due to a lowering of the 
sweating threshold, in symptomatic postmenopausal women.  
However, the trigger remains unknown. 
Oestrogen is likely involved as these changes occur at times of relative oestrogen 
withdrawal; however, there is little correlation between hot flushes and 
circulating oestrogen levels.  This suggests that other mechanisms are involved. 
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Noradrenaline is thought to be the primary neurotransmitter responsible for 
lowering the thermoregulatory set point and triggering hot flushes.  Animal 
studies have shown that intrahypothalamic injection of noradrenaline acts to 
narrow the thermoregulatory zone and hot flushes can be provoked in 
symptomatic postmenopausal women with the α2-adrenergic antagonist 
yohimbine, and ameliorated with clonidine, an α-adrenergic agonist.  
Furthermore, clonidine has been shown to widen the thermoregulatory zone in 
humans. 
Serotonin or 5-hydroxytriptamine (5-HT) is involved in many bodily functions 
including mood, anxiety, sleep, sexual behaviour and eating, and is thought to 
play a key role in thermoregulation.  Oestrogen withdrawal is associated with 
decreased blood serotonin levels, which is returned to normal with oestrogen 
therapy.  Furthermore, selective serotonin reuptake inhibitors (SSRI), designed 
to increase the available serotonin at the serotonergic synapse, have been shown 
in placebo-controlled trials to be effective in reducing the number and severity 
of hot flushes. 
It has also been shown that flushing women have a diminished vasoconstrictor 
response to cold and that they have increased blood flow to the forearm and 
hand during a flushing episode.  Alterations in skin blood flow during a flushing 
attack have also been demonstrated in castrate men, and, as with women, 
improvements in symptoms are seen with hormone replacement.   
The aim of this thesis was to better understand the mechanism of flushing in 
postmenopausal women and hypogonadal men by assessing the role of cutaneous 
vessels. 
I measured cutaneous microvascular perfusion, using LASER Doppler imaging with 
iontophoresis, in postmenopausal women who flush and compared it with 
postmenopausal women with no flushing, and found that perfusion responses to 
vasoactive agents were increased in women with flushing.  Paradoxically, these 
women with apparently ‘better’ endothelial function had evidence of serum 
cardiovascular risk factors.  
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In a double-blind longitudinal cross over study, the role of the alpha-adrenergic 
system in the pathophysiology of flushing was investigated, by treating women 
with clonidine and placebo.  There was an increase in perfusion responses with 
both clonidine and placebo.  Clonidine was not shown to be superior to placebo 
in reducing the number and severity of flushes. 
The role of serotonin, both peripherally and centrally was studied by treating 
postmenopausal women, who experienced severe flushing, with venlafaxine (a 
serotonin and noradrenaline reuptake inhibitor that acts as a selective serotonin 
reuptake inhibitor at low doses).  Flushing symptoms, as assessed by hot flush 
diaries and Greene climacteric scale (GCS) scores, were reduced, as were skin 
blood flow perfusion responses.  Central serotonin transporters (SERT) were 
assessed in vivo using SPECT (single photon computed tomography) imaging and 
a radioligand, [123I] -beta-carbomethoxy-3-β-(4 iodophenyl)tropane ([123I] beta-
CIT), with a high affinity for serotonin transporters.  [123I] beta-CIT binding was 
significantly reduced, and this was associated with a significant reduction in BDI 
scores; in a group of non-depressed women. 
Adiposity is associated, both, with an increased risk of postmenopausal flushing 
and impaired endothelial function, but in this study, there were no differences 
demonstrated between obese and lean participants at baseline, despite 
significant differences in serum markers of endothelial dysfunction. 
Oestrogen receptors are also present on endothelial cells and as the most 
commonly used, and most effective, treatment for vasomotor symptoms, 
cutaneous microvascular perfusion was assessed following 8 weeks of HRT, and 
demonstrated an increase in both endothelium dependent and independent 
vasodilation.   
Hot flushes are also common in men on luteinising hormone releasing hormone 
(LHRH) agonists for prostate cancer therapy.  Perfusion responses in these men 
were assessed prior to commencement of therapy (baseline), and after 8 and 
then 24 weeks of therapy.  No differences were detected at baseline, between 
those who developed flushing as a result of treatment, and those who did not.  
At 8 weeks, those with flushing demonstrated increased skin blood flow 
compared to those without flushing.  At 24 weeks, 2 gentlemen with flushing had 
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kept diaries and these demonstrated an improvement in flushing, but no 
alteration in perfusion responses. 
ACh- and SNP-stimulated vasodilation was, however, reduced when compared to 
healthy controls.  
In this thesis, the data appear to support a role of skin blood flow in the 
mechanism of hot flushing in both postmenopausal women and hypogonadal 
men, which may be controlled or altered via neurotransmitters at a local level.  
The placebo response was significant, but alterations in skin blood flow do not 
appear to have mediated the adiposity effect. 
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Introduction 
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History 
The Greek philosopher Aristotle (384-322 BC) noted that women stop giving birth 
after the age of 50 and he believed that the apparent abundance of menstrual 
blood compared with seminal fluid underpinned the ascendency of the male in 
almost every species.  Life, he thought, is dependent on heat and moisture and 
over a lifespan an animal can use up its innate heat, becoming colder and drier 
and nearer to death.   
To Hippocrates (460-370 BC), the cessation of bleeding meant the reassimilation 
of the unruly female body with the male, knowable and supposedly more orderly 
body. 
In sixth century Byzantium, Aëtius Ameidenus, a physician, stated “the menses 
do not cease before the thirty fifth year nor appear after the fiftieth; rarely 
some menstruate until the sixtieth year.  Those who are very fat cease early”.  
But there was still no term for it and it was discussed rarely before the 
seventeenth century.  
In 1816, ‘la menespausie’ was described by a French physician, C.P.L. de 
Gardanne.  Meno derived from the Greek word for month, and pause from the 
Greek word pauses or halt, literally meaning halting of monthly cycles. 
But, it was not until the late nineteenth century, alongside the introduction of 
anaesthesia, antisepsis and germ-theory, that there was research into the 
secretions of endocrine glands.  In 1538, Vesalius, an anatomist, described the 
ovaries as female testicles, however, Stensen pointed out that as they contained 
ova, that they should be called ovaries.  However, it would be another 200 years 
before surgeons noted cessation of menstruation following removal of the 
ovaries, leading to a conclusion that menstruation was due to a ‘peculiar 
condition of the ovaries’. 
Reference to symptoms that we would now commonly associate with the 
climacteric are difficult to find.  In 1628, Robert Burton’s The Anatomy of 
Melancholy refers to hot flushes and other symptoms and a cooling diet was 
recommended as therapy in 1675.  Thomas Sydenham notes the tendency of 
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women aged 45-50 to develop ‘hysteric fits’ and suggests bloodletting as a 
treatment in 1701 and in 1899, in an article entitled ‘Epochal Insanities’, under 
the heading ‘Climacteric Insanity’, physicians were invited to treat the 
menopause as a syndrome in need of attention (1). 
In this same year, the Merck Manual featured several treatments, including a 
course brownish powder available in pills flavoured with vanilla or in a tablet 
form, called Ovarin, which was derived from dried and pulverised cow ovaries.  
Other routes of administration and formulations were available, including self-
injections of an extract of testicles of dogs and guinea pigs reported by Charles 
Edouard Brown-Sequard (2). 
Interestingly, whilst these treatments sound unpalatable, they are arguably 
more acceptable than those suggested by William Tyler Smith some 50 years 
earlier.  He advocated a course of injections of ice water into the rectum, the 
introduction of ice into the vagina, and the application of leeches to the labia 
and cervix for a disorder that he describes as; 
“attended by vivid sensations of heat, flushing of the face and neck, 
with giddiness, almost amounting to insensibility…followed by 
relaxation of the neck, great coldness or chills, and faintness, with 
perspiration over the whole of the body.  The paroxysms are so violent 
as to wake patients out of their sleep.  …these paroxysms can occur 
many times in twenty-four hours”.     
In the early twentieth century Edward Sharpey-Schafer (1850 – 1935) laid down 
the physiological foundations of endocrinology and F.H.A. Marshall (1878 – 1949) 
and William Jolly (1873 – 1945) made detailed investigations of ovarian 
endocrinology.  The secretions now known as hormones were named on the 
suggestion of a Cambridge classicist, from the Greek ‘I excite’, and the term was 
first used in Britain in 1905 by Ernest H. Starling, Professor of Physiology and 
University College London. 
After 1910 the existence of sex hormones was no longer being questioned and 
the Association for the Study of Internal Secretions was founded in June 1917, 
becoming the Endocrine Society in 1952.  Edward Doisy, a biochemist and Edgar 
Allen, a zoologist, had devised the criteria which established it as an acceptable 
field of scientific study by 1936.  Ovarian hormones were now being isolated and 
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synthesised; oestrin in 1923, progesterone in 1929, oestriol in 1930, oestrone in 
1930 and oestradiol in 1936. 
Bernhard Zondek (1891 – 1966) found small quantities of oestrone in the urine of 
human males and discovered that the urine of pregnant mares was another rich 
source leading to commercialisation.  The manufacture of the first synthetic 
oestrogen stilboestrol (DES, diethylstilboestrol) in 1938 at the University of 
Oxford was quickly followed by another, dienoestrol.   
From 1940 to 1970, DES was given to pregnant women in the mistaken belief it 
would reduce the risk of pregnancy complications and losses, but in 1971, it was 
shown to cause a rare vaginal cancer in girls and women who had been exposed 
to this drug in utero and use in this group was stopped.  Approval for use in the 
treatment of menopausal symptoms was granted by the FDA in 1941. 
By 1947, there were 53 formulations sold by 23 companies for the treatment of 
menopausal disorders (2) and the use of oestrogens increased dramatically until 
reports in 1975 of increased endometrial carcinoma caused a decline in its use.  
The addition of a progestagen, in those with a uterus, saw an increase in use 
again through the 1980s to 1990s, until the publication of the Women’s Health 
Initiative (WHI) trial in 2002 and the Million Women Study (MWS) in 2003.  
Over the last 11 years, there has been extensive research and reanalysis, and we 
are beginning to understand a little more about the treatments for symptoms of 
the menopause, however there is still a way to go.  Our knowledge of the 
underlying mechanisms of the symptoms that women experience during this time 
is limited; and this is the foundation of directed, appropriate and safe 
treatments. 
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Reproductive Physiology and Endocrinology 
The main functional unit of the ovary is the ovarian follicle.  At birth, all 
follicles are composed of a germ cell (oocyte) surrounded by a single layer of 
granulosa cells.  This is known as a primordial follicle.  The number of these are 
maximal at the time of birth, approximately one to two million, and decrease 
with age (see figure 1) (3). 
 
Figure 1: Decreasing numbers of primordial follicles with age 
Richardson SJ, Senikas V, Nelson JF.  Follicular depletion during the menopausal 
transition: evidence for accelerated loss and ultimate exhaustion.  J Clin Endocrinol Metab 
1987; 65: 1231-7 (3). 
 
Primordial follicles are housed in the cortex of the ovary and are surrounded by 
stroma called tunica albuginea (see Figure 2, P26).  Prior to puberty a number of 
these primordial follicles will undergo atresia, so that at the time of first 
ovulation, there may be as few as 400 000 remaining. 
At the time of puberty, under the influence of increasing levels of hypothalamic 
gonadotrophin releasing hormone (GnRH), the normal pituitary releases pulses of 
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luteinising hormone (LH) and follicle stimulating hormone (FSH) with increasing 
amplitude and frequency (Figure 3).   
Primordial follicles are recruited into a process termed folliculogenesis, during 
which follicle growth occurs.  Granulosa cells increase in number, an antrum 
develops within the follicle (adjacent to the oocyte) and cells of the stroma 
(theca cells) surround the follicle.  A mature follicle is termed a Graafian follicle 
(see Figure 2 and 4).   
Granulosa cells are responsible for production of oestrogens through 
aromatisation of androgens produced in theca cells (follicular phase) (see Figure 
4).  At a critical level of oestradiol, there is initiation of the positive feedback 
on LH, leading to the mid-cycle LH-surge and the first ovulation. 
Luteinisation of the granulosa cells of this dominant (Graafian) follicle occurs, 
forming the corpus luteum (luteal phase), which generates high volumes of 
progesterone and oestradiol. 
Granulosa cells also produce inhibin A and B.  Inhibin A is produced by the 
granulosa cells of the dominant follicle and levels are high during both the 
follicular and luteal phase.  Inhibin B is produced by granulosa cells of the 
follicles in the recruited cohort and levels are highest in the follicular phase but 
decrease following the LH surge.   
Ovarian steroids inhibit LH and FSH through a negative feedback mechanism (see 
figure 3), except midcycle when positive feedback leads to the gonadotrophin 
surge.  The inhibins (particularly Inhibin B) also inhibit FSH.   
During the ovarian cycle, there are also changes to the endometrium, designed 
to support pregnancy should fertilisation occur.  During the follicular phase (see 
Figure 5), there is proliferation of the stroma and glands.  By day 12 the glands 
are large and dilated and blood vessels are also more prominent. 
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Figure 2: Histology of an ovary 
ta; tunica albuginea.  gf; Graafian follicle.  tf; follicle.  pf; primordial follicle.  se; surface 
epithelium.  sf; secondary follicle 
 
 
Figure 3: Hypothalamic Pituitary Ovarian Axis 
 
  34 
 
Figure 4: Graafian follicle 
 
 
 
Figure 5: Human menstrual cycle 
Developmental Biology, Chapter 17; Hormones and mammalian egg maturation (4) 
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Following ovulation and during the luteal phase (see Figure 5), the large 
quantities of progesterone induce secretory changes in the glands and swelling 
of the stromal cells.  There is now a rich blood supply and the capillaries 
become sinusoidal. 
In the event that fertilisation does not occur, there is breakdown of the corpus 
luteum with a resultant fall in oestradiol and progesterone, leading to break 
down and shedding of the endometrium. 
Reproductive Ageing  
The average age of menopause in the UK is 51.15 years (5), however the change 
in gonadotrophins and sex steroids actually starts in the late 30s as the rate of 
decrease in the ovarian follicle numbers escalates.   
Levels of serum FSH begin to increase in women still having regular cycles.  
Figure 1 shows a rapid decrease in the number of primordial follicles after the 
age of 40 years.  Fewer follicles result in decreased secretion of inhibin B, with a 
subsequent increase in FSH that can maintain oestradiol until follicle depletion 
(6). 
In women whose menses occur at intervals of more than 3 months, FSH levels 
are increased and there is a substantial decrease in circulating levels of 
oestradiol and the inhibins (6).  However, repetitive sampling in an individual 
woman may show various patterns, with high or low FSH, oestradiol and inhibin 
(7). 
Anti-Müllerian Hormone (AMH), secreted by granulosa cells, however, is unique 
amongst female sex hormones in that it is stable within and across menstrual 
cycles (8).  Concentrations decline with increasing reproductive age (9) and it 
correlates with ovarian primordial follicle number (10); it is therefore used as a 
determinant of ovarian (follicular) reserve, particularly in assisted conception 
settings.  
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The Menopause 
Definition 
Menopause is an inevitable event for women in the process of normal ageing.  
Ageing can be defined as the natural progression of changes in structure and 
function that occur with the passage of time in the absence of known disease.  
The 2001 Stages of Reproductive Ageing Workshop (STRAW) Working group 
describes the female reproductive axis to be composed of the hypothalamic-
pituitary axis and the Mullerian-derived structures.  Menopause (non-functioning 
reproductive axis) occurs at a time when a woman is otherwise healthy as a 
result of oocyte depletion in the ovary (11).      
Menopause has been defined by the World Health Organisation and STRAW 
Working Groups as the permanent cessation of menstrual periods that occurs 
naturally or is induced by surgery, chemotherapy or radiation (12).   
Natural menopause is a retrospective diagnosis that can only be made after 12 
months of amenorrhoea, that is not associated with some other physiological 
(e.g. lactation) or pathological cause and occurs on average between the ages of 
50 and 51 (13).   
The STRAW working group viewed reproductive ageing as a process, not an 
event, with the end (menopause) easily identifiable, but the beginning not so, 
and that is the purpose of the staging system.  A number of terms including 
‘climacteric’, ‘perimenopause’, ‘menopausal transition’, ‘postmenopause’ and 
‘menopause’ have been used to refer to the stages of reproductive ageing 
surrounding the final menstrual period (14). 
The World Health Organisation (WHO)  recommended the use of 
‘perimenopause’ and ‘menopausal transition’ in place of ‘climacteric’ in 1996 
and a model was developed in 2001 to describe the stages of the menopausal 
transition (see figure 6) (11).  This model identifies seven stages of reproductive 
life and is primarily based on the characteristics of the menstrual cycle and 
secondarily on follicular phase Follicle Stimulating Hormone (FSH) levels.  As 
women progress through the menopausal transition, the menstrual cycle length 
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becomes irregular and FSH levels are raised in response to decreased ovarian 
hormone concentrations.  Menstrual cycles are then missed and ultimately stop, 
as does ovulation.  
 
Figure 6: Proposed staging and revision of nomenclature 
Reproduced from the Executive Summary, Stages of Reproductive Ageing Workshop 
(STRAW), Soules MR et al, J Womens Health Gend Based Med. 2001 Nov;10(9):843-8 (11). 
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In 2007, ReSTAGE collaborators proposed modifications of this STRAW staging 
system, which included simplifying the definition of the bleeding criterion for 
late transition to amenorrhoea of at least 60 days, inclusion of the FSH criteria 
of a serum FSH value ≥ 40IU/l to facilitate prediction of proximity to the final 
menstrual period (FMP), and adoption of the persistent 7-or-more-day difference 
in cycle length as the bleeding criterion for onset of early transition (see figure 
7) (15). 
 
Figure 7: ReStage proposed modifications of STRAW staging system 
Reproduced from Recommendations from a multi-study evaluation of proposed criteria for 
Staging Reproductive Aging.  Harlow SD, Crawford S, Dennerstein L, Burger HG, Mitchell 
ES, Sowers M-F for the ReSTAGE Collaboration.  Climacteric 2007, 10 (2): 112–119 (15). 
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And in 2011, STRAW+10 provided a more comprehensive basis for assessing 
reproductive aging in both the research and clinical context.  It simplified 
bleeding criteria for the early and late menopausal transition, recommended 
modifications to criteria for the late reproductive and early postmenopause 
stage, provided information on the duration of the late transition and early 
postmenopause, and recommended the application regardless of women’s age, 
ethnicity, body size, or lifestyle characteristics (see Figure 8) (16).   
 
Figure 8: STRAW + 10 
Reproduced from Executive summary of the Stages of Reproductive Aging Workshop + 10: 
addressing the unfinished agenda of staging reproductive aging.  Harlow SD, Gass M, Hall 
JE, Lobo R, et al for the STRAW + 10 Collaborative Group.  Climacteric 2012; 15:105–114 
(16). 
  40 
Epidemiology 
Studies estimating age at natural menopause are mostly based on samples of 
Caucasian women in Western societies (17-19), however, there is one 
international study of 18,997 women from 11 countries which found that the 
median age at natural menopause was 50 years (range, 49-52 years) (20).  There 
are reports of younger ages at menopause in non-Caucasian women; Africans 
(21, 22), African Americans (23, 24), and Hispanics (25, 26) of Mexican descent 
may have an earlier age at menopause than Caucasian women, while Japanese 
(27, 28) and Malaysian (29-31) women report a median age at menopause similar 
to that for women of European descent (13). 
It is widely known that for smokers, menopause occurs 1-2 years earlier than for 
non-smokers (32).  It has also been found that an earlier natural menopause is 
associated with less education, low social class, nulliparity or having fewer 
children, never having used oral contraceptives, and low relative weight (17, 
33).  Most of these factors may affect the hypothalamic-pituitary-gonadal axis 
and its regulation of gonadotropins and sex steroid hormones. 
Smoking is associated with elevated FSH levels (34), however a study 
investigating the relationship between smoking and changes in AMH, found no 
statistically significant association (35), however smoking may be associated 
with a greater rate of follicular decline (36).  Both animal (37) and human (38) 
studies have demonstrated that polycyclic aromatic hydrocarbons in cigarette 
smoke are toxic to ovarian follicles, and there may also be alterations in sex 
steroids, including lower concentrations of oestrone, oestradiol and oestriol 
(39). 
Data from a large multicenter study (SWAN, Study of Women’s Health Across the 
Nation) of a multiracial/multiethnic sample of 14,620 women (40) was analysed 
to examine the independent association of a number of factors with age at 
natural menopause.  The results demonstrated that current smoking, lower 
educational attainment and nonemployment were related to earlier age at 
natural menopause and that prior use of oral contraceptives and parity were 
associated with later age at menopause.  However, the results demonstrated 
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that Japanese women have a later menopause than Caucasian, African-
American, Hispanic and Chinese (13).  
A further large study of 95,704 ethnically/racially diverse women found that 
Japanese-American race/ethnicity was independently associated with relatively 
late natural menopause and Latinas were found to experience relatively early 
natural menopause, with those born in the United States experiencing the event 
later than those born outside the United States (41).  The results were also 
consistent with previously published results regarding smoking, low body mass, 
age at menarche and parity.  
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Menopausal Transition  
There are a number of symptoms associated with perimenopause and decreasing 
oestrogen levels, although some women will experience none of these.  They 
include hot flushes and night sweats (vasomotor symptoms), vaginal symptoms, 
depression, anxiety, irritability and mood swings (psychological effects), joint 
pains, migraines or headaches, sleeping problems and urinary incontinence.   
With improved healthcare and increased life expectancy (death rates decreased 
by 19% in the last 10 years), women spend a considerable proportion of their 
lives (30 years on average) after the menopause (42).  At present 36% of the 
women in the UK are over 50 years of age (42).  It is estimated that 
approximately 75% of women will experience some symptoms related to 
oestrogen deficiency during the menopausal transition, and 40% will seek 
medical advice for the management of menopausal symptoms. 
Hot Flushes 
The terms hot flush (U.K.), hot flash (U.S.), and vasomotor symptom are 
commonly used synonymously.  Hot flushes are characterised by a feeling of 
intense warmth, often accompanied by profuse sweating, anxiety, skin 
reddening and palpitations, and sometimes followed by chills. 
Hot flushes are the most common, occurring in approximately 73% of women (43) 
causing significant morbidity in 25%, affecting social life and even the ability to 
work (44).  They are the most common indication for the prescription of 
hormone replacement therapy (HRT) since it is effective in over 80% of cases.  In 
1995, 37% of American women took HRT, principally for this purpose.   
Flushing commonly occurs when hypooestrogenism follows a period of oestrogen 
exposure.  If left untreated, hot flushes resolve within one year, or less, in the 
majority of postmenopausal women (45).  A third will report symptoms that last 
up to 5 years after natural menopause, and in 20% hot flushes persist for up to 
15 years(45) or longer.  Menopause induced by surgery is associated with about a 
90% probability of hot flushes during the first year (46) and symptoms associated 
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with surgical menopause are often more abrupt and severe and can last longer 
than those associated with a non-surgical menopause (47). 
Hot flushes can occur in both men and women after acute gonadal steroid 
withdrawal, such as ovariectomy in young women or orchidectomy in men; in 
men or women who are hypogonadal; or in those who take gonadotrophin-
releasing hormone (GnRH) agonists, antagonists or other anti-gonadal agents 
which cause oestrogen (in women) or testosterone (in men) levels to fall (48). 
Physiology of a hot flush 
Skin temperature changes during a hot flush are minimal over most of the body, 
with large temperature changes recorded only in the digits (temperature 
increase from around 28°C to 33°C) (49).  Although the greatest temperature 
changes have been found in the fingers and toes, the symptom of flushing is 
usually experienced mainly in the face, neck and upper trunk, and it seems that 
the subjective sensation of heat is out of proportion to the actual temperature 
increase, which in these areas may be only about 1°C.  Furthermore, the 
temperature increase often persists for several minutes after the sensation of 
warmth has passed, indicating that the flush is only experienced while the skin 
temperature is increasing (50).  The perceived severity of a hot flush is therefore 
probably related more to the rate of temperature change than to actual 
temperature increase.   
The increase in skin temperature results from a sudden peripheral vasodilatation 
which precedes the subjective sensation of the flush by at least 1 min and 
persists for several minutes afterwards, thereafter declining slowly (51).  A rise 
in heart rate coincides with the sensation of a hot flush and usually returns to 
normal quickly once the flush has resolved (52, 53).  There is no significant 
change in blood pressure either during or following a menopausal hot flush (53).  
Although many women report palpitations during a hot flush, no change in 
cardiac rhythm has been found during a hot flush during electrocardiograph 
(ECG) recording (52). 
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Pathophysiology/Mechanism of a hot flush 
The exact pathophysiology of flushing is not known, although it is generally 
accepted that falling oestrogens play a main role.  As already stated, flushes 
generally occur at times of relative oestrogen withdrawal and replacing it will 
result in improvement in most women.  However, oestrogen concentrations 
remain low after the menopause whereas most vasomotor symptoms will 
diminish with time, and therefore a fall in oestrogen concentration would not 
seem to provide the complete answer.  It has also been found that circulating 
levels of oestrogen do not differ significantly between symptomatic and 
asymptomatic postmenopausal women (54). 
Furthermore, oestrogen withdrawal, rather than low circulating oestrogen 
levels, is thought to be the central change that leads to hot flushes.  There are 
several observations to support this theory.  The abrupt oestrogen withdrawal 
due to bilateral oophorectomy in premenopausal women is associated with a 
higher prevalence of flushes than in those women who experience a gradual 
physiological menopause. Also, young women with gonadal dysgenesis, who have 
low levels of endogenous oestrogen, do not experience hot flushes unless they 
receive several months of oestrogen therapy and then abruptly discontinue its 
use (55). 
As a hot flush closely resembles a systemic heat dissipation response; both are 
characterised by sweating and cutaneous vasodilatation and can be provoked by 
heating (51, 56); it is thought that there may be some dysfunction in 
thermoregulation in symptomatic postmenopausal women.  
Core body temperature (Tc) in humans is regulated by thermoregulatory nuclei 
within the medial preoptic area of the hypothalamus, through the activation of 
mechanisms that conserve or dissipate heat, such as vasodilatation or 
vasoconstriction (55, 57, 58).  It has therefore been widely hypothesised that a 
hot flush represents an alteration in the central thermoregulatory set-point in 
the hypothalamus (51, 59, 60).   
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It is thought that Tc in humans is maintained within a thermoneutral zone within 
which major thermoregulatory responses do not occur, and above and below 
which thermoregulatory mechanisms come into action.  
Studies by Freedman et al, using an ultrasensitive temperature probe, suggest 
that hot flushes are triggered by small elevations in core body temperature 
acting within a narrowed thermoneutral zone in symptomatic postmenopausal 
women (see figure 9) (61).  This group found that small but significant elevations 
in Tc precede most (76%) hot flush episodes (59, 62, 63).  These same 
investigators subsequently found that postmenopausal women with hot flushes 
had a narrower thermoregulatory zone (0°C) compared with postmenopausal 
women who do not flush (0.4°C).  This narrowing was mainly due to a lowering 
of the sweating threshold in symptomatic women (64).  Since heat loss 
mechanisms can be triggered by a 0.01o elevation of core body temperature 
above the regulatory zone, the subtle changes in temperature before a hot 
flush, coupled with a narrow homeostatic temperature zone, may trigger the 
heat loss mechanisms that lead to hot flush symptoms.   
Figure 9: Thermoneutral zone 
Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with 
hot flashes.  Am J Obstet Gynecol 1999; 181:66-70. (61) 
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Subsequently, the same group found that oestrogen (E2) replacement in 
symptomatic postmenopausal women raised the Tc sweating threshold and 
reduced hot flush occurrence without any affect on fluctuations in Tc.  Elevation 
of the sweating threshold may be responsible for improvement of vasomotor 
symptoms with oestrogen therapy since it would reduce the likelihood that Tc 
fluctuations would trigger a hot flush (65). 
It is known that the Tc sweating threshold in premenopausal women varies with 
the menstrual cycle, being lower in the follicular phase when oestrogen and 
progesterone levels are low, and higher in the luteal phase, when levels are high 
(66, 67).  Despite this lowering of the sweating threshold in the follicular phase, 
premenstrual women without premenstrual syndrome rarely experience hot 
flushes (68).  It has been shown that both symptomatic and asymptomatic 
postmenopausal women undergo fluctuations in Tc (69).  Freedman’s group 
subsequently went on to demonstrate that symptomatic postmenopausal women 
are distinguished from asymptomatic postmenopausal women and from 
premenopausal women in the luteal and follicular phases by significantly lower 
Tc sweating thresholds and higher maximum sweat rates (66). 
Using functional magnetic resonance imaging (fMRI), this group also 
demonstrated different areas of activation in postmenopausal women during a 
hot flush compared to sweating in asymptomatic amenorrhoeic women (70).  
Most recently, they have demonstrated a rise in brainstem activity, in 
symptomatic postmenopausal women, preceding the detectable onset of a hot 
flush, followed by increased activity in the insular and prefrontal areas (71), 
leading them to conclude that pre-hot flush activity may reflect the functional 
origins of internal thermoregulatory events and insular, prefrontal and striatal 
activity may be associated with the phenomenological correlates of hot flushes. 
Whilst there has been extensive study investigating the central control of this 
altered thermoregulation, little consideration has been given to the possibility 
that peripheral vascular reactivity may also play an important role in the 
pathophysiology of hot flushing.  It has been shown that women experiencing 
severe flushing exhibit a diminished vasoconstrictor response to cold stimulation, 
and that with improvement in vasomotor symptoms the vasoconstrictor response 
returns to normal (72).  Symptomatic postmenopausal women also exhibit 
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consistently poor peripheral vascular control, which shows a dose-related 
improvement with oestrogen therapy (73).  This impairment of vasomotor 
control affects thermoregulation, and although it can be postulated that this all 
occurs due to a central disorder of thermoregulation, the possibility of 
peripheral vascular dysfunction cannot easily be dismissed 
It is clear that the mechanism behind these thermoregulatory changes is not 
fully accounted for, although it is likely that there are changes in core body 
temperature prior to a hot flush and this precipitates alterations in 
neuroendocrine pathways involving the steroid hormones, noradrenaline, the 
endorphins and serotonin (57).   
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Oestrogen 
Oestrogen is a steroid hormone whose name comes from the Greek estrus (sexual 
desire) and gen (to generate).  The three most commonly occurring are oestrone 
(E1), oestradiol (E2) and oestriol (E3).  Oestradiol is the primary oestrogen from 
menarche to menopause, after which oestrone predominates. 
Oestrogens in premenopausal non-pregnant women are formed by aromatisation 
of androstenedione and testosterone in the granulosa cells of the ovary (see 
figure 10).  Receptors are located in the cell nucleus and are members of the 
superfamily of receptors known as nuclear ligand-activated transcription factors.  
Activated oestrogen receptors bind to oestrogen response element genes, 
resulting in gene expression.  The genes subsequently expressed may then result 
in the synthesis of receptors, growth factors, enzymes, brain-derived 
neurotrophic factors and other proteins which act to regulate cellular 
functioning.   
 
Figure 10: Steroid synthesis 
 
In addition, steroid receptors may also be present in mitochondrial membranes 
and over the last 20 years, studies have focused on non-genomic effects of sex 
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steroids regulating cell function through the rapid activation of multiple 
signalling cascades and second messenger systems (74).   
There are other sites of oestrogen biosynthesis throughout the body and these 
become important after the menopause.  These include adipose tissue and skin 
(75), osteoblasts (76) and chondrocytes in bone, vascular endothelial (77) and 
aortic smooth muscle cells (78) as well as a number of sites in the brain, 
including the medial preoptic/anterior hypothalamus, the medial basal 
hypothalamus and the amygdala (79). 
It has been suggested that the oestrogen synthesised in these compartments is 
probably only biologically active at a local tissue level in a paracrine fashion 
(80).  Thus the total amount of oestrogen synthesised by these extragonadal 
sites may be small, but the local tissues concentrations are probably quite high 
and exert significant biological influence locally (81).   
The effect of decreasing levels of oestrogen has been extensively studied.  
Changes in mood, anxiety, depression, insomnia, headaches/migraine and 
alterations of cognitive functions are thought to be linked to changes in 
serotonergic, noradrenergic and impairment of opioidergic peptide synthesis and 
secretion in postmenopausal women.  HRT has also been shown, in most cases, 
to restore levels of these neurotransmitters and that this is accompanied by an 
improvement in mood, psychological and cognitive disturbances (82). 
Changes in core temperature may also be associated with alterations in 
neuroendocrine pathways involving steroid hormones, noradrenaline, the 
endorphins and serotonin (57).  Noradrenaline and serotonin are thought to be 
the key neurotransmitters involved. 
Peripheral vasodilation and sweating is the peripheral response to centrally 
controlled temperature regulation and are also hallmarks of flushing.  Peripheral 
vasodilation occurs as a result of withdrawal of vasoconstriction (10-20%) and 
activation of sympathetic vasodilator nerves in the skin (80-90%).  This active 
vasodilation is mediated by cotransmission from sympathetic cholinergic nerves, 
with a moderate role for nitric oxide (83). 
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All blood vessels are lined by a single layer of cells called endothelial cells, 
which act as the interface between the rest of the vessel wall and the 
circulating blood.  Amongst their many roles, they are responsible for release of 
nitric oxide which acts as a potent vasodilator.  One of the best characterised 
examples of rapid sex steroid signalling is the activation of endothelial nitric 
oxide synthase in endothelial cells by oestradiol, a process initiated by the 
activation of membrane bound oestrogen receptors (84). 
Administration of HRT to postmenopausal women with Type 2 diabetes has also 
been shown to improve vascular reactivity, but it is not known if this contributes 
to its efficacy in treating flushing (85). 
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Noradrenaline 
Noradrenaline (NA) is thought to be the primary neurotransmitter responsible for 
lowering the thermoregulatory set point and triggering hot flushes (55, 64). 
Animal studies have shown that intrahypothalamic injection of noradrenaline 
acts to narrow the thermoregulatory zone (86).  Noradrenergic stimulation of 
medial preoptic area in monkeys (87) and baboons (88) by microiontophoretic 
application of noradrenaline causes peripheral vasodilation and heat loss and a 
drop in core body temperature.   
It has also been shown that plasma levels of the noradrenaline metabolite 3-
methoxy-4-hydroxyphenylglycol (MHPG) are significantly increased both before 
and during hot flush episodes in postmenopausal women (59).  
This theory is supported by clinical studies showing that clonidine, which is a α2-
adrenergic agonist that reduces brain NA, significantly reduces hot flush 
frequency (89, 90), in particular by decreasing the intensity of the flushes.  It 
has also been demonstrated that clonidine acts to widen the thermoregulatory 
zone in humans (91, 92). 
It has also been shown, in a controlled laboratory investigation, that yohimbine 
(α2-adrenergic antagonist that elevates brain NA) provokes hot flushes in 
symptomatic women (93). 
Castration in rats is associated with an increase in hypothalamic noradrenaline 
turnover (94) and oestrogen replacement decreases this activity (95).   
Postmortem studies have shown that most α2-receptors in the human brain are 
inhibitory, presynaptic receptors.  Given that oestrogens modulate brain 
adrenergic receptors (96, 97), it is possible that the oestrogen withdrawal at 
menopause is associated with the deficit of the inhibitory α2-receptor function in 
symptomatic postmenopausal women (withdrawal of tonic inhibition).  This 
could lead to increases in noradrenaline and a subsequent narrowing of the 
thermoneutral zone. 
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Oestrogen and testosterone can also stimulate natural endorphin production and 
thus may exert a modulatory effect on noradrenaline release both directly and 
indirectly (see figure 11) (98).   
Figure 11: Model of pathogenesis leading to alteration of sweating threshold 
This is a model proposed by Shanafelt (58), integrating and summarising the 
neurotransmitters that are thought to play a role in hot flushing. (+) increased, (-) decreased. 
 
Whilst the hypotensive effect of clonidine is thought to be mediated mainly 
through selective stimulation of presynaptic alpha-adrenergic receptors in the 
region of the vasomotor centre in the medulla (99), a direct action of clonidine, 
with constriction of skin though not of muscle vessels, has been demonstrated in 
the human forearm after intra-arterial injection of the drug (100).   
It has also been suggested that increased forearm blood flow, induced by 
intravenous infusion of adrenaline, angiotensin and noradrenaline, was 
significantly less in symptomatic postmenopausal women when treated for at 
least 6 weeks with clonidine compared with that induced in the women by 
infusions given before treatment (101). 
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It is clear that the mechanism is not fully understood, it may exert its effect on 
hot flushing through a reduction in peripheral vascular reactivity (102) and also 
through central mechanisms (103). 
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Serotonin 
5-Hydroxytryptamine (5-HT), commonly known as serotonin, was identified in 
1948 by Rapport (104), and was the name given to the a substance identified in 
serum (sero) that was a potent vasoconstrictor (tonin).   
Synthesis 
It is an intermediate product of tryptophan metabolism and is synthesised in the 
human body from the essential amino acid L-tryptophan (see Figure 13). 
L-tryptophan is converted to serotonin via a series of reactions.  The enzyme 
tryptophan hydroxylase (TPH) adds a hydroxide to tryptophan’s benzene ring, 
thus forming the molecule 5-hydroxytryptophan.  A further enzyme, aromatic 
amino acid decarboxylase (AAAD), removes a carbon dioxide molecule from 5-
hyroxytryptophan, consequently forming 5HT.  TPH is the rate-limiting step in 
the formation of 5HT and it exists in two isoforms; TPH1, found in several tissues 
(105) and TPH2, which is a neuron-specific isoform (106). 
 
Figure 12: Synthesis of serotonin 
 
Centrally produced 5-HT is dependent on the amount of tryptophan available to 
cross the blood brain barrier, as it is impermeable to 5-HT.  Tryptophan is in 
competition with other large neutral and branched amino acids for the active 
transporter required for blood brain barrier carriage (107), in contrast to 5-
hydroxytryptophan which moves freely across (108). 
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Over 95% of total body serotonin is produced and stored by the enterochromaffin 
cells of the duodenum (109), with only a small amount produced by the raphe 
nuclei of the brain (110), and neuroendothelial cells that line the lung.  
Release and transportation 
Serotonin released into the circulation by the enterochromaffin cells is rapidly 
taken up by platelets, which makes platelets the fundamental regulators of 
plasma 5-HT concentration.  Platelet uptake is dependent on the serotonin 
transporter (SERT).  After 5HT is transported by SERT across the platelet plasma 
membrane, it is either sequestered into dense granules by vesicular monamine 
transporters (VMAT) or degraded by monoamine oxidase (MOAO) to 5-
hydroxyindole acetic acid (5-HIAA).  MOAO is an intracellular enzyme, and 
therefore 5HT must be transported into the cell before it can be metabolised, 
SERT facilitates this. 
Serotonin uptake into dense granules protects the organism from 5-HT induced 
uncontrolled, harmful vasoconstriction or vasodilation.  So far, however, the 
reason for platelet 5-HT transport is unknown. 
 
Figure 13: Platelet serotonin transport 
VMAT (vesicular monamine transporters).  SERT (serotonin reuptake transporter).  5-HT 
(serotonin). 
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SERT is a member of the Na+Cl- dependent solute carrier 6 family, which includes 
transporters of noradrenaline and dopamine, however the detailed mechanism 
by which it depends on transmembrane solute gradients is still not fully 
understood (111). 
Function 
The function of serotonin as a neurotransmitter in the central nervous system is 
well known, including its role in mood, anxiety, sleep, sexual behaviour and 
eating, but it is also important for platelet aggregation and regulation of 
vascular tone.    
Sites of extra-pulmonary vascular synthesis have not yet been identified, so the 
current understanding of 5HT in the periphery is that the systemic vasculature is 
exposed to 5HT though its release from platelets via SERT or to freely circulating 
5HT (112). 
Receptors 
The effects of serotonin are mediated by its interaction with one of it receptors.  
A recent review of serotonin receptor subtypes has identified 7 distinct families 
of 5-HT receptors, with 15 subpopulations (113).   
With the exception of 5HT3, which is a ligand-gated ion channel receptor, all 
other 5HT receptors are G-protein-coupled receptors that activate an 
intracellular second messenger cascade to produce an excitatory or inhibitory 
response. 
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Table 1: Serotonin receptors, type, mechanism, potential, subgroup and location. 
Adapted from Jonnakuty, C. and Gragnoli, C. (114)
Family Type Mechanism Potential Subgroup Location 
5HT1 G1/G0-protein coupled Decreasing cellular levels of cAMP Inhibitory 5HT1A Presynaptic serotonergic neurons 
Postsynaptic non-serotonergic neurons in corticolimbic 
areas 
5HT1B Heart and stomach fundus 
5HT2 Gq/G11-protein 
coupled 
Increasing cellular levels of IP3 and DAG Excitatory   
5HT3 Ligand-gated Na
+and 
K+ cation channel 
Depolarising plasma membrane Excitatory  GI system 
CNS (brainstem, higher cortical areas) 
5HT4 Gs-protein coupled Increasing cellular levels of cAMP Excitatory  GI system 
5HT5 G1/G0-protein coupled Decreasing cellular levels of cAMP Inhibitory 5HT5A Exclusively CNS; cortex, hippocampus, cerebellum 
5HT5B No functional protein encoded in humans 
5HT6 Gs-protein coupled Increasing cellular levels of cAMP Excitatory  cognition, learning, appetite control, convulsive disorders 
5HT7 Gs-protein coupled Increasing cellular levels of cAMP Excitatory   
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Role in hot flushes 
In addition to the wide range of physiological functions already mentioned, 
serotonin is also thought to play a key role in thermoregulation (115). 
Blood 5-HT levels have been shown to be lowered both in spontaneous and 
surgically menopausal women, i.e. after oestrogen withdrawal and at a time 
when hot flushes occur, and in both groups the 5-HT level was restored to 
normal values after treatment with oestradiol (116, 117).   
In menopausal women, treatment with oestrogen has been found to augment 
serotonergic activity (118) and an increased urinary excretion of 5-HIAA, the 
main metabolite of 5-HT, was found after oestrogen treatment (119). 
Furthermore, selective serotonin reuptake inhibitors (SSRI), designed to increase 
the available serotonin at the serotonergic synapse, have also been shown in 
placebo-controlled trials to be effective in reducing the number and severity of 
hot flushes (120), although the mechanism is poorly understood. 
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Fat 
Previous studies have examined potential risk factors that may predispose 
certain women to hot flushes.  Some of these studies have found that smoking 
(121, 122) increases the risk of flushes, whilst moderate alcohol use decreases 
the risk (123), and these were independent of sex hormone levels.  It was also 
largely accepted for years that postmenopausal women with a high BMI were 
afforded some protection to flushing due to peripheral conversion of androgens 
to oestrogens in adipose tissue.  This was borne of the theory that more adipose 
tissue equals more conversion of androgens and therefore higher levels of 
circulating oestrogen with a reduction in likelihood of flushing.   
However, contrary to this, hot flushing is associated with high body mass index, 
which may occur due to relative hypooestrogenism (124) or to the insulating 
nature of fat.  A change in frequency of flushes also follows an increase in blood 
glucose suggesting a possible role for carbohydrate metabolism (125), increased 
insulin resistance being commonly associated with obesity. 
It is also been suggested that obesity is associated with hot flushes through a 
mechanism that involves alterations in cytokines, including leptin (126).  Leptin 
is a highly conserved cytokine-like protein that is expressed by adipocytes in 
proportion to body fat mass and has been related to insulin resistance (127).   
After menopause, adipose tissue becomes the main source of oestrogen.  This 
can only occur after conversion of DHEA to androstenedione, elaborated from 
the adrenal cortex, followed by aromatisation to oestrogen (see Figure 9).  This 
is catalysed by aromatase cytochrome P450.  Aromatase is expressed in various 
sites in humans and is controlled by tissue-specific promoters.  Aromatase is 
expressed in the stromal mesenchymal cells of adipose tissue.  These stromal 
cells grow in culture into fibroblasts and are believed to be preadipocytes (75).  
When serum is present in culture, expression of aromatase is stimulated by 
glucocorticoids.  This effect of serum stimulating aromatase expression has been 
mimicked by members of the Class I cytokine family, including IL-6.  Tumour 
necrosis factor α (TNFα) also stimulates aromatase expression in adipose stromal 
cells in the presence of dexamethasone. 
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Obesity is also linked to impaired vasoreactivity when compared to lean 
populations.  (128).  Obesity leads to insulin resistance and endothelial 
dysfunction, mainly through fat-derived metabolic products, hormones, and 
cytokines (adipocytokines) (129).  Sex steroid hormones also modulate vascular 
function through regulation of endothelium-derived factors (130).  It is possible 
that poorly functioning endothelium and relatively lower circulating levels of 
oestrogen in obese women could be linked to worse vasomotor symptoms 
associated with the menopausal transition and post-menopause. 
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Men 
Prostate cancer is the most common cancer diagnosed in men in the UK.  It 
represents 24% of all new cancer cases and 6% of all cancer deaths.  By the time 
a man reaches age 76, he will have a 1 in 6 chance of being diagnosed with 
prostate cancer.  Between 1998 and 2007 new cases rose by 35% and it is 
estimated that the number of men with prostate cancer will increase by 50% 
over the next 20 years.  This may be as a consequence of both an ageing 
population and a longer duration of survival as mortality rates for prostate 
cancer have been reducing since 1994 (whether as a result of improved 
screening, diagnosis or treatment).   
Prostate cancer was described in 1853 and surgical castration has been used 
since around 1896, although it wasn’t until 1941 that androgens were discovered 
to play a role in prostate cancer and that androgen ablation causes regression of 
primary and metastatic androgen dependent prostate cancer.  In 1966, chemical 
castration won Huggins the Nobel Prize for medicine and this is now certainly 
the most typical method of androgen deprivation. 
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Prostate Cancer 
Prostate cancer is the second leading tumour in males, with approximately 
680,000 new cases annually worldwide and accounts for 11.7% of all male 
cancers.  It is largely a disease of older men; the majority of patients are older 
than 65 years, and most of the deaths from prostate cancer are in this age 
group. 
Staging of disease 
Clinical and pathologic staging of prostate cancer involves determination of the 
anatomic extent and burden of tumour based on the best available data. The 
TNM system [primary tumour (T), regional lymph node (N), and metastases (M)] 
is the most widely used system for prostate cancer staging.  It stratifies patients 
according to the method of tumour detection, separating nonpalpable 
'incidental' prostate cancers detected during transurethral resection for clinically 
benign prostatic hyperplasia and palpable cancers detected by digital rectal 
examination.   
Gleason Score 
Gleason grading (131) is a strong predictor of survival among men with prostate 
cancer.  The Gleason system, introduced in 1974, is an architectural grading 
system that ranges from 1 (well differentiated) to 5 (poorly differentiated).  The 
Gleason score (GS) is the sum of the primary and secondary patterns with a 
range of 2 to 10.  It has long been appreciated that patients with GS ≥ 7 are at 
greater risk of extraprostatic extension and biochemical recurrence (132). 
It is used together with the clinical stage of the disease and the prostate specific 
antigen (PSA) to categorise risk (see Table 2) and plan treatment. 
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 PSA (ng/ml)  Gleason Score  Clinical Stage 
Low Risk <10 and ≤6 and T1-T2a 
Intermediate 
Risk 
10-20 or 7 or T2b-T2c 
High Risk >20 or 8-10 or T3-T4 
Table 2: Risk stratification criteria for men with localised prostate cancer 
Men with clinical stage T3-T4 cancers have locally advanced disease 
 
The National Institute for Health and Clinical Excellence published guidelines in 
2008 for the management of prostate cancer based on both the stage of the 
disease and risk stratification (133).  Treatments range from watchful waiting 
and active surveillance to radical surgical treatments and adjuvant therapies in 
the form of radiotherapy, cryotherapy and brachytherapy. 
 
Androgen Deprivation Therapy (ADT) 
Huggins and Hodges first reported the dramatic clinical effects of suppressing 
serum testosterone levels in men with advanced prostate cancer in 1941 (134).  
ADT was achieved by surgical castration or suppression of GnRH production at 
the level of the hypothalamus with diethylstilbestrol (DES).  Within a short 
period, hormonal therapy became widely accepted and Huggins and Hodges were 
awarded the Nobel Prize in 1967 for this pioneering work (135). 
Today, ADT is the gold standard treatment for advanced prostate cancer.  It is 
also sometimes used to treat patients with biochemical failure even without 
evidence of local or systemic recurrence, and as an adjunct in patients 
undergoing radiation for high-risk localised disease.   
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Approximately 90% of men will undergo medical castration therapy with 
gonadotrophin-releasing hormone (GnRH) agonist, while the other 10% have 
bilateral orchidectomy (136).   
Gonadotrophin releasing hormone (GnRH) agonists 
The Veterans Administrative Cooperative Urological Research Group (VACURG) 
was initiated in 1959 to investigate the role of ADT in the treatment of prostate 
cancer (137).  Ultimately a daily dose of 3mg DES was thought best and became 
the accepted regimen.  DES, however, was associated with cardiovascular 
toxicity. 
It was not until 1971 that the decapeptide, luteinising-hormone-releasing-
hormone (LHRH) was purified (138), and it was the availability of long-acting 
synthetic LHRH agonists in the 1980s which revolutionised the hormonal 
treatment of prostate cancer.  Leuprolide acetate was the first LHRH agonist 
evaluated as a treatment for advanced prostate cancer and was found to be 
equivalent to 3mg of DES in reducing serum testosterone to castrate levels and 
had a lower incidence of cardiovascular toxicity (139). 
Over the next 30 years, a number of other LHRH agonists were developed and all 
had similar abilities to lower serum testosterone to castrate levels and similar 
side effect profiles. 
Chronic exposure to LHRH agonists causes downregulation of receptors in the 
anterior pituitary gland, leading to decreased luteinising hormone (LH), which is 
responsible for promoting testosterone production in the Leydig cells of the 
testes, thereby suppressing testosterone production.  Injection of LHRH agonist 
initially triggers the secretion of LH, which results in a testosterone surge lasting 
1 to 2 weeks.  The desired castrate levels are reached within 3 weeks after 
initiation of therapy. 
Microsurges of testosterone may occur, particularly at times of repeat 
injections.  It has been suggested that repeated testosterone breakthroughs may 
be associated with inferior 5-year nonevidence of disease and, for this reason, 
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monitoring of testosterone concentrations throughout therapy has been 
recommended by some (140). 
Recent research has focused on GnRH antagonists, which results in more rapid 
androgen deprivation without the testosterone surge (141).  Degarelix binds to 
and subsequently blocks GnRH receptors in the anterior pituitary gland, leading 
to decreased secretion of LH and FSH and a reduction in testosterone 
concentrations to castrate levels in 1-3 days.  Further trials are needed, 
however, to study long-term effects in comparison with LHRH agonists.  
Side effects 
An immediate and potentially life threatening effect of GnRH agonists in the 
treatment of, particularly high-volume metastatic, prostate cancer is the ‘flare 
phenomenon’.  This is attributed to a surge of testosterone levels due to the 
initial stimulation of GnRH receptors, and is prevented by pretreatment with 
anti-androgen, which inhibits the stimulatory effect of the testosterone surge at 
the level of the androgen receptor (142). 
Other longer term side effects include increased fracture risk, maximal in the 
first year after initiation of therapy (143), gynaecomastia, memory loss, erectile 
dysfunction and loss of muscle mass with increases in adipose tissue.  Current 
data also suggest that men who are receiving long-term ADT are at risk for 
developing insulin resistance (144), hyperglycaemia, and the occurrence of 
metabolic syndrome (145), thus leading to an increased risk of cardiovascular 
complications. 
Total and free testosterone levels during treatment were 1.8-fold and 2.3-fold 
higher in obese men, which may contribute to the association between obesity 
and increased prostate cancer mortality (146). 
Of particular interest to us, and in common with peri and postmenopausal 
women, is the presence of hot flushing, documented as early as the 19th century, 
and therefore, predating the link between androgens and the disease. 
In some studies, following bilateral orchidectomy, as many as 50% of patients 
will experience hot flushes.  With LHRH agonists, as many as 75% in some 
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studies, with symptoms continuing for months, years and even beyond 
discontinuation of therapy in some.  In a study of 63 men, 48% still experienced 
flushes 5 years after treatment (147).   
Alterations in skin blood flow have also been identified in men (148) and 
dependence on sex steroid levels suggest mechanisms may be similar to those 
found in women (149). 
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Hypothesis 
The pathophysiology of vasomotor symptoms in postmenopausal women and 
hypogonadal men include alterations in subcutaneous microvascular reactivity. 
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Summary of Aims and Objectives 
There are several aims which will be explored in this thesis:  
1. Hot flushing is associated with vasodilation of skin blood vessels most 
particularly of the upper body and face, similar to that which occurs in an 
attempt to cool the body during increases in core body temperature.  
Whilst it has been suggested that flushing may be as a result of a 
narrowed thermoneutral zone, that is a centrally controlled mechanism, 
little consideration has been given to the potential role of a peripheral 
mechanism.  Subcutaneous microvascular reactivity has been studied in 
postmenopausal women with flushing and compared to matched women 
with no flushing. 
2. The alpha-adrenergic system is thought to play a key role in 
thermoregulation in humans, mainly thought to be as a result of central 
manipulation.  Clonidine is an alpha-adrenergic agonist, thought to act 
principally in the vasomotor centre of the medulla, and has been shown in 
placebo-controlled trials to have a beneficial effect on flushing.  What is 
the effect of successful treatment of flushes with clonidine on 
subcutaneous microvascular reactivity when compared to placebo? 
3. The decline in prescribing HRT has led to an increased interest in non-
hormonal alternatives and in recent years, serotonin has become a focus 
for study.  The use of selective serotonin reuptake inhibitors (SSRI) has 
been demonstrated in placebo-controlled trials to be associated with the 
relief of flushing.  It is possible to study its effect not only on peripheral 
microvasculature, but also to study the serotonin reuptake inhibitor 
(SERT) in vivo in the human brain. 
4. Although there has been a notable decline in the prescription of HRT, this 
remains the single most effective treatment for flushing.  There is 
increasing evidence of the effect of oestrogen on the endothelium and 
HRT has been shown to improve vascular reactivity in postmenopausal 
women with Type 2 diabetes, but it is unknown whether this contributes 
to its efficacy in treating flushing. 
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5. Obesity is linked to impaired vasoreactivity when compared to lean 
populations.  Are vasomotor symptoms in obese peri- and post-
menopausal women due to altered endothelial function as assessed by 
peripheral microvascular reactivity? 
6. And, as already stated, alterations in skin blood flow have been identified 
in men who flush and a dependence on sex steroid levels suggest that 
mechanism underlying their flushing may be similar to those found in 
women. 
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Chapter 2 
Materials and Methods 
  
  71 
Introduction 
This chapter describes the methods employed in recruiting volunteers for the 
study and the measurement of subcutaneous microvascular perfusion by LASER 
Doppler imaging and iontophoresis (LDI+Ion) together with endocrine and 
metabolic assessments.  This chapter also discusses measurement of the density 
of the serotonin transporter with single photon emission computed tomography 
(SPECT) scanning. 
Subjective and objective measurements of flushing were also recorded and these 
too will be discussed here. 
This study was conducted with the ethical approval of Scotland A Research 
Ethics Committee (REC Reference 09/MRE00/40).  Pilot data was collected with 
ethical approval (REC 07/50704/43) under the title; A study to investigate the 
value of LASER Doppler iontophoresis as a biomarker for vasomotor symptoms.  
This pilot study will be discussed separately. 
There were 3 different groups of participants in this study and they will each be 
discussed in turn, prior to detailed methods descriptions. 
All subjects were given an information leaflet at least 24 hours prior to 
participation and gave written informed consent.   
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Group 1 
Forty postmenopausal women (defined as either last menstrual period greater 
than 12 months prior to participation in study or FSH≥20IU/L) who were between 
the age of 45 and 65 years old and who had at least 20 hot flushes per week.  20 
of these women also had SPECT imaging, which was carried out at the Southern 
General Hospital.   All participants in this group received venlafaxine as part of 
the study. 
Exclusion criteria 
Any participant with known hypertension, insulin-dependent diabetes, significant 
cardiovascular disease, bleeding disorders, or who were taking any 
antidepressants or drugs known to affect vascular reactivity were excluded. 
Study design  
Figure 14: Group 1 study design 
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Methods 
An initial visit (Visit 1) took place at least 24 hours following presentation of the 
appropriate study information leaflet.  At this visit there was an opportunity to 
ask any remaining questions before signing a consent form.  A full medical 
history was taken and hot flush diaries presented.  These were completed for 4 
weeks prior to baseline measurements of LDI + ION.  At Visit 2, hot flush diaries 
were collected, and measurements of height, weight, blood pressure, and hip 
and waist circumference were taken.  LDI + ION measurements were completed 
and a blood sample was collected before venlafaxine was prescribed and 
dispensed by clinical trials pharmacy.  Clear instructions on the use of the 
tablets were given (one 37.5mg tablet in the morning and one at night, to be 
taken after food), a reminder of potential side effects (particularly nausea) and 
contact information was highlighted in the information leaflet.  An 8 week 
return appointment was made. 
At Visit 3 (after 8 weeks), hot flush diaries were collected, LDI + ION was 
repeated and a blood sample was collected.  A 2 week supply of decreased dose 
of venlafaxine (37.5mg once daily) was prescribed and dispensed by the clinical 
trials pharmacy.  A decreased dose was not required in those wishing to continue 
therapy, a letter was provided requesting that GP continue treatment. 
Greene Climacteric Scale, Becks Depression Inventory and Hospital Anxiety and 
Depression Scale questionnaires were completed by all participants at V1 and 
V3. 
Twenty of the participants in this group had also volunteered for SPECT imaging 
which was carried out at the Southern General Hospital (V2b and V3b).  Detailed 
information on this will be provided later in this chapter.  Venlafaxine was not 
commenced until the baseline scan had been completed, and a repeat scan was 
also carried out at 8 weeks. 
Letters detailing participation in the study were sent to participants’ General 
Practitioners with consent. 
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Group 2 
Twenty postmenopausal women (definition as above) who were between the age 
of 45 and 65 years old and who had at least 20 hot flushes per day.  These 
women were assessed by either their General Practitioner or at a local 
menopause clinic and were prescribed HRT, although had not commenced 
treatment yet. 
Exclusion criteria 
As for Group 1, but also including past history of DVT, stroke, breast cancer, and 
exposure to HRT within one month for transdermal preparations, three months 
for oral preparations and 6-9 months for an estradiol implant. 
Study design 
 
Figure 15: Group 2 study design 
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Methods 
As with group 1, an initial visit (V1) took place at least 24 hours following 
presentation of the appropriate study information leaflet.  At this visit there was 
an opportunity to ask any remaining questions before signing a consent form.  A 
full medical history was taken and hot flush diaries presented.  These were 
completed for 4 weeks prior to baseline measurements of LDI + ION.  At Visit 2 
(V2), hot flush diaries were collected, and measurements of height, weight, 
blood pressure, and hip and waist circumference were taken.  LDI + ION 
measurements were completed and a blood sample was collected.  An 8 week 
return appointment was made. 
Participants then commenced HRT, as prescribed by GP or hospital practitioner, 
and hot flush diaries were recorded until the return appointment. 
At visit 3 (V3) (after 8 weeks), hot flush diaries were collected, LDI + ION 
measurements were repeated and a blood sample was collected. 
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Subgroup from Group 1 and Group 2 
It was the aim that at least 15 women from Group 1 and Group 2 should have a 
BMI greater than 30kg/m2; these women formed a subgroup to assess whether 
increased flushing seen in women who are obese is due to altered endothelial 
function as assessed by peripheral microvascular reactivity. 
As these women were recruited to group 1 and group 2, inclusion and exclusion 
criteria were as above. 
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Group 3 
Twenty men with prostate cancer for whom gonadotrophin-releasing hormone 
(GnRH) agonist therapy was to be prescribed, and who were between the age of 
55 and 75 years old were to be recruited to this group. 
Exclusion criteria 
Any participant with known hypertension, insulin-dependent diabetes, significant 
cardiovascular, renal or liver disease, bleeding disorders, or taking any drugs 
known to affect vascular reactivity were excluded.   
Study design 
 
Figure 16: Group 3 study design 
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Methods 
As with groups 1 and 2, an initial visit (V1) took place at least 24 hours following 
presentation of the appropriate study information leaflet.  At this visit (V1) 
there was an opportunity to ask any remaining questions before signing a 
consent form.  A full medical history was taken and measurements of height, 
weight, blood pressure, and hip and waist circumference were taken.  At visit 2 
(V2) LDI + ION measurements were completed and a blood sample was collected.  
An 8 week return appointment was made. 
Participants then commenced GnRH agonist therapy as prescribed by their 
hospital practitioner.  Hot flush diaries were presented to the participant, who 
was asked to complete these if flushing developed.   
At V3 (after 8 weeks), hot flush diaries were collected, LDI + ION measurements 
were repeated and a blood sample was collected. 
Flushes are most likely to coincide with achievement of castrate levels of 
testosterone a few weeks after commencement of therapy and increase in 
frequency at approximately three months.  For this reason, participants were 
asked to return again at 24 weeks (V4). 
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Recruitment, screening and selection 
Groups 1 and 2 
Volunteers were recruited from the Greater Glasgow and Clyde area.  A variety 
of media were utilised to publicise the study.  Initial recruitment for Groups 1 
and 2 was generated from a press release in the Glasgow Herald newspaper (see 
Appendix II) which coincided with an advertisement on the Glasgow University 
homepage.  As a consequence of this, I was invited to speak about hot flushes 
and the study on BBC Radio Scotland (see Appendix II).  Also being interviewed 
was Joan McFadden, an agony aunt who writes a column for the Daily Record, 
and a few months later there was further exposure in a piece written by her 
which included an interview of a study participant (see Appendix II). 
Recruitment posters were displayed in Menopause clinics across the city, and a 
number of general practitioners agreed to display posters and leaflets in their 
surgeries.  We also displayed posters and attended breast screening services in 
Glasgow as this was an age-appropriate group of women. 
To further increase exposure, I spoke at a British Menopause Society Women’s 
Health Meeting, which is designed as an informative day for those medical 
practitioners with a specific interest in women’s health.  Wellbeing of Women 
organised a Christmas Fair to which some 500 women were invited.  A copy of 
our recruitment poster was inserted into the invitations.  Unfortunately I was 
not able to attend the Fair as it was scheduled during a week of adverse winter 
weather and virtually all transport ceased.  There was however still some 
interest generated from the invitations. 
A notice was also put on the Menopause Matters website, which generated a 
number of enquiries, however most of these were from women in England who 
could not attend the Western Infirmary in Glasgow for 3 visits. 
A number of interested volunteers were also identified at Professor Lumsden’s 
menopause clinic, which I attended weekly. 
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Interested volunteers contacted us either by telephone or email to express an 
interest in the study.  Basic information about the study was given and screening 
questions were asked, and if the volunteer was still interested and thought to be 
suitable, formal study information was sent either by email or post.  Contact 
details were taken and a suitable time arranged for a call back.  If the volunteer 
wished to participate, appointments for visit 1 (V1) were arranged.   
Group 3 
Men for group 3 were identified from the Greater Glasgow and Clyde Prostate 
cancer multidisciplinary team meeting, a weekly meeting attended by Urology 
surgeons, Oncologists, Pathologists, Radiologists and Biochemists.  Prior to 
commencing recruitment for this group, the study protocol was presented to the 
group. 
All new cases of prostate cancer (mean/week=13) were discussed at this meeting 
and potentially suitable gentlemen were identified.  These gentlemen were then 
approached at their next hospital appointment.  Basic information was given 
about the study, as they had usually had a significant volume of information 
regarding their diagnosis and treatment options at this visit, an information 
leaflet was given to them, and a contact number was taken and a suitable time 
to call arranged. 
Posters were also displayed in urology and oncology clinics to alert clinicians to 
the study. 
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Body Composition 
Height 
Height was measured using a stadiometer.  The participant was measured 
barefoot, with their back positioned against the stand and their arms relaxed in 
the lateral position.  The head was also positioned against the stand, with the 
line of sight perpendicular to the stand.  Measurement was performed when the 
volunteer was positioned and relaxed, and a movable headboard was lowered on 
to the top of the head with light pressure allowing hair compression.  The 
measurement was made to the nearest 0.01 metre. 
Body Mass 
Body mass was measured using weighing scales (Seca, Germany).  The same 
scales were used for all volunteers throughout the study.  Subjects were dressed 
without shoes when weighed.  Body mass was measured with both feet on the 
balance and with arms positioned in the lateral position.  Body mass index (BMI, 
kg/m2) was calculated as: 
BMI = weight (kg) / height (m)2 
Waist and hip circumference 
Circumferences were measured using a non-elastic tape measure, and 
measurement was made with the abdominal muscles relaxed, at the end of 
normal expiration.  Waist circumference was measured at the umbilical level.  
Hip circumference was measured around the point of maximal width around the 
hip region, at approximately the region of the pubic symphysis.  The same 
investigator performed the measurements on each volunteer, on every occasion.  
Waist to hip ratio was determined by dividing the waist circumference by the hip 
circumference. 
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Blood pressure 
Blood pressure was measured using an Omron automated monitor.  Participants 
were seated with back supported and arm resting on the table.  The cuff size 
and placement was correct and the participant was rested in a controlled 
environment for at least 5 minutes as recommended by the European Society of 
Hypertension guidelines on blood pressure measurement (150).  Legs were 
uncrossed and the participant was relaxed and not talking. 
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Plasma Preparation and Analysis 
Fasting blood sampling 
A fasting blood sample was taken using 21G Vacuette® SAFETY blood collection 
set + luer adapter from an anticubital vein.  Three samples were collected in 
Vacuette® gel tubes, one 9ml ethylenediamine tetra-acetic acid (EDTA – lilac 
top), one 6ml lithium heparin (LiHep – green top) and one 4ml citrate (blue top). 
Plasma preparation and storage 
All blood samples were prepared in the laboratory within one hour of collection.   
Haematocrit 
All Vacuette® samples were turned on a roller for five minutes.  Two glass 
capillary tubes were ¾ filled with whole blood from LiHep Vacuette®.  The rest 
of the sample was kept to be spun with the others (see below).  Capillary tubes 
were plugged with plasticine at marked end and placed in haematocrit 
centrifuge (Thermo Scientific Heraeus Pico 21) with the plugged end to the 
outside rim.  The two capillary tubes were balanced in the centrifuge by placing 
at opposite ends to each other.  Spin for 12 minutes at 13.3 xg.  Haematocrit 
(Hct) was read by placing the capillary tubes on the reader one at a time and 
recording the values.  If the values were different, a mean was taken and 
recorded. 
Remaining samples 
The remaining LiHep, EDTA and citrate samples were all spun in an underbench 
centrifuge (Beckman GS-6KR) at 3000rpm, 4oC for 10 mins.  Using a fine tip 
pastette, plasma was aspirated and dispensed into labelled 2.0ml screwcap 
microtubes.  Four 1 ml aliquots were closed with lilac lids (EDTA)(to correspond 
with Vacuette® top), two 1 ml aliquots closed with blue lids (Citrate) and two 1 
ml aliquots closed with green lids (LiHep).  All samples were placed into a small 
labelled (participant study number, date and Hct result) specimen bag and 
stored at -80oC. 
  84 
Enzyme-linked immunoassays 
All enzyme-linked immunoassay (ELISA) procedures were based on a ‘sandwich’ 
technique.  Commercially produced plates were used for all ELISA.  The wells of 
the plates were coated with a monoclonal antibody to the protein of interest.  
The addition of plasma to the wells bound protein to the antibody, with unbound 
molecules removed by washing.  A second antibody specific to another area of 
protein was then added, with unbound molecules removed by a second washing.  
The second antibody was linked to an enzyme which would catalyse the 
conversion of a non-fluorescent substrate to a fluorescent product.  The 
intensity of the subsequent fluorescence was directly proportional to the amount 
of protein in the initial sample. 
Insulin was measured using a commercially available ELISA with <0.01% cross-
reactivity with proinsulin (Mercodia, Uppsala, Sweden).  Adiponectin, IL-6, 
VCAM-1, ICAM-1, and TNFα were analysed using commercially available kits (R&D 
Systems Europe, Abingdon, UK).  High sensitivity kits were used for TNFα and IL-
6.  All samples for each participant were run in a single analyser run.  The 
accuracy and precision of the assays was monitored using quality control sera 
(Mercodia AB, Uppsala, Sweden.  R&D Systems Europe, Oxford, UK).   
CRP, Cholesterol, Glucose, HDL, LDL, and Triglyceride were measured by 
standardised methods by vascular biochemistry at Glasgow University.  All 
analysis was carried out on the ILAB 600 clinical chemistry analyzer, using Roche 
kits for HDL-cholesterol, triglyceride, and cholesterol.  CRP, glucose, Apo A1 and 
APO B kits were from Randox Laboratories.  All chemistries were calibrated using 
the assigned kit calibrators and checked against the relevant quality control.  
Vascular biochemistry is a member of the NEQAS UK wide external quality 
control scheme for all chemistries, with the exception of glucose. 
LDL-cholesterol was calculated as follows; 
Total cholesterol – HDL-cholesterol-(Trig/2.2). 
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Measuring vascular function 
There are a number of methods that can be employed to measure vascular 
function.   
Endothelial dysfunction and vascular injury have been described as precursors of 
atherosclerosis, which can result in coronary artery disease.  In the normal 
coronary vasculature, acetylcholine releases nitric oxide (NO) and causes 
vasodilation, but in the presence of atherosclerosis and endothelial dysfunction 
(with decreased NO), acetylcholine causes vasoconstriction secondary to smooth 
muscle cell activation.  Direct measurements of coronary flow responses are 
invasive and not readily repeatable, but brachial artery flow-mediated 
vasodilation (FMD) has been reported to be impaired in patients with abnormal 
coronary endothelial function, compared to those with normal coronary 
endothelial function, and so peripheral tests can be used as surrogates for 
coronary reactivity. 
Whilst FMD is used to assess larger conduit arteries, peripheral vessels have 
traditionally been evaluated using venous occlusion plethysmography (VOP).  
This test involves placing a strain gauge around the forearm, and cuffs at the 
wrist and the upper arm.  The wrist cuff is inflated to 200 mm Hg to prevent 
blood circulation in the hand and after the upper arm cuff is inflated to 40 mm 
Hg, venous occlusion causes forearm engorgement, which is then recorded on 
the plethysmograph to derive measurement of resting blood flow.  The cuff is 
then inflated to suprasystolic pressures for between 4 and 10 minutes and then 
deflated, thereby measuring hyperaemic blood flow.  Plethysmography is, 
however, technically difficult, and the recognition of a good waveform is 
somewhat subjective.   
Microvascular function can of course also be assessed ex-vivo using wire 
myography. 
However, none of these methods are specific to skin, and VOP measurements 
may include blood flow related to vessels in the muscle groups of the area under 
observation.  LASER Doppler imaging is specific to the cutaneous 
microcirculation and as flushing is accompanied by warming of the skin as a 
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result of vasodilation of skin microvasculature, this method has advantages over 
the other methods.  Iontophoresis of acetylcholine and sodium nitroprusside via 
perspex chambers on the skin allows assessment of vascular responses without 
the need for intravenous or intraarterial cannulation.  As it is entirely non-
invasive, this method is also completely painless, and may therefore be more 
acceptable to participants.  It also has high temporal resolution as a result of 
continuous measurements.   
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LASER Doppler Imaging with Iontophoresis 
Non-invasive skin perfusion can be measured using LASER Doppler Imaging with 
Iontophoresis (LDI+Ion) (see Figure 17) (151). 
Iontophoresis is a technique which allows for transdermal delivery of vasodilator 
agents acetylcholine (ACh) and sodium nitroprusside (SNP) across the skin under 
the influence of an applied current.  In the past iontophoresis has been used in 
conjunction with LASER Doppler flowmetry, a non-invasive method for assessing 
microvascular perfusion at a single point (152).  More-recently, iontophoresis has 
been combined with LASER Doppler imaging, which reduces measurement 
variability (153, 154). This is because unlike LASER Doppler flowmetry, LASER 
Doppler imaging measures perfusion across many points (155), and an average 
measure of perfusion can be computed for any chosen area. 
 
 
Figure 17: LASER Doppler Imaging with Iontophoresis (LDI+Ion) 
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Iontophoresis of acetylcholine (ACh) at the anode tests endothelial function 
since its vasodilator action involves binding to muscarinic receptors on 
endothelial cells, with subsequent generation of NO.  It is therefore said to be 
‘endothelium dependent’.  Vasodilatation is ultimately mediated by action of NO 
on vascular smooth muscle (via the cGMP pathway) and so iontophoresis of an 
NO donor, sodium nitroprusside (SNP), delivered at the cathode, is used as an 
‘endothelium-independent’ control to test the integrity of vascular smooth 
muscle (See figure 18).  
Drug delivery is achieved using a battery-powered constant-current iontophoresis 
controller (MIC-1e; Moor Instruments Ltd., Axminster, U.K.).  The chambers used 
for iontophoresis (ION 6; Moor Instruments Ltd.) are constructed of Perspex 
(internal diameter 22mm; area 3.8cm2) with an internal platinum wire 
electrode.  Two chambers are attached to the skin of the volar aspect of the 
forearm by means of double-sided adhesive discs (see Figure 18), avoiding hair, 
broken skin, and superficial veins.  The chambers are connected to the anode 
and cathode connections on the iontophoresis controller and the voltage across 
the chambers is monitored.  A thermometer is also attached to the arm in order 
to measure skin temperature. 
2.5ml of 1% ACh (Sigma) is introduced to the anodal chamber and 2.5ml of 1% 
SNP (Sigma) is introduced to the cathodal chamber.  The vehicle for these drugs 
is 0.5% sodium chloride (NaCl).  Both of these agents are delivered 
simultaneously during each period of current administration.  Fluid is prevented 
from escaping by placing circular 32mm coverslips over the chambers. 
The iontophoresis protocol involves incremental current delivery with four scans 
at 5µA, four at 10µA, four at 15µA and two at 20µA, giving a total charge of 
8mC. 
The LASER doppler imager (Moor Instruments, UK) is equipped with a red LASER 
(wavelength 633nm, power 1mW, beam diameter 1mm).  The LASER is scanned 
in a raster fashion over both chambers and through the coverslips.  The 
backscattered light is collected by photodetectors and converted into a signal 
proportional to perfusion in arbitrary perfusion (flux) units (PU) that is displayed 
as a colour-coded image on a monitor (see figure 19).  Perfusion measurements 
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are obtained using the imager manufacturer’s image analysis software by 
outlining a region of interest (ROI) around the internal circumference of the 
chamber (see Figure 20).  Statistical analysis of the ROI is subsequently 
performed to yield the median flux value (see Figure 21) across approximately 
700 measurement points.  Twenty repetitive scans are taken during each LDI 
assessment, the first being a control (before current administration), followed 
by the incremental current protocol as described above (fourteen scans), and 
followed by a further five scans with no current administration.  An assessment 
of the overall response to the drugs is obtained by calculating the area under the 
curve (AUC). 
This technique is reproducible with between-day and within-day coefficients of 
variation of 6.4 ±3.3% and 8.9 ±5.3% respectively (151).  Variability being 
reduced by averaging perfusion over a large skin area (156).  Good 
reproducibility has also been demonstrated between arms (157).   
LASER Doppler imaging with Iontophoresis has been taught to me by Professor 
William Ferrell, who is a senior author on a number of publications validating 
this method (151, 156, 157).  Whilst the published work from his group report 
good temporal and inter-arm reproducibility, I acknowledge that their data do 
not necessarily reflect my own practice.   
All participants fasted for at least 5 hours prior to assessment (water only 
permitted).  Prior to the procedure, patients were allowed to acclimatize for 15 
minutes in a temperature-controlled room, to exclude temperature variation 
bias on skin perfusion responses to vasoactive agents.  Participants all lie in a 
semi-recumbent position with the flexor aspect of the forearm exposed on an 
arm rest (see Figure 17). 
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Figure 18: Iontophoresis of acetylcholine and sodium nitroprusside 
 
 
Figure 19: Colour-coded image proportional to perfusion 
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Figure 20: Define ROI 
 
 
Figure 21: Median values of perfusion 
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Power calculation 
A change in vascular function of 25-30% is considered to be significant for the 
study in view of the observation that this order of change is clinically significant 
as indicated by studies of diabetic and non-diabetic women (158).  A 25% change 
in vascular function at alpha = 0.05, with 20 subjects per group would give a 
power of 0.86 (acetyl choline).   
Data analysis 
Measurement of vascular responses, in the whole group, was performed using 
raw values.  Comparisons were by General Linear Model.  Because of the marked 
differences in variances between basal perfusion values and the maximal 
responses to the drugs, but the similar coefficients of variation, log10 
transformation of the data was performed to equalise the variances and thereby 
permit parametric data analysis. 
Statistical analysis was performed using Minitab ® 16.2.2. 
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SPECT scanning of SERT using [123I] -beta-CIT 
It is possible to study the serotonin transporter (SERT) in vivo in the human brain 
by using radioligands that bind to SERT in combination with single photon 
emission computed tomography (SPECT).  The iodine-labelled radioligand [123I]β-
carbomethoxy-3-β-(4 iodophenyl)tropane ([123I]β-CIT) has a high affinity for both 
SERT and the dopamine transporter (DAT).   
Radioligand Preparation 
The radioligand ([123I]β-CIT) was prepared by Dr. Sally Pimlott at the Western 
Infirmary, Glasgow.   
[123I] -beta-CIT was prepared via electrophilic iododestannylation of the 
corresponding tributylstannyl precursor (159).  Briefly, reagents were added to 
carrier free Na123I (370-740 MBq) in approximately 10-20 µl of 0.05 M NaOH, in 
the following order: 30 µg tributylstannyl precursor in 300 µl glacial acetic acid 
followed by 10% V/V peracetic acid.  The reaction proceeded for 20 minutes at 
room temperature. 500 µl of NaOH was then added.  The mixture was purified by 
reverse-phase HPLC and the solvent removed by rotary evaporation.  The [123I] -
beta-CIT was formulated as 150 MBq in 5 ml ≤6% ethanol in isotonic citrate 
acetate buffer and filtered through a 0.22 µm filter.  The [123I] -beta-CIT was 
produced with an isolated radiochemical yield of 70.1 ± 8.6 % (n = 27), and had a 
radiochemical purity of between 96.8 to 100% (> 99 % for 25 synthesis).  
Pyrogenicity tests and sterility tests were performed.   
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SPECT Imaging 
This protocol has been previously validated and described (160).  [123I] -beta-CIT 
binds with high affinity in vitro to both DAT and SERT (161).  In vivo studies in 
both humans and nonhuman primates have shown that [123I] -beta-CIT 
accumulates in two distinct brain regions.  In the striatum, where the density of 
DAT is much higher than that of SERT, [123I] -beta-CIT binding mainly reflects 
DAT density, whereas in the brainstem and diencephalon binding seems to be 
specific for SERT. 
The kinetics of [123I] -beta-CIT binding differ markedly between the DAT-rich and 
SERT-rich regions.  The slow uptake in the striatum, which reaches a peak after 
20-30 hours, is in contrast to the faster kinetics seen in the brainstem and the 
diencephalon, where peak activity is attained after 2-4 hours after 
administration.  In this study, early imaging of SERT regions at 3 hours was 
performed for two reasons: first, to reduce the effects of radioactive decay, and 
second to minimize any possible effect of DAT on the SERT measurement 
because DAT uptake is proportionally lower at 3 hours. 
Brain SPECT imaging was performed with a dedicated Neurofocus 900 SPECT 
scanner (spatial resolution 7mm full width at half maximum with a line source in 
air; NeuroPhysics, Shirley, Massachusetts), which acquires sequential single 
transaxial brain sections.  Up to 25 axial sections 6 mm apart were scanned and 
the energy window (140-178 keV) was placed symmetrically around the 123I 
gamma energy of 159 keV.  A linear attenuation correction was applied, based 
on an automatically detected ellipse matching the outer head surface. 
All scans were performed by Mrs Mary Hansen, and supervised by Dr Jim 
Patterson, until his retirement, and then by Dr Alice Nicol at the Neurological 
Institute, Southern General Hospital.   
Subjects were scanned starting 2 – 3 hours after IV administration of [123I] -beta-
CIT.  To minimize thyroid uptake of radioactive iodine, 120mg of potassium 
iodide was administered orally to each subject at least one hour prior to [123I] -
beta-CIT injection.  Scanning time was approximately 50 min per scan. 
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Exclusion criteria included weight greater than 20 stones (127kg), difficulty lying 
flat, and short neck, for the purposes of lying on the scanning table for the 
length of time required to complete the scan, and fitting inside the scanner (see 
Figure 22).  Other exclusion criteria specific to SPECT scanning can be seen in 
Figure 23. 
 
 
Figure 22: Participant in SPECT scanner 
Participants were made comfortable with pillows, and encouraged not to move for the 
duration of the scan.  They could listen to music if they chose. 
  96 
 
Figure 23: Exclusion criteria to participation in SPECT scanning  
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Image analysis 
Region of interest (ROI) analysis, carried out by Dr. Alice Nicol, blinded to the 
subject’s clinical history, was used to extract data from the [123I] -beta-CIT 
scans.  A standard ROI template was constructed with the aid of two image 
templates: (1) the standard magnetic resonance imaging template known as 
ICBM152, which is based on 152 normal MRI scans and is available from the 
Statistical Parametric Mapping web site of the Functional Imaging Laboratory 
(http://www.fil.ion.ucl.uk/spm/); and (2) and an in-house cerebral perfusion 
template based on 32 normal SPECT scans of cerebral perfusion. 
The ROI template consisted of manually drawn regions representing the brain 
stem/diencephalon ROI (referred to as the brain stem ROI below for brevity), 
and a reference ROI.  The striatum ROI (7.6 cm3 on each side) was drawn on 
three axial sections 5 mm apart and encompassed the head of caudate and 
putamen in both hemispheres.  The brain stem ROI (23 cm3) was drawn on seven 
axial sections 5mm apart and comprised the thalamus-hypothalamus, mid-brain, 
and pons.  The reference ROI (35 cm3) was drawn on three axial sections 5 mm 
apart in the medial and lateral occipital lobe bilaterally.  The occipital region 
was chosen to represent nonspecific and nondisplaceable [123I] -beta-CIT uptake 
(i.e., activity not associated with binding to transporters) because it has a 
negligible density of both dopamine and serotonin transporters, as does the 
cerebellum. 
The [123I] -beta-CIT uptake in each ROI was expressed as mean counts per pixel, 
and the specific uptake in each transporter ROI was calculated as:   
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Transporter binding ratio for SERT was then defined as the ratio of specific 
uptake to uptake in the occipital reference region using the formula:   
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Under equilibrium conditions the binding ratio is proportional to transporter 
binding potential, and provided transporter affinity and nonspecific binding are 
invariant across subjects, the ratio is then a measure of transporter availability 
(Bmax). 
Data analysis 
Statistical analysis was performed by Dr. Rajeev Krishnadas using SPSS v19.  A 
paired-samples t-test was conducted to compare the means of Beta-CIT uptake, 
BDI scores, Flush frequency, ACh - AUC, SNP – AUC, Flush score, HFRDIS and NTA, 
before and after treatment with Venlafaxine. Mean difference of scores, the 95% 
CI of the mean differences and effect sizes (Cohen’s d) were also calculated 
(162).  
Percentage change (reduction) in each of the above variables from baseline was 
calculated using the formula:  
	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	× 100 
where X is the variable of interest ([123I] -beta-CIT binding ratio; BDI scores; 
Flushing frequency; Flushing score; ACh-AUC; SNP-AUC). 
The relationship between the reduction in the [123I] -beta-CIT binding ratio 
(predictor variable) and other variables (dependent) of interest - namely BDI 
reduction; Flush frequency, and score, reduction; ACh reduction; SNP reduction 
- were examined using multivariate analysis of covariance (MANCOVA) with age 
as a nuisance covariate in the model.  The p values were corrected for multiple 
testing using Holm-Bonferroni family wise error correction. 
Power calculation 
It was not possible to perform a power calculation for the SPECT study in this 
group, as there is no study from which to extract data.  It is, however, generally 
accepted that a sample size of 15 is adequate, and studies with smaller groups 
have been published.  
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Qualitative Measurements 
Hot flush diaries 
Participants documented the number of, and the severity of flushes on a scale of 
1 to 3.  Participants also recorded the number of times that they were awake 
through the night, night time awakening (NTA), secondary to flushing (see Figure 
24). 
This 3-category diary defines severity as mild, moderate or severe, and although 
it has not been formally validated, it is considered valid by the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMEA) and is 
considered acceptable for use in clinical trials (163, 164).   
 
Figure 24: Hot flush diary 
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Hot Flush Related Daily Interference Score 
At the end of each 7 day diary period, participants completed a hot flush related 
daily interference scale (HFRDIS).  This 10-item questionnaire (see Figure 25) 
aims to determine the impact of hot flashes on daily activities and quality of life 
(165).  Women rated the degree of hot flush interference (during the past week) 
for each item on a scale from 0 (does not interfere) to 10 (completely 
interferes); a higher total score indicates greater interference (score range, 0-
100). 
 
Figure 25: Hot Flush Related Daily Interference Score 
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Greene Climacteric Scale 
This scale published in 1998, by Greene (166) is intended to be a brief and 
standard measure of core climacteric symptoms or complaints to be used for 
comparative and replicative purposes across different types of studies (see 
Figure 26).   
Symptoms were thought to fall into three major independent groups (see Figure 
11); vasomotor (V), somatic (S), and psychological (P).  The psychological group 
may be further sub-divided into an anxiety (A) and a depressed (D) mood 
component.  An additional item on loss of sexual interest (S(21)) was added and 
intended as a `probe' item to be followed up by more appropriate and sensitive 
evaluation of problems in that area. 
This scale was completed at baseline (i.e. before treatment) and following 
treatment as appropriate to group. 
 
Figure 26: Greene Climacteric Scale 
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Becks Depression Inventory 
Becks Depression Inventory (BDI) is a 21-item self-report instrument (see Figure 
27 and 28) for measuring the severity of, and not diagnosing, depression in 
adults and adolescents aged 13 and older.  BDI II is a revision of the original BDI 
based on descriptive statements regarding symptoms that had been reported 
frequently by psychiatric patients with depression and only infrequently by non-
depressed psychiatric patients (167).   This assessment was administered at 
baseline (i.e. before any treatment) and following treatment as appropriate to 
group.  A total score of 0-13 is considered to be minimal, 14-19 is mild, 20-28 is 
moderate, and 29-63 is severe.  
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Figure 27: Becks Depression Inventory (BDI) II Page 1 
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Figure 28: Becks Depression Inventory (BDI) II Page 2 
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Hospital Anxiety and Depression Scale 
Low serotonin transporter availability is correlated with high anxiety (168).  
Venlafaxine is used as an approved drug treatment for generalised anxiety 
disorder.  Becks Depression Inventory II is not designed to assess anxiety as a 
separate entity from depression.  Therefore an amendment to ethical approval 
was sought and granted on 16 August 2010 to include Hospital Anxiety and 
Depression Scale (HADS) (see Figure 29).  Each participant who participated in 
the study after this date completed this questionnaire at visit 2 and visit 3. 
 
Figure 29: Hospital Anxiety and Depression Scale 
 
  
  106 
Statistical Analysis 
Hot flush diary data was calculated as follows; flush/day = total number of 
flushes/week divided by the number of diary days completed, and a mean taken 
of the weeks completed.  Hot flush score = mean daily flush frequency 
multiplied by mean score.  A mean was taken of the weeks completed.  NTA 
(night time awakening) = total number of NTA/week divided by the number of 
diary days completed, and a mean taken of the weeks completed.  HFRDIS (hot 
flush related daily interference scale) was completed once per diary week, and a 
mean was taken of the weeks completed.   
Statistical comparison of all qualitative measurements was made by Wilcoxin 
Signed Rank test of paired non-parametric data using Minitab ® 16.2.2 and 
graphs drawn using GraphPad Prism 5. 
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Chapter 3 
Flushing postmenopausal women and their non-
flushing contemporaries – a study comparing 
cutaneous microvascular perfusion. 
  108 
Acknowledgement 
The work presented in this chapter, and chapter 4, is from a study which formed 
the basis of a BSc project by Dr. Helen Fox MBChB (see Preface).  Initiation of 
the project as well as recruitment and some participant assessments were 
completed by Dr. Fox; however final participant assessments, full analysis of 
data, and subsequent publications have been completed as part of the work that 
I present in this thesis.  Dr. Fox is a co-author in the publications (169, 170). 
  
  109 
Introduction 
A hot flush is a period of intense heat which resembles a heat dissipation 
response, in that both are characterised by sweating and peripheral 
vasodilation. 
Physiological thermoregulation in humans comprises changes in heat dissipation 
(as above), and heat generation (shivering) in response to various internal and 
external stimuli.  The central control of thermoregulation is in the medial 
preoptic area of the hypothalamus (MPOAH) and it has already been mentioned 
that hypotheses exist surrounding alterations to the thermoneutral zone within 
this area.  However, what is not well studied is the effector mechanism of 
thermal control. 
Information on internal (core) and surface (skin) temperatures is relayed to the 
MPOAH which then coordinates the appropriate response.  This area is often 
related, conceptually, to a thermostat, which initiates heat generation when it 
is “too cold” and heat loss when it is “too hot”. 
As a hot flush is a transient episode of “too hot”, focus of this chapter is on the 
mechanisms employed to dispense this heat. 
Resting skin blood flow in thermoneutral environments is approximately 
250ml/min.  During exercise or heat exposure, increases in body temperature 
trigger cutaneous vasodilation, which increases the blood flow to the skin 
several fold (83).   
The vasoconstrictor system in human skin is active in thermoneutral 
environments and withdrawal of this is responsible for 10-20% of the cutaneous 
vasodilation during heating.  However, the large increases in skin blood flow are 
mediated primarily by activation of sympathetic vasodilator nerves in the skin.  
Studies from the 1950s have shown that the increase in skin blood flow with 
body heating was blocked by anaesthetic blockade of cutaneous nerves and that 
this blockade reduced skin blood flow to pre-heating levels (171).   
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The mechanism of active vasodilation also includes a moderate role for nitric 
oxide (NO). 
Therefore alterations in thresholds for vasodilation in response to core body 
temperature changes could be as a result of changes in tonic vasoconstriction, 
active vasodilation thresholds or nitric oxide levels. 
Co-transmission of an unknown neurotransmitter is also thought to be required 
for ACh mediated vasodilation, and vasoactive intestinal peptide (VIP) is also 
thought to play in role in activation of NO stimulated by histamine release from 
mast cells.  See Figure 30. 
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Figure 30: Mechanisms of cutaneous vasodilation 
Derived from; In vivo mechanisms of cutaneous vasodilation and vasoconstriction in 
humans during thermoregulatory challenges.  Kellogg, D.L.  J Appl Physiol 100: 1709-
1718.(172) 
 
It has been shown that postmenopausal women who flush have a diminished 
vasoconstrictor response to cold (72) and that they have increased blood flow to 
the forearm and hand during a flushing episode (173)  This altered (potentially 
heightened) peripheral vascular reactivity is another proposed mechanism 
responsible for the pathophysiology underlying hot flushes.   
The objective of this study was to assess vascular function in postmenopausal 
women who flush and compare it with postmenopausal women who do not flush.   
An additional aim was to study factors which might influence vascular reactivity, 
and to examine associations between hot flushes and endothelial function and 
several circulating cardiovascular disease (CVD) risk factors.  These included 
lipids and apolipoproteins, inflammatory markers and intercellular adhesion 
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molecule-1 (ICAM-1), the latter being linked to vascular dysfunction and higher 
risk of CVD and especially diabetes in several studies (127). 
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Hypothesis 
Subcutaneous microvascular reactivity is increased in postmenopausal women 
with severe flushing compared to post-menopausal women who do not flush. 
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Methods 
Participants 
A total of 32 postmenopausal women who each experience at least 20 
flushes/day and 14 non-flushing women were recruited. 
Flushing participants and controls formed part of a double-blind, cross-sectional, 
longitudinal study, whereby flushing participants were asked to take clonidine 
and placebo in a crossover design.  These results will be discussed in chapter 4.  
Baseline results comparing flushing participants to controls will be discussed in 
this chapter. 
Recruitment of volunteers followed Scottish media coverage, as well as from 
gynaecology and menopause clinics.  A number of women were also recruited 
from the West of Scotland Breast Screening Centre in Glasgow. 
Participating women were all aged 50-65 years, non-smokers, not known to be 
hypertensive, non-diabetic and not taking any drugs which could affect vascular 
function.  Menopausal status was determined by either an FSH greater than 20 
Units/Litre or amenorrhoea for 1 year or longer.   
Study Design 
All study participants were assessed at baseline using LASER Doppler Imaging 
with iontophoresis of vasoactive compounds (LDI + Ion).  Control participants had 
this measurement repeated at 4 weeks.  Blood was also obtained at the time of 
LDI assessment.  Each participant in the flushing group was requested to keep a 
‘Hot Flush’ diary for 3 weeks prior to assessment. 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 01/50704/43).  All patients 
gave written informed consent. 
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Body composition 
Measurements of body mass, height, and blood pressure were made as described 
in chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made at baseline for 
flushing and control participants.  Control participants had this measurement 
repeated at 4 weeks.  This technique is described in detail in chapter 2.   
Plasma analysis 
A fasting blood sample was taken from each participant using 21G Vacuette® 
SAFETY blood collection set + luer adapter from an anticubital vein.  Three 
samples were collected in Vacuette® gel tubes, one 9ml ethylenediamine tetra-
acetic acid (EDTA – lilac top), one 6ml lithium heparin (LiHep – green top) and 
one 4ml citrate (blue top). 
ICAM, VCAM, TNF –α, IL-6, Insulin and Adiponectin were measured by ELISA 
technique as described in Chapter 2. 
CRP, Cholesterol, Glucose, HDL, LDL, and Trig were measured by standardised 
methods at The Institute of Cardiovascular and Medical Sciences at Glasgow 
University, as described in Chapter 2. 
Statistical analysis 
Measurement of vascular responses was performed using raw values.  
Comparisons were by General Linear Model.  Because of the marked differences 
in variances between basal perfusion values and the maximal responses to the 
drugs, but the similar coefficients of variation, log10 transformation of the data 
was performed to equalise the variances and thereby permit parametric data 
analysis. 
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Log10 transformation of the plasma data were also performed to allow for 
parametric data analysis with comparison by Student’s t-test.  In addition, 
plasma data were adjusted for BMI, Age, Years since last menstrual period (LMP) 
and Parity using general linear model. 
Demographic data were analysed using Mann Whitney U test, and blood pressure 
analysis by Student’s t-test.  
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Results 
32 women with severe hot flushing and 14 women with no hot flushing, aged 
between 50 and 65, who were medically fit and were not taking drugs that might 
impact on vascular reactivity, were recruited and had LDI assessment of vascular 
reactivity of the subcutaneous vessels.   
Demographic data and body composition 
A full set of demographic characteristics were available for 29 flushing women 
and 13 control women. 
 Flush Control P 
n 29 13  
Age (years) 56 (53-61) 54 (52-57) 0.25 
Years since last menstrual 
period (LMP) 
8 (1-12) 5 (1-6) 0.15 
Smoking 0 0 1 
Body Mass Index (BMI) 25.1 (24.3-28.1) 23.0 (20.9-31.9) 0.28 
Parity 2 (0-3) 2 (2-3) 0.74 
*Systolic Blood Pressure 126.07 ± 2.67 120.25 ± 4.29 0.25 
*Diastolic Blood Pressure 70.48 ± 2.11 72.66 ± 2.34 0.61 
Table 3: Demographic characteristics of study subjects 
Data are median (interquartile range).  Statistical analysis was performed using the Mann-
Whitney U test.  All women are non-smokers and not known to be hypertensive.  *Data are 
median ± SD 
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Responses to acetylcholine (ACh) and sodium nitroprusside 
(SNP) 
Vascular reactivity for 32 flushers and 14 controls (non-flushers) was measured 
using LDI + Ion.  Data was analysed as described above.  
The response of the subcutaneous vessels was greater in women who flushed 
than in those who did not (see Figure 31).  The enhanced vascular response 
occurred following administration of both the endothelium-dependent (ACh) and 
independent vasodilators (SNP), (ACh, p = < 0.001, SNP, p = 0.001). 
 
Figure 31: Dose Response Curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in control women compared with flushing women.  
Data are mean ± SEM. 
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When comparing control participants at two time points 4 weeks apart, there is 
no difference in cutaneous microvascular perfusion for either endothelium 
dependent or endothelium independent vasodilator agent.  P=0.622 and P=0.597 
respectively (see Figure 32). 
 
Figure 32: Dose Response Curves for control group on two occasions 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in control women at baseline compared with 4 
weeks later.  Data are mean ± SEM.  
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Plasma Analysis 
Women with flushing had significantly lower HDL-cholesterol levels (P=0.02), 
lower apolipoprotein A1 (P=0.002), and higher ICAM-1 levels (P=0.03). 
These results were not affected by adjustment for body mass index (BMI), age, 
years since last menstrual period (LMP) and parity:  HDL-cholesterol (P=0.007), 
Apolipoprotein A1 (P<0.001), and I-CAM (P=0.05).  See Table 4. 
  
  121 
 Flushing Control P Adjusted 
P 
R-Sq 
(%) 
Cholesterol 
(mmol/l) 
5.77 (5.01-6.35) 5.93 (5.05-6.57) 0.91 0.97 6.86 
Triglyceride 
(mmol/l) 
1.17 (0.82-1.73) 1.09 (0.82-1.53) 0.83 0.97 11.33 
Low Density 
Lipoprotein (LDL)-
cholesterol 
(mmol/l) 
3.51 (2.92-4.42) 3.17 (2.63-4.30) 0.29 0.29 14.14 
High Density 
Lipoprotein (HDL)-
cholesterol 
(mmol/l) 
1.46 (1.21-1.76) 1.84 (1.51-2.10) 0.01 0.01 40.17 
Total Cholesterol 
to HDL-cholesterol 
ratio 
3.77 (3.08-4.74) 2.98 (2.59-3.73) 0.02 0.04 26.33 
Apolipoprotein A1 
(mg/dl) 
155.30 (146.2-
170.7) 
194.80 (172.4-
200.3) 
<0.001 <0.001 94.81 
Apolipoprotein B 
(mg/dl) 
78.30  
(71.0-104.7) 
80.40  
(63.0-100.5) 
0.23 0.29 11.01 
Insulin (mu/l) 5.69 (3.48-9.16) 6.17 (5.27-8.68) 0.59 0.67 22.99 
Glucose (mmol/l) 5.30 (5.10-5.60) 5.60 (5.25-5.85) 0.68 0.69 29.14 
Adiponectin 
(mg/ml) 
11.6 (8.6-15.1) 11.7 (9.7-14.7) 0.38 0.48 11.51 
C-Reactive Protein 
(CRP) (mg/l) 
1.70 (0.64-5.85) 0.90 (0.35-1.42) 0.07 0.18 19.7 
Inter-Cellular 
Adhesion Molecule 
1 (ICAM-1) (ng/ml) 
243 (202-263) 187 (164-228) 0.02 0.05 18.87 
Table 4: Plasma analysis 
Data are median (interquartile range).  Statistical analysis was performed using Student’s t-
test on log transformed data.  Adjusted P calculated using general linear model to adjust for 
BMI, Age, Years since last menstrual period (LMP) and Parity. 
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Correlations 
In the control group HDL-cholesterol also correlated with vascular reactivity as 
measured by AUC for the ACh response (P=0.01, R-Sq 48.3%), but not in the flush 
group.  Again, this relationship remained significant when adjusted for body 
mass index (BMI), age, and waist hip ratio (WHR), P=0.035, R-Sq 60.7%. Also, Apo 
B was inversely related to Ach mediated vascular reactivity in the control group 
(P=0.02, R-Sq 46%, and adjusted P=0.004, R-Sq 80.8%) (see Figure 33). 
 
Figure 33: ACh corrected AUC correlation with HDL Cholesterol and Apolipoprotein B in 
control participants 
Correlation plots and regression lines with 95% confidence intervals for ACh corrected AUC 
and HDL cholesterol and Apolipoprotein B in control participants.  
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 Flush ACh Control ACh Flush SNP Control SNP 
 P R sq P R sq P R sq P R sq 
Cholesterol 0.69 0.6 0.10 4.7 0.8 0.2 0.76 1 
Triglyceride 0.67 0.7 0.26 12.6 0.22 5.5 0.82 0.6 
LDL 0.51 1.7 0.06 30.9 0.76 0.4 0.66 2 
HDL 0.69 0.6 0.01 48.3 0.4 2.7 0.50 4.7 
ApoA1 0.87 0.1 0.09 25.7 0.43 2.3 0.35 8.9 
ApoB 0.52 15 0.02 46 0.94 0 0.43 6.4 
Insulin 0.35 3.2 0.21 15.4 0.79 0.3 0.67 1.9 
Glucose 0.58 1.1 0.86 0.3 0.98 0 0.80 0.7 
Adiponectin 0.78 0.3 0.53 4.1 0.48 1.9 0.91 0.1 
CRP 0.46 2.0 0.50 4.6 0.17 6.9 0.79 0.7 
ICAM-1 0.15 7.6 0.75 1 0.08 11 0.47 5.3 
 
Table 5: Correlations of vascular reactivity as determined by corrected area under the curve 
(AUC) and plasma results. 
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Summary of results 
Responses to acetylcholine (ACh) and sodium nitroprusside 
(SNP) 
The response of the subcutaneous vessels was greater in women who flushed 
than in those who did not for both endothelium dependent and independent 
measures.  
There was no difference in endothelium dependent or independent responses in 
control participants at two time points 4 weeks apart.   
Plasma analysis 
Women with flushing had significantly lower HDL-cholesterol, lower 
apolipoprotein A1 and higher I-CAM levels when compared to controls. 
In the control group HDL-cholesterol correlated with endothelium dependent 
vascular reactivity and Apolipoprotein B inversely correlated with the same. 
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Discussion 
In this group of postmenopausal women, those with severe flushing have a 
greater vasodilator response than those women with no flushing.  This is in 
keeping with previous studies showing a diminished vasoconstrictor response, 
and increased blood flow during a hot flush (72, 173).  The alteration to their 
vascular function seems to be an increased vasodilatory response in comparison 
with asymptomatic women  
This increase has been demonstrated to be present in both the endothelium 
dependent (ACh) and independent (SNP) responses.  It is therefore possible to 
suggest that there is an increased response of the vascular smooth muscle to the 
NO donated by SNP compared to asymptomatic postmenopausal women.  Sodium 
nitroprusside dissociates in the circulation to release NO, which activates 
guanylate cyclase in vascular smooth muscle and increases intracellular 
production of cGMP.  cGMP stimulates calcium movement from the cytoplasm to 
the endoplasmic reticulum and reduces calcium available to bind with 
calmodulin. Vascular smooth muscle then relaxes and vessels dilate. 
Endothelium dependent responses are also increased this group of flushing 
women compared with non-flushing women as a result of administration of 
acetylcholine which acts to stimulate NO production by endothelial cells, by 
binding to muscarinic receptors.  However, the endothelial produced NO must 
still act upon vascular smooth muscle to have a response.  Therefore, in order to 
examine the endothelial response in isolation, the vascular smooth muscle 
response can be removed from the equation by analysing the difference in the 
ACh and SNP response, no variation was found.  It is possible, then, that the 
enhanced response in the flushing group, is due purely to an increased 
vasomotor smooth muscle response. 
It is also possible that there are other endothelial derived factors activated that 
may cause vasodilation.  Prostacyclins may be involved, since administration of 
aspirin prior to LDI, leads to reduced endothelial dependent responses following 
both oral (174) and intravenous (175) aspirin, although this has not been 
demonstrated by all studies (151, 154).   
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Electrically induced vasodilation has also been implicated, however, the vehicle 
0.5%NaCl and the chamber size used have been shown to minimise an 
electrically induced hyperaemic response.  Furthermore, application of a local 
anaesthetic agent in an attempt to eliminate the ‘axon reflex’ thought to be a 
possible cause of electrically induced hyperaemia did diminish this response, but 
also caused vasoconstriction (156), therefore any vasodilatory effects would be 
superimposed upon already vasoconstricted vessels. 
This apparently ‘better’ vascular response in women who flushed excessively 
may be anticipated to suggest a protective phenotype against vascular risk since 
impaired skin microvascular function has been linked to several conditions 
associated with greater CVD risk to include diabetes (176), maternal obesity 
(177), and hypercholesterolaemia (178) as well CAD itself (179).   However, by 
contrast, results of recent studies suggest the presence of menopausal flushing 
may be a marker of cardiovascular risk, as marked by reduced flow-mediated 
dilation (brachial artery) and greater aortic calcification in flushers in the Study 
of Women’s Health Across the Nation Heart Study (180).  To examine these 
issues in more details, CVD risk factors in these women were examined.    
Women who flushed in the present study had lower levels of HDL-cholesterol and 
ApoA1, and higher levels of ICAM-1 than asymptomatic women. Recent work 
from the Emerging Risk Factor Collaboration, which represents the most 
complete lipid-CVD risk analyses performed anywhere, has shown that greater 
non-HDL-cholesterol (or total cholesterol) but lower HDL-cholesterol are strong 
and independent risk factors for vascular disease in both men and women (181) 
thereby in keeping with greater vascular risk over the long term. 
The blood and vascular data therefore appear contradictory, but can they be 
explained? 
It could be said that these women have an imbalance between endothelium-
derived vasodilators that have anti-thrombotic and antimitogenic properties and 
vasoconstrictors with proatherogenic activity (182).  However, greater 
vasodilatory response is usually considered a sign of vascular health. 
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Endothelium-derived NO is now recognised to be an anti-inflammatory and anti-
arteriosclerotic molecule; mice lacking the endothelial-type NO synthase gene 
exhibit hypertension and enhanced vascular remodelling in response to injury 
(183).  One possibility is that these postmenopausal flushing women are at 
increased risk of cardiovascular disease compared with their non-flushing 
counterparts and have reduced synthesis of NO as a result of endothelial 
dysfunction, and as a result of this have increased sensitivity to NO and 
therefore when exposed to NO, have a greater vasodilatory response. 
The study by Bechlioulis and colleagues (184) found that women in the early 
stages of menopause had endothelial dysfunction, but that this was not 
associated with a change in plaque size, as the carotid intima-media thickness 
was comparable to that in the premenopausal controls.  Perhaps the results of 
the present study indicate an increased response to NO due to increased 
sensitivity as a result of longer term underlying endothelial dysfunction leading 
to decreased NO synthesis. 
Although there appeared to be no endothelial dependent variation between 
groups when the difference in independent and dependent responses were 
examined, it is possible that the increased response which was smooth muscle 
driven, is superimposed on a background of early endothelial dysfunction that 
will become more apparent with time. 
As with Findings from the Study of Women’s Health Across the Nation Heart 
Study (180), Gambacciani (185) found arterial blood flow was altered only in 
women with hot flushes.  This too, is in support of Bechlioulis (184) as they also 
demonstrated that severity of flushes was the most important independent 
predictor of endothelial dysfunction.   
However, flow mediated dilation (FMD) is expressed as percentage change 
meaning that a larger percentage change will occur with a small diameter 
increase in a narrow vessel, than the same increase in a vessel with a higher 
baseline lumen diameter.  It is possible then that flushers overall have more 
dilated brachial arteries to begin with, which would be consistent with the 
results of the present investigation. 
  128 
Also, it is possible that smaller diameter cutaneous vessels and the vasodilation 
that has been found to be associated with hypooestrogenism (186), cannot be 
extrapolated to larger vessels such as those studied using the flow mediated 
dilation (FMD) technique. 
While measures of peripheral vascular function are used as surrogate markers for 
coronary vascular function, there is a paucity of data showing any clear 
correlation.  This may be as a result of the difference in size of vessels studied.  
However there is evidence demonstrating that peripheral vascular function acts 
a prognostic tool.  Impaired brachial artery FMD predicts cardiac events in 
hypertensive postmenopausal women(187).   We have demonstrated in our 
group, a positive correlation between HDL and ACh-mediated vasodilation in the 
control group, as well as a negative correlation for ApoB.  This may give further 
credence to the use of peripheral vascular function as a surrogate for coronary 
vascular function, in women without flushing.  Further, larger, studies would, of 
course, be required. 
Women with climacteric symptoms have a lower level of plasma antioxidant 
activity (188), and oxidative stress is associated with cardiovascular risk.  Leal 
also demonstrated that HRT decreases oxidative stress in addition to decreasing 
number of flushes.  A recent review (189) suggested that a possible reason for 
the opposite effects of the beneficial effect of HRT in younger women within the 
first year of use (190) and detrimental effects in women distant to the 
menopause may be as a result of genuinely altered vascular reactivity making 
them vulnerable to the effects of HRT. 
Although total cholesterol, elevated LDL-C and low HDL-C are well established 
risk factors for cardiovascular disease (CVD), an association with endothelial 
dysfunction has not been consistently demonstrated. It is also possible that there 
is an uncoupling of central and peripheral control, with impulses from the 
hypothalamus overshadowing peripheral responses. Whatever, the mechanisms 
for this discrepancy between microvascular function and CVD risk factors, in 
particular lipids, the link between CVD risk factors and outcomes is of course far 
better established and thus the results more informative about future risk.  
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Chapter 4 
Alpha-adrenergic system 
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Introduction 
As already demonstrated in Chapter 3, postmenopausal women with severe 
flushing have shown an increased vasodilator response when compared to those 
women with no flushing.   
Physiological thermoregulation in humans, described in great detail by 
Charkoudian (83), comprises changes in heat dissipation (cutaneous 
vasodilatation and sweating) and heat generation (shivering) in response to 
various internal and external stimuli.   
During exercise or heat exposure, increases in body temperature trigger 
cutaneous vasodilatation and sweating, concurrently the evaporation of sweat 
decreases skin temperature thereby cooling the blood in dilated skin vessels 
before it returns to the core.   
In the human, cutaneous circulation is controlled by sympathetic adrenergic 
vasoconstrictor nerves and sympathetic vasodilator nerves.  Sympathetic 
vasoconstrictor nerves release noradrenaline, which interacts with postsynaptic 
α1—and α2-receptors on cutaneous arterioles.  In addition, these nerves release 
one or more co-transmitters that also cause vasoconstriction.  Within a 
thermoneutral environment, there is tonic activation of the vasoconstrictor 
system.  Withdrawal of the activity of this system during hyperthermia is 
responsible for 10% to 20% of the cutaneous vasodilatation, whilst large increases 
in skin blood flow are mediated primarily (80-90%) by activation of sympathetic 
vasodilator nerves in the skin (83). 
Local cooling stimulates the mobilisation of α2-receptors from the Golgi 
apparatus to the vascular smooth muscle plasma membrane (191) and human 
studies have demonstrated inhibition of cold-induced vasoconstriction during 
iontophoresis of α2-antagonist to the dorsal aspect of the finger (192). 
Whilst peripheral vasculature may be amongst the mediators of 
thermoregulation, the control centre is the preoptic area of the hypothalamus 
and noradrenaline is thought to be the primary neurotransmitter responsible for 
lowering the thermoregulatory set point here, triggering hot flushes (55, 64). 
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Animal studies have shown that intrahypothalamic injection of noradrenaline 
acts to narrow the thermoregulatory zone (86).  It has also been shown that 
plasma levels of the norarenaline metabolite 3-methoxy-4-hydroxyphenylglycol 
(MHPG) are significantly increased both before and during hot flush episodes in 
postmenopausal women (59). Hot flushes can be provoked in symptomatic 
postmenopausal women with the α2-adrenergic antagonist yohimbine, and 
ameliorated with clonidine, an α2-adrenergic agonist (93).  
 It has also been 
demonstrated that clonidine acts to widen the thermoregulatory zone in humans 
(91, 92). 
Clonidine is an α2-adrenergic agonist which is licensed for the treatment of 
hypertension, migraines and postmenopausal vasomotor symptoms. Clonidine is 
thought to exert its hypotensive effect through stimulation of α-adrenergic 
receptors in the vasomotor centre of the medulla (193).  It has also been shown 
to have a beneficial effect on menopausal flushing (194-196), in particular by 
decreasing the intensity of the flushes.  The mechanism is not fully understood, 
however it may exert its effect on hot flushing through a reduction in peripheral 
vascular reactivity (102) and also through central mechanisms. 
The aim is to study the role of the alpha-adrenergic system at a peripheral level 
utilising clonidine and its effect on flushing. 
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Hypothesis 
Subcutaneous microvascular reactivity is altered in flushing postmenopausal 
women on successful treatment of their flushes with clonidine when compared 
to placebo. 
  134 
Methods 
Participants 
A total of 32 postmenopausal women who each experienced at least 20 
flushes/day were recruited to participate in this study.  Recruitment of 
volunteers followed Scottish media coverage, as well as from gynaecology and 
menopause clinics.  A number of women were also recruited from the West of 
Scotland Breast Screening Centre in Glasgow. 
Participating women were all aged 50-65 years, non-smokers, not known to be 
hypertensive, non-diabetic and not taking any drugs which could affect vascular 
function.  Menopausal status was determined by either an FSH greater than 20 
Units/Litre or amenorrhoea for 1 year or longer.   
Study Design 
This was a double-blind, cross-sectional, longitudinal study of crossover design.  
Study participants were all seen at baseline when skin blood flow was assessed 
using LASER Doppler Imaging with Iontophoresis (LDI + Ion) of vasoactive 
compounds.  Participants were randomised in a double-blind manner to receive 
either Clonidine 0.1mg/day or placebo and after 4 weeks, LDI + Ion was assessed 
as before.  The participants were then crossed over to receive the alternate 
treatment for 4 weeks and LDI + Ion assessment performed for the final time 
(see Figure 34).   
A washout period between treatments was not required as Clonidine has a short 
half life and any effects upon peripheral vascular reactivity are likely to be 
rapid.  Qualitative measures were obtained at the same time points. 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 01/50704/43).  All patients 
gave written informed consent. 
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Figure 34: Study design 
 
Body composition 
Measurements of body mass, height, and blood pressure were made as described 
in Chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made at baseline and after 
4 weeks of treatment with each of clonidine and placebo in a cross-over design.  
This technique is described in detail in chapter 2.   
Hot flush diary 
Each participant was asked to keep a ‘Hot Flush’ diary for 3 weeks prior to initial 
assessment and throughout the study, as described in detail in Chapter 2. 
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Qualitative Measurements 
Greene Climacteric Scale 
Each participant completed this questionnaire at each visit as described in 
Chapter 2. 
Statistical analysis 
Measurement of vascular responses was performed using raw values.  
Comparisons were by General Linear Model.  Because of the marked differences 
in variances between basal perfusion values and the maximal responses to the 
drugs, but the similar coefficients of variation, log10 transformation of the data 
was performed to equalise the variances and thereby permit parametric data 
analysis 
Demographic data were analysed using Mann Whitney U test, and blood pressure 
analysis by Student’s t-test.  
Diary data, HFRDIS and qualitative data were compared using Wilcoxin Signed 
Rank test of paired non-parametric data.  Diary data included analysis of mean 
number of flushes per day, hot flush score and night time awakening. 
For comparison of clonidine and placebo treatment, neither log nor square root 
transformation resulted in a Gaussian distribution.  Therefore graphs are 
presented as raw – baseline perfusion values and analysis of the data was by 
Mann Whitney analysis of the corrected area under the curve (AUC); that is the 
AUC calculated from raw values with the baseline data subtracted. 
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Results 
32 women with severe hot flushing, aged between 50 and 65, who were 
medically fit and were not taking drugs that might impact on vascular reactivity, 
were recruited and had LDI assessment of vascular reactivity of the 
subcutaneous vessels.  Following initial assessment, 7 women declined continued 
participation in the study; therefore there is data for 25 women comparing 
clonidine to placebo. 
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Demographic characteristics 
Full demographic criteria can be seen below in Table 6. 
 Flush 
n 25 
Age (years) 59 (55-63)[51-65] 
Years since last menstrual 
period (LMP) 
8 (2.3-10.8)[0.3-23] 
Smoking 0 
Body Mass Index (BMI) 25.5 (24.2-28.4)[22.3-37.2] 
Parity 2 (0-3)[0-5] 
*Systolic Blood Pressure 126.8 ± 14.4 
*Diastolic Blood Pressure 72.3 ± 11.23 
Table 6: Demographic characteristics 
Data are median (interquartile range)[range].  *Data are mean ± SD 
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Responses to acetylcholine (ACh) and sodium nitroprusside 
(SNP) 
There was no difference in the response of subcutaneous vessels when 
comparing treatment with clonidine to treatment with placebo in either the 
endothelium dependent or independent response (P=0.98 and P=0.50 
respectively, Mann Whitney) (see Figure 35). 
On examination of the baseline LDI assessment (i.e. no treatment), there was a 
statistically significant increase in AUC with both clonidine and placebo during 
administration of the endothelium dependent vasodilator (P=0.04 and 0.01 
respectively, Mann Whitney).  This did not appear to be present during 
administration of endothelium independent vasodilator (P=0.29 and 0.06 for 
clonidine and placebo respectively, Mann Whitney) (see Figure 35). 
 
Figure 35: Dose Response Curve 
Flux raw – baseline values (perfusion units) with increasing charge for acetylcholine and 
sodium nitroprusside in flushing women when treated with clonidine and compared to 
treatment with placebo and to baseline.  Data are mean ± SEM.  As described in text, data 
are analysed as AUC and compared by Mann Whitney.  P values for clonidine vs placebo are 
0.98 and 0.50 for Ach and SNP respectively.  P values for clonidine vs baseline are 0.04 and 
0.29 for Ach and SNP respectively.  P values for placebo vs baseline are 0.01 and 0.06 for 
Ach and SNP respectively.  
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As there appeared to be a consistent difference between groups the difference 
was calculated and the analysis repeated.  There was no significant difference 
detected.  (clonidine vs placebo: p=0.85, clonidine vs baseline: p=0.095, and 
placebo vs baseline; p=0.22) (see Figure 36). 
 
Figure 36: Dose Response Curve 
Endothelial response (difference between endothelium dependent and independent 
responses).  Clonidine vs Placebo; p=0.85.  Clonidine vs Baseline; p=0.095.  Placebo vs 
Baseline; p=0.22.  Data are mean ± SEM. 
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Hot Flush Diaries 
In this group of women, for the duration of this study, there was no statistically 
significant improvement in either the number or severity of flushes when 
comparing clonidine to placebo (P=0.21).  However, when examining clonidine 
against baseline (no treatment) there was a reduction in the number of flushes 
experienced (P=0.02) and the severity of the flushes also appeared to be 
reduced (P=0.01).  There was no improvement in night time awakening or hot 
flush related daily interference (see Table 7). 
    P values 
 Placebo Clonidine Baseline P vs C C vs B P vs B 
Flush 
frequency(mean 
flush/day) 
5.2 
(2.6,18.8) 
4.4 
(0.7, 19.4) 
6.1 
(3.1, 17.6) 0.21 0.02 0.25 
Night time 
awakening (NTA) 
2.7  
(0.4, 5.3) 
2.5  
(0.6, 4.31) 
2.5  
(0.63, 4.7) 0.45 0.79 0.73 
Hot flush related 
daily interference 
score (HFRDIS) 
37.3  
(2.7, 89.3) 
33.8  
(5.0, 100.0) 
44.2  
(8.5, 89.0) 0.50 0.43 0.70 
Hot flush score 
11.9  
(4.4, 56.3) 
8.9  
(0.6, 58.2) 
12.1  
(5.7, 52.9) 0.13 0.01 0.40 
Table 7: Statistical comparison of placebo, clonidine and baseline 
Flush/day = total number of flushes/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  Hot flush score = mean daily flush frequency 
multiplied by mean score.  A mean was taken of the weeks completed.  NTA (night time 
awakening) = total number of NTA/week divided by the number of diary days completed, and 
a mean taken of the weeks completed.  HFRDIS (hot flush related daily interference scale) 
was completed once per diary week, and a mean was taken of the weeks completed.  
Placebo and Clonidine weeks, diaries were completed for 4 weeks each, and baseline 
diaries were completed for 3 weeks.   
Data are P values determined by Mann Whitney analysis of mean values as demonstrated in 
table 2. 
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Qualitative Data 
Greene Climacteric Scale 
GCS Scores were significantly lower following treatment with clonidine than at 
baseline (P=0.001), and were significantly lower following treatment with 
clonidine than following treatment with placebo (P=0.01).  However, there was 
no difference when comparing placebo to baseline scores (P=0.48).  This held 
true when examining only the scores relating to vasomotor symptoms (P=0.002, 
0.004, and 1 respectively) (see Figure 37). 
 
Figure 37: GCS in flushing women comparing clonidine, placebo and baseline 
Total GCS scores; Clonidine vs Baseline P=0.001, Clonidine vs Placebo P=0.01, and Placebo 
vs Baseline P=0.48.  Vasomotor scores; Clonidine vs Baseline P=0.002, Clonidine vs 
Placebo P=0.004, and Placebo vs Baseline P=1.  Wilcoxin Signed Rank test of paired data. 
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Summary of Results 
Responses to acetylcholine (ACh) and sodium nitroprusside 
(SNP) 
There was no difference in the response of subcutaneous vessels when 
comparing treatment with clonidine to treatment with placebo in either the 
endothelium dependent or independent response. 
There was a statistically significant increase in AUC with both clonidine and 
placebo from baseline during administration of the endothelium dependent 
vasodilator but not with the endothelium independent vasodilator. 
Diary data 
Clonidine vs. Placebo 
There was no improvement in either the number or severity of flushes. 
Clonidine vs. Baseline 
There was a reduction in the number and severity of flushes. 
Placebo vs. Baseline 
There was no improvement in number or severity of flushes. 
Qualitative Data 
Green Climacteric Scores were reduced from baseline with clonidine.  There was 
no difference with placebo from baseline, and clonidine was better than 
placebo. 
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Discussion 
Dilation of cutaneous vessels, with resultant increase to blood flow, is a 
hallmark of flushing.  This resembles a heat dissipation response, whereby 
increases in core temperature trigger nonevaporative heat loss through 
vasodilation of subcutaneous vessels.  In the rat, cutaneous vasodilation of the 
tail is a primary mechanism of thermoregulation and it has been shown that 
after ovariectomy, tail skin temperature increases, and that this effect can be 
abolished by treatment with oestrogens (197).  Furthermore, castration in rats is 
associated with increased hypothalamic noradrenaline levels (198) and oestrogen 
replacement decreases turnover (95). 
Monoamines, especially noradrenaline (NA), have been shown to play an 
important role in the control of thermoregulation.  Noradrenergic stimulation of 
the pre-optic area of the hypothalamus in monkeys (87) and baboons (88) by 
microiontophoretic application of NA causes peripheral vasodilation, heat loss 
and a drop in core temperature, similar to changes which occur in women during 
hot flushes. 
This is consistent with NA involvement in hot flushes, which is further supported 
by clinical data showing that clonidine, an α2-adrenergic agonist that reduces 
brain NA, reduces hot flush frequency.  Yohimbine, an α2-adrenergic antagonist 
has also been shown to provoke hot flushes (93). 
Whilst clonidine did decrease the number and intensity of flushes in our group of 
women, this was not significant when compared to placebo.  This is perhaps not 
surprising as a recent meta-analysis examining ten trials comparing clonidine to 
placebo found only 4 showed an improvement in number and severity of flushing 
and 2 out of 4 were of poor quality (120). 
What is surprising, perhaps, is the increase in vascular reactivity seen with both 
clonidine and placebo when compared to baseline measurements, with no 
difference between the two treatments.   
The placebo effect is well documented, and in randomised controlled trials 
(RCTs) is designed to assess the efficacy of the potential treatment.  The 
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magnitude of the placebo response is found to be partly dependent on the 
condition.  In studies of anti-depressant medications, placebo response rates 
average approximately 30%, ranging from 12% to more than 50% and in RCTs of 
hormone therapy for vasomotor symptoms in menopause, the placebo response 
rate averages 51% (199).  This may explain the subjective diary results and it has 
been suggested that if harnessed reliably, the placebo response, may enhance 
treatment outcomes (200). 
The increase in cutaneous microvascular perfusion seen after 4 weeks of 
treatment with placebo is more difficult to explain.  The placebo effect is well 
recognised and long studied in analgesia and it was in 1978 that endogenous 
opioids were first shown to be involved in placebo analgesia.  Levine et al 
demonstrated that the opiate antagonist naloxone was able to reduce the 
placebo response in dental postoperative pain (201).  Since then, placebo and 
placebo-related effects have been analysed and specific mechanisms at both the 
biochemical and cellular level have been uncovered.  Benedetti has conducted 
an extensive review of a number of these mechanisms, and amongst them is a 
reduction of β-adrenergic activity of the heart, changes of metabolic responses 
in different brain regions (possibly inhibition of serotonin reuptake), as well as 
modulation of immune factors including IL-2 and IFN-γ (202).  It is therefore 
possible that placebo treatment could affect peripheral vascular reactivity, but 
this would clearly require further study. 
Equally, the peripheral effects of clonidine are not clear.  Ginsburg et al, found 
that an increase in forearm blood flow induced by intravenous infusion of 
adrenaline, angiotensin and noradrenaline was significantly less in women 
treated for at least 6 weeks with clonidine compared with that induced in the 
women by infusions given before treatment. (101). However, these results would 
seem to contradict these.  One possible explanation is that the treatment 
duration in this study (4 weeks) was insufficient to elicit peripheral 
vasoconstriction.  However, a more likely explanation may relate to differences 
in methodology.  Ginsburg used venous occlusion plethysmography to measure 
hand and forearm perfusion but, for the forearm, overall change in perfusion 
will be much more strongly influenced by change in blood flow to the forearm 
muscles, rather than the skin.  However, the LDI + ION methodology only 
assesses skin perfusion, and is therefore more appropriate for studies of flushing.  
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Ginsburg et al found that constrictor responses in the hand were unchanged.  
Hand perfusion would be less affected by muscle blood flow as there are fewer 
muscles, and may therefore be more comparable with these results.   
One could argue that a 4 week duration following commencement of clonidine 
was too long to see the peripheral vasoconstriction that might be elicited by the 
treatment as this anti-hypertensive agent has a dual action.  When first 
administered, clonidine stimulates peripheral α1-adrenoceptors (ARs) resulting 
in vasoconstriction, but subsequently acts on the central ARs to inhibit 
sympathetic drive resulting in vasodilation (203).  The central action 
predominates over the peripheral, therefore perhaps any initial decrease in 
cutaneous microvascular perfusion that there may have been is now overridden 
by the centrally mediated and predominant vasodilatory effect.   
This may in fact, explain the increase in perfusion responses seen in our group of 
women after 4 weeks of clonidine, and may explain why anecdotally there often 
appears to be an initial improvement in symptoms followed by a return of 
vasomotor symptoms. 
However, clonidine is used for postoperative shivering because it is thought that, 
like general anaesthetic agents and sedatives, it decreases shivering thresholds 
by a generalised impairment of central thermoregulatory control (91).  These 
same authors also demonstrated that clonidine administration increased the 
sweating threshold.  They went further to suggest, that as the thermoregulatory 
effects of clonidine resembled those of volatile anaesthetics, it was likely that 
the alteration in the shivering and sweating thresholds were as a result of 
central thermoregulatory inhibition (92).   
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Chapter 5 
Serotonin 
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Introduction 
We have already demonstrated that postmenopausal women with severe flushing 
have a greater vasodilator response than matched women with no flushing (see 
Chapter 3).  This seems logical, as one of the hallmarks of hot flushes is the 
dilatation of cutaneous vessels, which results in increased blood flow (flushing, 
increased skin temperature and nonevaporative heat loss.   
However, it is generally accepted that oestrogens promote cutaneous 
vasodilation and therefore heat dissipation (83), and in this study, in an 
environment that is likely to be relatively oestrogen deficient for all, there is an 
increase in the vasodilator response in only the flushing women.  This is difficult 
to quantify accurately as postmenopausal oestradiol levels are too low to 
measure with routine laboratory tests, but it has previously been shown that 
circulating levels of oestrogen do not differ significantly between symptomatic 
and asymptomatic postmenopausal women (54), therefore whilst it is likely that 
oestrogen plays a part, it is certainly not alone. 
Serotonin, in addition to its extensive role as a neurotransmitter in the central 
nervous system has been implicated in thermoregulation.   
Animal studies in the 1960s suggested that increases in hypothalamic release of 
serotonin resulted in an increase in body temperature, and that control of core 
temperature was as a result of finely balanced 5-HT, adrenaline and 
noradrenaline (204, 205).  
In addition, elevated levels of serotonin with severe hyperthermia are associated 
with the drug 3,4-methylenedioxymethamphetamine (MDMA), which causes 
release of monoamines in the central nervous system, specifically elevating 
extracellular levels of serotonin. 
The 2 subtypes believed to be most closely associated with thermoregulation are 
the 5-HT1A receptor and the 5-HT2A receptor (206, 207).  Administration of 5-HT2A 
antagonists prevents hyperthermia in animal models of the serotonin syndrome, 
and direct stimulation of 5-HT2A receptor induces hyperthermia in rodents (207, 
208).  In contrast, peripheral administration of 5-HT1A agonists to humans and 
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rodents results in a reduction in core body temperature, which can be blocked 
by 5-HT1A antagonists (209, 210).  This information suggests that a balance 
between the 5-HT2A and 5-HT1A receptors might be important for 
thermoregulation in mammals.   
Sympathetic control of the cutaneous vascular bed during a febrile reaction, 
often accompanied by sweating, occurs via a pathway descending from the 
hypothalamus and basal forebrain to the spinal cord (211).  Dysfunction here 
would be in keeping with Freedman’s hypothesis.  Animal studies have also 
demonstrated that activation of inhibitory 5-HT1A receptors have been shown to 
cause a fall in body temperature associated with dilation of the cutaneous 
vascular bed (212).     
Vasodilatation, as a response to increases in core temperature, occur firstly as a 
result of loss of sympathetic tone in the subcutaneous vessels, followed by 
active vasodilatation (83).  In animal studies, 5-HT1A receptor activation causes 
dilation of the cutaneous vascular bed associated with marked inhibition of 
cutaneous sympathetic nerve activity (213), and hyperthermia has been elicited 
by activation of 5-HT2A (214). 
A hot flush resembles a heat loss mechanism, with peripheral vasodilatation and 
sweating, and we have shown that peripheral cutaneous vascular responses to 
vasoactive substances are increased in postmenopausal women with severe 
flushing (169).   
A low blood oestrogen level (as one might expect to see in postmenopausal 
women)  has been shown to correlate with a high concentration of the 5-HT2A 
receptor subtype on blood platelets (215) and an upregulation of central 5-HT2A 
receptors (216).   
Selective serotonin reuptake inhibitors (SSRI) are designed to increase the 
available serotonin at the serotonergic synapse and have been shown in placebo-
controlled trials to be effective in reducing the number and severity of hot 
flushes (120).    
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Serotonin exhibits strong vasoactive properties (217), possibly through 
stimulation of 5-HT receptors on endothelial cells (110).  Venlafaxine, too, has 
been found to be effective in reducing flushing (218) and although it is a 
serotonin and noradrenaline reuptake inhibitor, at low doses it probably acts as 
an SSRI (219).   
In an attempt to explain the involvement of 5HT and its receptors in the 
pathophysiology of a hot flush, focus has largely been on the effect that mild 
stress has on the central control of thermoregulation.  It has been suggested that 
anxiety, coffee, alcohol and small increases in ambient temperature increase 5-
HT moduline in the cortex, hippocampus and hypothalamus leading to increased 
release of 5-HT by blockade of inhibitory 5-HT1A receptors, and increased 
activation of the upregulated 5-HT2A receptors, leading to an imbalance of 
thermoregulation and activation of heat dissipation functions (see Chapter 1, 
Figure 7.) (220).   
However, the role of serotonin in central regulatory pathways is complex 
because binding at some serotonin receptors can exert a negative feedback on 
other serotonin receptor subtypes.  Thus the effect of a change in serotonin 
activity varies depending on the type of receptor activated.   
Further study is needed on the role of 5-HT and its receptors in subcutaneous 
microvascular responses, central receptor availability and their relationships 
with symptoms of the menopause (specifically vasomotor). 
This study aimed to assess the role of serotonin in flushing and the mechanism 
whereby venlafaxine improves vasomotor symptoms both peripherally, by 
examining cutaneous microvascular perfusion, and centrally by studying the 
serotonin transporter (SERT) in vivo in the human brain.  Examination of central 
SERT is made possible by using the iodine-labelled radioligand [123I] -beta-CIT, 
which binds with a high affinity to SERT (161), in combination with single photon 
emission computed tomography (SPECT). 
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Hypothesis 
The altered endothelial function of women who flush is reversed by successful 
treatment of the flushes by venlafaxine.  This is reflected in altered skin blood 
flow and vascular response to vasoactive agents, acetylcholine and sodium 
nitroprusside.  This will be correlated with alterations in central SERT 
availability.  
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Methods 
Participants 
A total of 46 women were recruited to receive venlafaxine treatment.  22 of 
these women were recruited to undergo SPECT scanning in addition to LDI + ION. 
Recruitment of volunteers followed Scottish media coverage, as well as from 
gynaecology and menopause clinics.  A number of women were also recruited 
from the West of Scotland Breast Screening Centre in Glasgow. 
Participating women were all aged 45-65 years, non-smokers, not known to be 
hypertensive, non-diabetic and not taking any drugs which could affect vascular 
function.  Menopausal status was determined by either an FSH greater than 20 
Units/Litre or amenorrhoea for 1 year or longer.   
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Study Design 
The study had a longitudinal design (see Figure 38).  At visit 1 (V1), consent was 
obtained and baseline questionnaires were completed.  At visit 2 (V2), baseline 
cutaneous microvascular perfusion was assessed using LASER Doppler imaging 
with iontophoresis  (LDI + ION), and participants returned for repeat assessment 
at V3 following 8 weeks of treatment with venlafaxine 37.5mg twice daily.  
Qualitative measures were obtained at the same time points. 
Participation in the SPECT subgroup was offered to each participant, and SPECT 
scans were carried out, in addition to LDI + ION, before treatment (V2) and after 
8 weeks of treatment (V3) 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 09/MRE00/40).  All patients 
gave written informed consent. 
 
Figure 38: Study design 
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Body Composition 
Measurements of body mass, height, waist and hip circumference, and blood 
pressure were made as described in Chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made at baseline and after 
8 weeks of treatment with venlafaxine 37.5mg bd.  This technique is described 
in detail in Chapter 2. 
Hot flush diary 
Each participant was asked to keep a ‘Hot Flush’ diary for 4 weeks prior to initial 
assessment and throughout the study, as described in detail in Chapter 2. 
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[123I] -beta-CIT Preparation and SPECT Imaging 
[123I] -beta-CIT was prepared via electrophilic iododestannylation of the 
corresponding tributylstannyl precursor (159) by Dr Sally Pimlot and is described 
in detail, together with the SPECT imaging protocol, in Chapter 2. 
SPECT Image Analysis 
Region of interest (ROI) analysis of the [123I] -beta-CIT scans, was carried out by 
an investigator blinded to the subject’s clinical history.  The ROI template 
consisted of manually drawn regions representing the brain stem/diencephalon 
ROI (referred to as the brain stem ROI below for brevity), and a reference ROI –
the occipital region.  The occipital region was chosen as the reference ROI that 
represented the nonspecific and nondisplaceable [123I] -beta-CIT uptake (i.e., 
activity not associated with binding to transporters) because it has a negligible 
density of both dopamine and serotonin transporters. 
The [123I] -beta-CIT uptake in each ROI was expressed as mean counts per pixel, 
and the specific uptake of [123I] -beta-CIT was calculated as:  
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Transporter binding ratio for SERT was then defined as the ratio of specific 
uptake to uptake in the occipital reference region using the formula:   
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Under equilibrium conditions the binding ratio is proportional to transporter 
binding potential, and provided transporter affinity and nonspecific binding are 
invariant across subjects, the ratio is then a measure of transporter availability 
(Bmax). 
  
  156 
Qualitative Measurements 
Greene Climacteric Scale 
Each participant completed this questionnaire at visit 2 and visit 3 as described 
in Chapter 2. 
Becks Depression Inventory 
Each participant completed this questionnaire at visit 2 and visit 3 as described 
in Chapter 2. 
Hospital Anxiety and Depression Scale 
Each participant who participated in the study after 16 August 2010 completed 
this questionnaire at visit 2 and visit 3 as described in Chapter 2. 
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Plasma analysis 
A fasting blood sample was taken from each participant using 21G Vacuette® 
SAFETY blood collection set + luer adapter from an anticubital vein.  Three 
samples were collected in Vacuette® gel tubes, one 9ml ethylenediamine tetra-
acetic acid (EDTA – lilac top), one 6ml lithium heparin (LiHep – green top) and 
one 4ml citrate (blue top). 
A small volume was removed from the 6ml lithium heparin sample before 
centrifuge and storage as described in Chapter 2.   
ICAM, VCAM, TNF –α, IL-6, Insulin and Adiponectin were measured by ELISA 
technique as described in Chapter 2. 
CRP, Cholesterol, Glucose, HDL, LDL, and Trig were measured by standardised 
methods at The Institute of Cardiovascular and Medical Sciences at Glasgow 
University, as described in Chapter 2. 
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Statistical analysis 
Measurement of vascular responses, in the whole group, was performed using 
raw values.  Comparisons were by General Linear Model.  Because of the marked 
differences in variances between basal perfusion values and the maximal 
responses to the drugs, but the similar coefficients of variation, log10 
transformation of the data was performed to equalise the variances and thereby 
permit parametric data analysis. 
Diary data, HFRDIS and qualitative data, in the whole group, were compared 
using Wilcoxin Signed Rank test of paired non-parametric data.  Diary data 
included analysis of mean number of flushes per day, hot flush score and night 
time awakening. 
Statistical analysis pertaining to the SPECT group was performed using SPSS v19 
by Dr Rajeev Krishnadas.  A paired-samples t-test was conducted to compare the 
means of Beta-CIT uptake, BDI scores, Flush frequency, ACh - AUC, SNP – AUC, 
Flush score, HFRDIS and NTA, before and after treatment with Venlafaxine. 
Mean difference of scores, the 95% CI of the mean differences and effect sizes 
(Cohen’s d) were also calculated (162).  
Percentage change (reduction) in each of the above variables from baseline was 
calculated using the formula:  
			 = 	
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	× 100 
where X is the variable of interest ([123I] -beta-CIT binding ratio; BDI scores; 
Flushing frequency; Flushing score; ACh-AUC; SNP-AUC). 
The relationship between the reduction in the [123I] -beta-CIT binding ratio 
(predictor variable) and other variables (dependent) of interest - namely BDI 
reduction; Flush frequency, and score, reduction; ACh reduction; SNP reduction 
- were examined using multivariate analysis of covariance (MANCOVA) with age 
as a nuisance covariate in the model.  The p values were corrected for multiple 
testing using Holm-Bonferroni family wise error correction.  
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Results 
46 women with severe hot flushing were recruited to receive venlafaxine 37.5mg 
bd and 22 of these women were recruited to undergo SPECT in addition to LDI + 
ION.   
Participation in the SPECT subgroup was offered to each participant.  Reasons 
for not wishing to take part included the additional time required to participate; 
the procedure required an additional 2 full days at a separate unit.   The space 
inside the scanner is small; therefore claustrophobia as well as a short neck, 
and/or weight greater than 130kg were also exclusion criteria.   
Following recruitment, three participants declined continued participation prior 
to initial assessment.  A further 2 women were excluded following V1, but 
before baseline measurements; one participant was commenced on therapy by 
her GP, which excluded her from the study, the other attended for Visit 2b 
(SPECT imaging), however there was no radioisotope available and she was 
unable to return for a rescheduled appointment as a result of personal time 
constraints.   
Following V1, 1 participant experienced a syncopal episode during baseline LDI + 
Ion measurements (V2), likely as a result of fasting, and had to withdraw from 
the study.  A further 10 withdrew during the treatment period and prior to 
treatment assessment (V3).  Seven as a result of nausea, one as a result of 
improved vasomotor symptoms prior to commencement of therapy, and 
therefore declined to start therapy, and one complained of muscle spasms whilst 
on treatment and therefore discontinued (see Figure 38).  31 women completed 
LDI + Ion assessments for baseline and treatment measurements, and 14 of these 
women also completed both baseline and treatment SPECT assessments (see 
Figure 39). 
  160 
 
Figure 39: Recruitment and Participant numbers 
Figure illustrating longitudinal study design with numbers of participants in LDI + ION 
(purple circle) group and SPECT (blue circle) subgroup.  Numbers of withdrawals with 
reasons (same colour-code) illustrated.   
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Demographic Characteristics 
 Baseline LDI+ION Treatment LDI+ION SPECT 
subgroup 
n 40 31 14 
Age (years) 58 (54-63) 
[46-65] 
58 (54-62) 
[46-65] 
58 (54-60) 
[46-64] 
Years since LMP 7 (1.1-10.8) 
[0.3-20] 
7 (1-10) 
[0.3-16] 
6.5 (1.4-8.5) 
[0.3-15] 
BMI 25.8 (24.2-29.7) 
[20.7-37.1] 
26.1 (24.5-30.3) 
[21.4-37.1] 
26.9 (24.8-29.7)  
[22.1-34.6] 
WHR 0.81 (0.76-0.83) 
[0.70-0.96] 
0.80 (0.75-0.83) 
[0.70-0.96] 
0.80 (0.76-0.82) 
[0.70-0.96] 
Parity 2 (1-3) 
[0-4] 
2 (1-3) 
[0-4] 
2 (1-3) 
[0-4] 
Smoking 0 0 0 
*SBP 128.5 ± 16.1 128.2 ± 15.1 122.8 ± 12.0 
*DBP 80.1 ± 8.9 79.6 ± 8.8 77.0 ± 7.9 
Table 8: Demographic characteristics 
Data are median (interquartile range)[range].  *Data are mean ± SD 
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Responses to iontophoresis of acetylcholine (ACh) and sodium 
nitroprusside (SNP) 
Following 8 weeks of venlafaxine therapy, enhanced vascular responses are seen 
to be decreased following administration of ACh (p =0.005), but not SNP (p = 
0.400).  See figure 40. 
 
Figure 40: Dose Response Curve 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in flushing women when treated with venlafaxine 
and compared to baseline (i.e. no treatment).  Data are mean ± SEM. 
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Hot Flush Diaries 
One participant did not return either baseline or treatment diary data, and one 
further participant did not return treatment diary data. 
Diary data was calculated as follows; flush/day = total number of flushes/week 
divided by the number of diary days completed, and a mean taken of the weeks 
completed.  Hot flush score = mean daily flush frequency multiplied by mean 
score.  A mean was taken of the weeks completed.  NTA (night time awakening) 
= total number of NTA/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  HFRDIS (hot flush related daily 
interference scale) was completed once per diary week, and a mean was taken 
of the weeks completed.   
Data are presented as mean ± standard deviation to illustrate the results as 
determined by above calculations.  It is also presented as median (interquartile 
range)[range] as the data were not normally distributed.   Statistical 
comparisons were therefore made by Wilcoxon Signed Rank Analysis of paired 
data. 
Treatment with venlafaxine significantly reduced the number of (p<0.001) and 
severity of flushes (p<0.001), frequency of night time awakenings (p<0.001), and 
perception of daily hot flush interference (p<0.001) (see Table 9 and Figure 41).  
Flushes were decreased by a mean of 4.9 ± 3.1 per day.   
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 Baseline 
n=39 
Treatment 
n=29 
P 
Flush frequency 
(flush/day) 
8.2 ± 3.9 
7.7 (5.8-9.5) 
[2.1-21.2] 
4.4 ± 3.92 
3.5 (2.5-6.1) 
[0.1-13.8] 
<0.001 
Night time awakening 
(NTA) 
2.4 ± 1.1 
2.4 (1.8-3.4) 
[0.3-4.6] 
1.2 ± 0.9 
1.0 (0.4-1.8) 
[0.04-3.6] 
<0.001 
Hot flush related daily 
interference score 
(HFRDIS) 
40.7 ± 22.1 
37.3 (23.3-58.7) 
[5.3-84.7] 
19.3 ± 17.7 
14.4 (7.8-21.8) 
[1.5-72.6] 
<0.001 
Hot flush score 16.2 ± 7.9 
15.8 (10.3-20.4) 
[1.9-42.4] 
8.0 ± 8.1 
6.4 (3.2-10.8) 
[0.03-41.3] 
<0.001 
Table 9: Hot flush diary data 
Data are mean ± SD, and median (interquartile range)[range].  P values are determined by 
Wilcoxon Signed Rank analysis of paired data.   
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Figure 41: Diary data 
Data are shown as box and whisker plots with median, IQR and range. 
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Perfusion responses and their correlation with demographic and 
diary data 
To evaluate the association between perfusion responses and diary data, 
including flush frequency, flush score, hot flush related daily interference scores 
(HFRDIS) and night time awakening (NTA); the correlation between each of these 
was examined. 
Perfusion responses were assessed as area under the curve (AUC) values for raw 
data minus baseline values.  Diary data were assessed as mean values as 
described in detail in chapter 2. 
There were no correlations demonstrated for any relationship (see Figure 42 and 
Figure 43 and Table 10). 
In addition there was no relationship demonstrated between the reduction in 
perfusion responses and the reduction in flush frequency or flush score (see 
Figure 44 and Table 11). 
We did not demonstrate any significant association between perfusion response, 
for either ACh or SNP, and age, body mass index (BMI) or waist hip ratio (WHR).  
Although there may be a trend towards increasing perfusion responses with 
increasing WHR (see Figure 45 and Table 10). 
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Figure 42: Correlation of perfusion responses with flush frequency and flush score 
Correlation plots and regression lines with 95% confidence intervals for perfusion 
responses, (ACh and SNP) and flush frequency and score.   Baseline and treatment 
measurements. 
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Figure 43: Correlation of perfusion responses with HFRDIS and NTA 
Correlation plots and regression lines with 95% confidence intervals for perfusion 
responses, (ACh and SNP) and hot flush related daily interference scores (HFRDIS) and 
night time awakening (NTA).   Baseline and treatment measurements. 
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Figure 44: Correlation of decrease in perfusion response with decrease in flush frequency 
and score 
Correlation plots and regression lines with 95% confidence intervals for reduction in 
perfusion response (baseline-treatment) for ACh and SNP and their association with the 
reduction in flush frequency and flush score.  
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Figure 45: Correlation of perfusion responses with age, BMI and WHR 
Correlation plots and regression lines with 95% confidence intervals for perfusion response 
at baseline (ACh and SNP) and their association with age, body mass index (BMI) and waist 
hip ratio (WHR).  
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  ACh AUC SNP AUC 
  Baseline Treat Baseline Treatment 
  r p r p r p r p 
flush freq/day 
Base 0.114 0.491   0.013 0.937   
Treat   0.077 0.698   0.049 0.806 
score/day 
Base 0.062 0.707   0.057 0.728   
Treat   0.034 0.864   0.039 0.842 
HFRDIS 
Base -0.122 0.458   0.104 0.530   
Treat   0.018 0.926   0.018 0.924 
NTA 
Base 0.190 0.248   0.122 0.458   
Treat   0.047 0.808   -0.014 0.942 
Age  0.121 0.456   0.085 0.604   
BMI  0.097 0.553   -0.001 0.997   
WHR  0.247 0.124   0.160 0.325   
Table 10: Correlation of perfusion responses (ACh and SNP) with flush frequency, flush 
score, HFRDIS, NTA, age, BMI and WHR. 
Table illustrating correlation of perfusion responses (ACh and SNP) with flush frequency, 
flush score, HFRDIS, NTA, age, BMI and WHR.   Baseline and treatment measurements.  
Analysis was performed using Spearman’s correlation of non-parametric data. 
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 ACh decrease SNP decrease 
 r-value p-value r-value p-value 
Flush frequency decrease 0.239 0.204 0.200 0.289 
Flush score decrease 0.005 0.979 -0.028 0.881 
Table 11: Correlation of decrease in perfusion response with decrease in flush frequency 
and score 
Table illustrating correlation of decrease in perfusion responses (ACh and SNP) with 
decrease in flush frequency and flush score.  Analysis was performed using Spearman’s 
correlation of non-parametric data. 
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Qualitative Data 
Greene Climacteric Scale 
Assessment of climacteric symptoms was made at baseline and following 8 weeks 
of treatment and total scores were found to be significantly reduced (p<0.001). 
 
Figure 46: Greene Climacteric Scale 
Data are shown as box and whisker plots with median, IQR and range. 
 
Symptom scoring can be divided into three major independent groups (as 
described in detail in Chapter 2), vasomotor, somatic and psychological.  
Psychological symptoms can be further subdivided into symptoms relating to 
anxiety and those relating to depression.  There is an additional item on loss of 
sexual interest, which is intended as a ‘probe’ item to be followed up by more 
appropriate and sensitive evaluation of problems in that area.  When these 
independent groups were individually analysed before and after treatment, 
there was a significant reduction in all groups of symptoms (p<0.001 and p=0.04 
in loss of sexual interest).  However, the greatest reduction was seen in 
depression (70% decrease), with anxiety and total psychological scoring 
decreased by 66% and 68% respectively.  Vasomotor symptoms decreased by 57%, 
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somatic scores by 52% and loss of interest in sex scores decreased by 30%.  See 
figure 47. 
 
 
Figure 47: Deconstructed GCS 
Data shown are scores for independent groups within Greene Climacteric Scale 
(psychological, anxiety, somatic, depression, vasomotor, loss of interest in sex), before 
treatment (A), and after treatment (B). 
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Becks Depression Inventory 
Becks Depression Inventory assessments were also made at baseline and 
following treatment, total scores were reduced (p<0.001) (See Figure 48).  When 
deconstructed into the individual elements, highest scores were given to 
‘changes to sleep pattern’ and ‘loss of interest in sex’ (see Figure 49).  These 
symptoms have been described in detail in the climacteric and could be as a 
consequence of vasomotor symptoms, therefore these elements were removed 
and the analysis repeated.  Scores were still significantly lower following 8 
weeks of treatment (p<0.001). 
 
Figure 48: Becks Depression Inventory II.  Becks 2 = Becks analysis with removal of 
‘changes to sleep pattern’ and ‘loss of interest in sex’. 
Data are shown as box and whisker plots with median, IQR and range. 
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Figure 49: Deconstructed Becks Depression Inventory II 
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Hospital Anxiety and Depression Scale 
An amendment to add the Hospital Anxiety and Depression Scale questionnaire 
to the protocol was submitted 22 June 2010 and a favourable opinion was 
granted 16 August 2010.  There is evidence that low serotonin transporter 
availability is correlated with high anxiety (168) and Becks Depression Inventory 
II is not designed to assess anxiety as a separate entity from depression.  In 
addition venlafaxine is used as an approved drug treatment for generalised 
anxiety disorder.  HADS was first used in this study on 20 August 2010 and 
continued to be used for the remainder of the study.  15 participants completed 
this questionnaire. 
Total scores were reduced following eight weeks of treatment (p=0.01). 
 
Figure 50: Hospital Anxiety and Depression Scale 
Data are shown as box and whisker plots with median, IQR and range. 
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SPECT Imaging 
The results illustrated in this section pertain only to those 14 individuals who 
underwent SPECT scanning.  
Following 8 weeks of treatment with venlafaxine, there was a significant 
reduction in [123I] -beta-CIT binding (see Figure 51 and 52), BDI scores, flush 
frequency and score, HFRDIS, NTA and ACh-AUC (see Table 12). The difference 
in SNP failed to reach statistical significance. 
 
Figure 51: Specific:non-specific [123I]-beta-CIT binding ratio in the brain 
Pretreatment (Pre) and following 8 weeks of treatment with venlafaxine 37.5mg bd (Post). 
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Figure 52: Sagittal brain [123I]-beta-CIT SPECT scan images at (A) baseline and (B) 
following treatment with venlafaxine. 
Images from 2 study participants, demonstrating a reduction in [123I]-beta-CIT binding ratio 
in the brainstem in the post-treatment scans (B) from the baseline scans (A).  The arrows 
point to the brainstem and [123I]-beta-CIT uptake is depicted by the colour scale shown, 
where white is high uptake.  
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Pre – 
treatment 
(Mean; SD) 
 
Post – 
treatment 
(Mean; SD) 
Mean 
difference 
(95% CI) t p 
 
 
Cohen’s d 
(effect 
size) 
[123I] -
beta-CIT 
1.06 (0.11) 0.45 (0.16) 0.61  
(0.50-0.71) 
12.371 <0.001 3.45 
BDI 
scores 
9.21 (9.29) 4.14 (6.38) 5.07  
(1.92-8.21) 
3.487 0.004 1.09 
Flushing  
frequency 
9.88 (5.17) 4.92 (4.06) 4.96  
(3.28-6.64) 
6.388 <0.001 1.85 
Ach - 
AUC 
5.86 (3.22) 3.56 (3.32) 2.30  
(0.27-4.32) 
2.459 0.029 0.66 
SNP-AUC 3.63 (2.9) 2.95 (3.15) 0.67  
(-0.78-
2.13) 
1.004 0.334 0.27 
Flush 
Score 
18.20 (10.05) 8.6 (8.6) 9.55  
(2.8-16.25) 
3.080 0.009 0.82 
HFRDIS 39.9 (26.32) 19.15 (19.77) 20.22  
(11.28-
30.37) 
4.714 <0.001 1.36 
NTA  2.41 (1.2) 1.17 (0.93) 1.22  
(0.27-0.62) 
4.390 0.001 1.21 
Table 12: Effect of treatment with venlafaxine on variables 
t= paired t test. Cohen’s d= corrected for dependence between means using Morris and 
DeShon’s correction. BDI= Becks depression inventory.  ACh-AUC= acetylcholine-area 
under the curve.  SNP-AUC= sodium nitroprusside-area under the curve.  HFRDIS= hot flush 
related daily interference score.  NTA= night time awakening. 
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Next, a MANCOVA was performed to explore if  the reduction in the [123I] -beta-
CIT binding ratio was associated with variance in other variables of interest, 
namely BDI reduction; flush frequency reduction; flush score reduction; Ach 
reduction; SNP reduction).  Since age showed a negative correlation with BDI 
score reduction (r = -0.38); ACh-AUC reduction (r=0.62) and SNP reduction (r=-
0.65), we included age as a nuisance covariate in the model.  On the 
multivariate analysis, [123I] -beta CIT reduction was associated with significant 
variance in BDI reduction (r2 = 0.54; p=0.004), but not flush frequency reduction, 
flush score reduction, ACh-AUC reduction or SNP reduction (See Table 13). 
Dependent variables Parameter 
estimate 
(Beta) 
t p 
BDI reduction 0.69 3.66 0.004 (0.02) 
Flushing reduction 0.12 0.41 0.68 (0.68) 
Ach-AUC reduction -0.29 -1.35 0.203 (0.61) 
SNP-AUC reduction 0.11 0.50 0.62 (0.68) 
Flush score reduction 0.26 0.29 0.77 (0.78) 
Table 13: Relationship between [123I]-beta-CIT reduction and other dependent variables 
Parameter estimates represent the strength of the relationship between the predictor and 
dependent variables.  A positive beta value represents a positive association.  Predictor 
variable: [123I] -beta-CIT reduction; Nuisance covariate: Age; values in brackets 
corresponds to the p values corrected using Holm-bonferroni family wise error procedure. 
BDI=  Becks depression inventory.   ACh-AUC= acetylcholine-area under the curve; SNP-
AUC= sodium nitroprusside-area under the curve. 
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Analysis of blood samples 
Whole group analysis of blood samples was carried out, i.e. 39 participants at 
baseline and 29 participants following 8 weeks of venlafaxine. 
Haematocrit 
As the technique of LASER Doppler imaging is dependent on scattering of light by 
red blood cells, there is a theoretical confounder in haematocrit values if found 
to be significantly different in individuals.  Therefore before samples of blood 
were spun, separated and stored, a sample of whole blood was taken and 
assessed for haematocrit as described in detail in Chapter 2.  There was no 
difference detected in haematocrit in individuals between visit 2 (baseline) and 
visit 3 (treatment) (see figure 53). 
 
Figure 53: Haematocrit 
Data are shown as box and whisker plots with median, IQR and range. 
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Plasma analysis 
Plasma was analysed for HDL, LDL, Triglycerides, Glucose, total Cholesterol, 
Apolipoprotein A1 and B, ICAM and VCAM, TNFα, IL6, Adiponectin and CRP.  
Samples were taken at visit 2 before treatment was commenced (base) and 
following 8 weeks of treatment with venlafaxine (treat).  The methods are 
described in detail in Chapter 2. 
CRP was found to be significantly higher when measured after 8 weeks of 
treatment, when compared to samples taken at baseline.  No other measures 
were found to be significantly different. 
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Figure 54: Plasma analysis 
Data are shown as box and whisker plots with median, IQR and range. 
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 Baseline (n=39) Treatment (n=29) P 
HDL (mmol/l) 1.57 (1.25-1.80) 
[0.85-2.20] 
1.52 (1.29-1.81) 
[0.79-2.39] 
0.99 
LDL (mmol/l) 3.30 (2.87-3.91) 
[2.20-4.94] 
3.72 (2.95-4.20) 
[2.50-5.53] 
0.08 
Triglycerides 
(mmol/l) 
0.96 (0.78-1.18) 
[0.38-2.06] 
0.99 (0.75-1.35) 
[0.33-1.81] 
0.72 
Glucose (mmol/l) 5.36 (5.01-5.65) 
[3.76-7.95] 
5.34 (5.01-5.63) 
[4.07-7.91] 
0.85 
Cholesterol 
(mmol/l) 
5.4 (4.96-6.12) 
[3.62-7.42] 
5.65 (5.09-6.16) 
[4.14-7.46] 
0.18 
ApoA1 (md/dl) 137.6 (117.6-155.5) 
[83.9-195.3] 
142.7 (125.8-160.4) 
[78.7-196.1] 
0.10 
ApoB (mg/dl) 92.6 (85.9-105.7) 
[71.3-122.9] 
98.3 (83.9-108.6) 
[68.9-149.7] 
0.29 
ICAM (ng/ml) 233.7 (186.6-251.6) 
[149.1-418.9] 
223.0 (205.3-250.1) 
[146.0-300.4] 
0.67 
VCAM (ng/ml) 590.6 (479.2-684.5) 
[362.9-1060] 
592.9 (506.8-679.6) 
[368.6-819.2] 
0.67 
TNFα (pg/ml) 0.8 (0.6-1.1) 
[0.4-6.8] 
0.8 (0.5-1.3) 
[0.4-3.0] 
0.81 
IL6 (pg/ml) 1.3 (1.0-1.9) 
[0.3-5.8] 
1.55 (1.1-2.5) 
[0.5-10.2] 
0.16 
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Adiponectin 
(µg/ml) 
79.04 (64.05-109.3) 
[30.96-183.6] 
91.60 (72.05-127.2) 
[39.65-639.2] 
0.05 
CRP (mg/l) 1.02 (0.60-1.55) 
[0.17-13.16] 
1.12 (0.66-2.99) 
[0.28-13.59] 
0.008* 
Table 14: Analysis of plasma at baseline and following treatment 
Data shown as median (IQR)[range].  P values are determined by Wilcoxin Signed Rank 
analysis of paired data. 
* Statistically significant result 
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Summary of Results 
Perfusion response to iontophoresis of acetylcholine (ACh) and 
sodium nitroprusside (SNP) 
Venlafaxine altered skin blood flow and vascular response to vasoactive agents, 
acetylcholine and sodium nitroprusside.  
Venlafaxine and vasomotor symptoms 
Venlafaxine improved both the number and severity of flushes, and also the 
number of times women are awakened at night as a result of flushes.  Hot flush 
related daily interference scores were also improved following 8 weeks of 
treatment with venlafaxine. 
Perfusion responses and their correlation with demographic and 
diary data  
Diary data 
No relationship was demonstrated in this group between perfusion responses to 
vasoactive agents and flush frequency, severity, night time awakening or 
HFRDIS.  This was true for both baseline assessment and assessment following 8 
weeks of treatment. 
Demographic data 
No correlation has been shown between perfusion responses to vasoactive agents 
and age, BMI or WHR. 
Qualitative Data 
Green Climacteric Scores, Becks Depression Inventory Scores, and Hospital 
Anxiety and Depression Scores were all reduced following 8 weeks of treatment 
with venlafaxine. 
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SPECT Scanning 
Following 8 weeks of treatment with venlafaxine, there was a significant 
reduction in [123I] -beta-CIT binding, BDI scores, flush frequency and score, 
HFRDIS, NTA and ACh-AUC. 
[123I] -beta CIT reduction was associated with BDI reduction. 
Blood analysis 
Haematocrit 
No differences were seen within the group between baseline and treatment 
assessments. 
Plasma analysis 
CRP was found to be significantly higher when measured following treatment as 
compared to measurement at baseline.  No other significant differences were 
determined. 
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Discussion 
As already stated, oestrogen withdrawal is associated with decreased blood 
serotonin levels, which is returned to normal with oestrogen therapy (216) and it 
is well documented that serotonin has a role to play in thermoregulation.   
We have shown that treatment with venlafaxine, designed to increase available 
serotonin at the serotonergic synapse, has altered the increased perfusion 
responses seen in flushing women. 
Serotonin is widely accepted to be a potent vasoconstrictor.  Serotonin receptors 
5-HT1B, 5-HT2A, 5-HT2B, 5-HT4, and 5-HT7 are present on vascular smooth muscle 
cells and endothelial cells (221).  These receptors regulate vascular tone by 
modulating contraction and relaxation of blood vessels, depending on the 
species, type of blood vessel and status of the endothelial cell layer (112). 
It has been postulated that flushing may be more than a symptom of the 
climacteric and that it may indeed be a sign of underlying cardiovascular disease 
(180, 185).  Our group has additionally shown that peri- and postmenopausal 
women have markers of an adverse cardiovascular risk profile when compared to 
matched non-flushing women (see Chapter 4) (169). 
5-HT1A receptors have been shown to be increased in atherosclerotic vessels, and 
activation of these in diseased vessels has been shown to cause vasoconstriction.  
Therefore, if those with flushing do have underlying cardiovascular disease, with 
which atherosclerosis and endothelial dysfunction is closely linked, perhaps the 
activation of 5-HT1A receptors with increasing levels of available 5-HT, following 
treatment with venlafaxine, may play a role in the decreased vasodilatory 
response seen in endothelial measurements.  
However, we may simply be demonstrating vasoconstriction in subcutaneous 
microvascular vessels as a result of increased activation of constrictor 5-HT 
receptors in healthy endothelium.   
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Subcontractile concentrations of 5-HT have also been shown to potentiate 
arteriolar contractile response to other vasoconstrictor agents, such as 
angiotensin II, noradrenaline and endothelin-1 (222, 223). 
In addition to alterations in the perfusion responses, we demonstrated 
significant improvements in flush frequency, flush severity, night time 
awakening and hot flush related daily interference.  However, this was not 
correlated with perfusion responses. 
SSRIs have been shown in placebo controlled trials to be effective in improving 
flush frequency and severity.  In a meta-analysis (120), paroxetine performed 
well, but two studies examining venlafaxine were conflicting.  Loprinzi (218) 
demonstrated a significant reduction in flush score and flush frequency when 
compared with placebo, whereas Evans (224) reported no improvement in flush 
frequency but did report an improvement in quality of life.  51% of venlafaxine 
users had a reduction in a measure of how hot flushes interfere with daily living, 
compared with 15% of placebo users (P<0.001).   
We were also able to demonstrate significant improvements in hot flush related 
daily interference scores, as well as improvements in the Greene Climacteric 
Scale (GCS).   
Interestingly the greatest reduction in GCS was in the depression scores, and we 
also found a significant reduction in BDI II and HADS scores.  Our participants, 
however, were not depressed, and indeed a diagnosis of depression was amongst 
the exclusion criteria for the study. 
There are many studies evaluating the risk of depression and low mood during 
the menopausal transition (225-229) and its relationship to changes in 
reproductive hormones, however data are not consistent.  Depressed mood 
certainly appears amongst commonly reported menopausal symptoms along with 
hot flashes and disturbances in sleep pattern.  Some believe that alterations in 
mood are the end result of endless flushes and night sweats, leading to poor 
sleep, exhaustion and ultimately low mood.  Amongst our participants, some of 
the highest scores in BDI II were given to changes in sleep, tiredness and loss of 
energy (Figure 48).  A recent study, however, found that amongst women who 
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reported symptoms of both hot flushes and depression, it was symptoms of 
depression that were more likely to present first (230).  It might be suggested, 
however, that irrespective of which presented first, an improvement in flushing 
resulting in an improvement in sleep and energy levels would result in an 
improvement in depression scores.   
Interestingly, however, there was no relationship demonstrated between 
decreases in BDI II scores and decreases in flush frequency or severity. 
There was, however, a dramatic reduction in [123I] -beta-CIT binding ratio post 
treatment with venlafaxine and this was associated with the reduction in BDI II 
scores. 
Whilst the antidepressant efficacy of SSRIs has been reasonably well established, 
the relationship between SERT binding and antidepressant efficacy is less clear.  
There is also a substantial body of molecular imaging data demonstrating the 
effects of serotonergic antidepressants on SERT but the significance of this has 
not been determined.  In this group, a percentage reduction in SERT was 
associated with a percentage reduction in BDI.  While pharmacokinetic studies 
specify that 80% occupancy of SERT is a necessary minimum for SSRI treatment 
of depression, most studies have failed to show a direct relationship between 
antidepressant occupancy and treatment response (231).  However more recent 
studies have found that treatment response in patients with Major Depressive 
disorder (MDD) treated with SSRIs was predicted by pre-treatment SERT binding 
in a number of key regions of depression including bilateral habenula, amygdala-
hippocampus complex and subgenual cingulate cortex in relation to SERT binding 
in the median but not dorsal raphe nucleus (232).  It should also be noted that 
the mean pre-treatment scores on the BDI were in the normal range. This was 
not expected since antidepressants have been shown to be most efficacious in 
severe depression (233) and the women in our study were not considered 
depressed on recruitment.  
Whether the relationship we demonstrate are related physiologically 
(mechanistically) is unclear. It could be argued that the reduction in BDI scores 
was secondary to a reduction in flushing. However we found no association 
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between BDI reduction and flushing frequency reduction or flush score reduction 
and so this explanation seems less likely. 
This might suggest that mood and vasomotor symptoms are discrete entities with 
some overlap, and altered as such with treatment with venlafaxine.  It also 
suggests that venlafaxine may be important in mood alteration beyond its use as 
a treatment for moderate to severe depression.  
This study has focused on central SERT as an index of the central serotonergic 
contribution to postmenopausal flushing and the peripheral vascular response to 
vasoactive agents following treatment to block SERT.  Although we have not 
measured either peripheral (platelet) SERT or serum serotonin, these data 
appear to demonstrate a separation of effects of venlafaxine in the periphery 
and the centre. 
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Chapter 6 
HRT 
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Introduction 
In this study, it has been demonstrated that postmenopausal women with severe 
flushing have increased cutaneous microvascular perfusion responses to 
vasoactive agents when compared to their non-flushing contemporaries.  It has 
also been shown that successful treatment with venlafaxine decreases this 
increased response. 
However, the most commonly used treatment for vasomotor symptoms in the 
climacteric and post-menopause is hormone replacement therapy (HRT).  We 
know that the overwhelming change occurring at the time of the menopause and 
during the climacteric is reduction in production of oestrogen by the ovaries as a 
result of follicle depletion, and we know that replacing oestrogen is a most 
effective treatment for flushes. 
As already stated, it is thought that a hot flush is the result of a narrowed 
thermoregulatory zone within the hypothalamus, resulting in heat loss 
mechanisms being triggered by only small increases in core temperature (61).  
There is uncertainty surrounding the trigger for this narrowing, however it has 
been suggested that imbalances in various neurotransmitters might be 
responsible and this has been discussed in chapter 1 and chapter 4.  It has been 
further suggested that a reduction in oestrogen concentrations could result in 
imbalances of these neurotransmitters (57).  
In humans, cutaneous circulation of the head, limbs and trunk is controlled by 
two types of sympathetic neurones: adrenergic neurones control cutaneous 
vasoconstriction and cholinergic neurones control vasodilation (172).  Skin blood 
flow changes in during the menstrual cycle in women suggest that female sex 
steroids modulate the sensitivity and responses of these circuits (234). 
Whilst these circuits might control the response, the effectors of vasodilation 
include the endothelium, and there is considerable evidence that oestrogen 
influences the endothelium.  Oestrogen receptors ERα and ERβ have been 
demonstrated to be present on endothelial cell plasma membrane (235, 236) and 
studies consistently demonstrate that oestradiol binding to ERα can induce 
endothelium-dependent vasodilation in vivo.  While the classical model of 
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steroid action involves a ligand that is bound to steroid receptors then binding to 
specific response elements on target genes to regulate gene transcription, more 
recently focus has been on the pathways involved in non-genomic oestrogen-
induced activation of endothelial nitric oxide synthase (74), however the role of 
ERβ is less clear. 
Cutaneous vasodilatation is one of the hallmarks of flushing and in the rat, 
where cutaneous vasodilatation of the tail is a primary mechanism of 
thermoregulation; ovariectomy has been shown to increase tail skin 
temperature,  and treatment with oestrogens can abolish this effect (197). 
What, then, is the effect of treatment with oestrogen (HRT) on increased 
cutaneous vasodilatation in postmenopausal flushing women? 
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Hypothesis 
The altered endothelial function of women who flush is reversed by successful 
treatment of the flushes by HRT.  This is reflected in altered skin blood flow and 
vascular response to vasoactive agents, acetylcholine and sodium nitroprusside.   
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METHODS 
Participants 
A total of 15 women who were commencing hormone replacement therapy were 
recruited. 
Recruitment of volunteers followed Scottish media coverage, as well as from 
gynaecology and menopause clinics.  A number of women were also recruited 
from the West of Scotland Breast Screening Centre in Glasgow. 
Participating women were all aged 45-65 years, non-smokers, not known to be 
hypertensive, non-diabetic and not taking any drugs which could affect vascular 
function.  Menopausal status was determined by either an FSH greater than 20 
Units/Litre or amenorrhoea for 1 year or longer.   
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Study Design 
Study participants were all seen at baseline when skin blood flow was assessed 
using LASER Doppler imaging (LDI) with iontophoresis (ION) of vasoactive 
compounds.  Participants returned for repeat assessment following 8 weeks of 
treatment with hormone replacement therapy.  Qualitative measures were 
obtained at the same time points. 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 09/MRE00/40).  All patients 
gave written informed consent. 
 
Figure 55: Study design 
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Body composition 
Measurements of body mass, height, and blood pressure were made as described 
in Chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made at baseline and after 
8 weeks of treatment with hormone replacement therapy.  This technique is 
described in detail in Chapter 2. 
Hot flush diary 
Each participant was asked to keep a ‘Hot Flush’ diary for 4 weeks prior to initial 
assessment and throughout the study, as described in detail in Chapter 2. 
Qualitative Measurements 
Greene Climacteric Scale 
Each participant completed this questionnaire at visit 2 and visit 3 as described 
in Chapter 2. 
Becks Depression Inventory 
Each participant completed this questionnaire at visit 2 and visit 3 as described 
in Chapter 2. 
Hospital Anxiety and Depression Scale 
Each participant who participated in the study after 16 August 2010 completed 
this questionnaire at visit 2 and visit 3 as described in Chapter 2. 
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Plasma analysis 
A fasting blood sample was taken from each participant using 21G Vacuette® 
SAFETY blood collection set + luer adapter from an anticubital vein.  Three 
samples were collected in Vacuette® gel tubes, one 9ml ethylenediamine tetra-
acetic acid (EDTA – lilac top), one 6ml lithium heparin (LiHep – green top) and 
one 4ml citrate (blue top). 
A small volume was removed from the 6ml lithium heparin sample before 
centrifuge and storage as described in Chapter 2.   
ICAM, VCAM, TNF –α, IL-6, Insulin and Adiponectin were measured by ELISA 
technique as described in Chapter 2. 
CRP, Cholesterol, Glucose, HDL, LDL, and Trig were measured by standardised 
methods at the SAS laboratory for cardiovascular biomarkers at The Institute of 
Cardiovascular and Medical Sciences at Glasgow University, as described in 
Chapter 2. 
Statistical analysis 
Measurement of vascular responses was performed using raw values.  
Comparisons were by General Linear Model.  Because of the marked differences 
in variances between basal perfusion values and the maximal responses to the 
drugs, but the similar coefficients of variation, log10 transformation of the data 
was performed to equalise the variances and thereby permit parametric data 
analysis 
Diary data, HFRDIS and qualitative data were compared using Wilcoxin Signed 
Rank test of paired non-parametric data.  Diary data included analysis of mean 
number of flushes per day, hot flush score and night time awakening. 
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Results 
15 women with severe hot flushing were recruited.  Following recruitment, 2 
women declined continued participation in the study; 13 women attended for 
baseline assessment, however a further 2 women did not attend for treatment 
LDI + Ion (see Figure 56).  Complete demographic and perfusion data are 
available for 11 participants (see Table 17). 
 
Figure 56: Recruitment and Participant numbers 
 
  
  202 
Demographic characteristics 
n 11 
Age 52 (51-54)[48-58] 
Years since LMP 3.5 (0.5-16.8)[0.1-20] 
BMI 30.1 (24.5-35.9)[19.4-69.5] 
Parity 1 (0-2)[0-3] 
*SBP 138.7 ± 14.5 
*DBP 84.5 ± 13.2 
Table 15: Demographic characteristics 
Data are median (interquartile range)[range].  All women are non-smokers.  *Data are mean ± 
SD 
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Responses to iontophoresis of acetylcholine (ACh) and sodium 
nitroprusside (SNP) 
Following 8 weeks of hormone replacement therapy, enhanced vascular 
responses were seen following administration of ACh (p<0.001) and SNP (p = 
0.01). 
 
 
Figure 57: Dose response curve 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in control women compared with flushing women.  
P<0.001 and P=0.01 respectively.  Data are mean ± SEM. 
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Hot flush diaries 
Only 5 participants completed baseline diary data, the overwhelming reason for 
this was an urgency to commence treatment.  All 11 participants who returned 
for LDI + Ion assessment following 8 weeks of treatment had completed a full 
complement of treatment diaries. 
Diary data was calculated as follows; flush/day = total number of flushes/week 
divided by the number of diary days completed, and a mean taken of the weeks 
completed.  Hot flush score = mean daily flush frequency multiplied by mean 
score.  A mean was taken of the weeks completed.  NTA (night time awakening) 
= total number of NTA/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  HFRDIS (hot flush related daily 
interference scale) was completed once per diary week, and a mean was taken 
of the weeks completed.   
Data is presented as median (interquartile range)[range] as the data were non-
parametric.   Statistical comparisons were therefore made by Wilcoxin Signed 
Rank Analysis of matched pairs, but also by Mann Whitney-U analysis* as a result 
of limited complete pairs of data. 
Treatment with HRT did not appear to significantly reduce the number of, or 
severity of, flushes, the frequency of night time awakenings, or the perception 
of daily hot flush interference (see Table 16 and Figure 58).    
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 Baseline 
n=5 
Treatment 
n=11 
P 
Flush frequency 
(mean flush/day) 
8.1 (1.7-11.0) 
[1.0-12.9] 
2.5 (0.7-4.5) 
[0.4-12.0] 
0.31 
*0.17 
Night time 
awakening (NTA) 
2.3 (0.9-5.3) 
[0.6-7.6] 
0.95 (0.3-2.3) 
[0.1-4.1] 
0.13 
*0.15 
Hot flush related 
daily interference 
score (HFRDIS) 
60.0 (35.0-77.8) 
[20.0-83.7] 
29.4 (16.7-48.5) 
[3.0-68.6] 
0.13 
*0.10 
Hot flush score 20.0 (2.3-29.7) 
[1.8-38.6] 
4.8 (0.9-11.4) 
[0.4-32.9] 
0.31 
*0.21 
Table 16: Hot flush diary data 
Flush/day = total number of flushes/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  Hot flush score = mean daily flush frequency 
multiplied by mean score.  A mean was taken of the weeks completed.  NTA (night time 
awakening) = total number of NTA/week divided by the number of diary days completed, and 
a mean taken of the weeks completed.  HFRDIS (hot flush related daily interference scale) 
was completed once per diary week, and a mean was taken of the weeks completed.  
Placebo and Clonidine weeks, diaries were completed for 4 weeks each, and baseline 
diaries were completed for 3 weeks.   
Data are P values determined by Wilcoxin Signed Rank analysis of paired data.  *p values by 
Mann Whitney test. 
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Figure 58: Diary data 
Data are shown as box and whisker plots with median, IQR and range. 
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Qualitative Data 
Unlike diary data, qualitative data were completed at assessment visits and for 
this reason is available for all participants. 
Greene Climacteric Scale 
Assessment of climacteric symptoms, as described by J.G. Greene (see Chapter 
2), were made at baseline and following 8 weeks of treatment and total scores 
were reduced (p=0.003). 
 
Figure 59: GCS 
Data are shown as box and whisker plots with median, IQR and range. 
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Becks Depression Inventory 
Becks Depression Inventory assessments were also made at baseline and 
following treatment, total scores were reduced (p=0.02) (See Figure 60). 
 
Figure 60: Becks Depression Inventory II 
Data are shown as box and whisker plots with median, IQR and range. 
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Hospital Anxiety and Depression Scale 
Becks Depression Inventory II is not designed to assess anxiety as a separate 
entity from depression.  Therefore an amendment to ethical approval was sought 
and granted on 16 August 2010 to include Hospital Anxiety and Depression Scale 
(HADS).  Each participant who participated in the study after this date 
completed this questionnaire at visit 2 and visit 3. 
Total scores were reduced following 8 weeks of treatment with HRT (p=0.01) 
(see Figure 61). 
 
Figure 61: Hospital Anxiety and Depression Scale 
Data are shown as box and whisker plots with median, IQR and range. 
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Blood analysis 
Serum haematocrit was analysed as described in Chapter 2, there was no 
difference observed between baseline and treatment. 
Plasma was analysed for HDL, LDL, Triglycerides, Glucose, total Cholesterol, 
Apolipoprotein A1 and B, ICAM and VCAM, TNFα, IL6, Adiponectin and CRP.  
Samples were taken at visit 2 before treatment was commenced (base) and 
following 8 weeks of treatment with HRT (treat).  The methods are described in 
detail in Chapter 2. 
ApoA1 and HDL were found to be significantly lower when measured after 8 
weeks of treatment (p=0.004 for both), when compared to samples taken at 
baseline.  No other significant differences were observed.  See Figure 62. 
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Figure 62: Plasma analysis 
Data are shown as box and whisker plots with median, IQR and range. 
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Summary of results 
Perfusion response to iontophoresis of acetylcholine (ACh) and 
sodium nitroprusside (SNP) 
HRT increased the cutaneous microvascular response to vasoactive agents, 
acetylcholine and sodium nitroprusside.  
Qualitative Data 
Green Climacteric Scores, Becks Depression Inventory Scores, and Hospital 
Anxiety and Depression Scores were all reduced following 8 weeks of treatment 
with HRT.   
Blood analysis 
Haematocrit 
No differences within the group between baseline and treatment assessments. 
Plasma analysis 
ApoA1 and HDL were found to be significantly lower when measured after 8 
weeks of treatment with HRT. No other significant differences were determined. 
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Discussion 
In this study cutaneous microvascular perfusion responses to vasoactive agents 
are increased following 8 weeks of treatment with hormone therapy.  If 
postmenopausal women with severe flushing have an increased risk of 
cardiovascular disease (see Chapter 3), improved cutaneous microvascular 
perfusion with treatment with HT may indicate ‘better’ endothelial function and 
a lower cardiovascular risk.  
Endothelial dysfunction, characterised by a failure to vasodilate, or indeed to 
vasoconstrict, in the presence of endothelial nitric oxide, is a significant 
predictor of cardiovascular (cv) events.  Oestrogen was thought to be 
cardioprotective (237), perhaps because of the disparity in cv-related deaths 
between men and women before midlife.  The Heart and Estrogen/Progestin 
Replacement Study (HERS) (238) and Women’s Health Initiative (WHI) 
publications failed to demonstrate a protective effect, and in fact, WHI showed 
a nonsignificant increase in risk associated with conjugated equine estrogens 
(CEE) and medroxyprogesterone acetate (MPA) (239), but this was in women 
starting treatment some 12 years after the menopause.   Many of these women 
would have had significant asymptomatic atherosclerosis, with adverse effects of 
oestrogen on thrombosis and inflammation (240). 
More recent clinical trial data have found no adverse effect or any beneficial 
effect on atherosclerosis progression with HT versus placebo when it is employed 
in recently menopausal women (241, 242).  However, it is plausible based on 
studies in nonhuman primates that initiating hormone therapy (HT) at the time 
of menopause may be cardioprotective (243).  Indeed, it has been suggested 
that there may be a critical window, most likely the late perimenopausal 
transition during which HRT may be of benefit in the modification of 
cardiovascular disease risk.  The Danish Osteoporosis Trial (DOPS trial) supports 
this timing hypothesis (window of opportunity); data demonstrated a significant 
reduction in coronary heart disease (CHD) and mortality in women who were 
randomised to HRT before age 60 or within 10 years of the menopause (244).   
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HT has also been shown to have beneficial effects on vascular relaxation in post-
menopausal women with type 2 diabetes (85).  In general, it is accepted that 
oestrogens promote cutaneous vasodilation (83).  Oestrogen receptors ERα and 
ERβ have been demonstrated to be present on the surface of endothelial cells 
and the classical model of steroid action involves binding to specific response 
elements on target genes to regulate gene transcription, with effects observed 
in hours to days (74).  However, over the last 2 decades it has been shown that 
sex steroids can regulate cell function through the raid activation of multiple 
signalling cascades and second messenger systems.  More recently, focus has 
been on non-genomic sex-steroid signalling and one the best-characterised 
examples is the activation of endothelial nitric oxide synthase (eNOS) in 
endothelial cells by oestradiol (84).    
In addition to this direct modulation of vascular function through regulation of 
endothelium-derived factors (nitric oxide), sex steroid hormones can also 
regulate intracellular calcium and calcium sensitivity of the vascular smooth 
muscle.  This vascular smooth muscle is innervated by efferent autonomic 
neurones, primarily sympathetic.  Consequently alterations in sympathetic 
vasoconstrictor activity and the transduction of this activity into vasomotor tone 
have significant effects on the regulation of blood flow; this may be the 
explanation for the vasodilation in the skin blood vessels (130). 
Hart et al suggest 3 sites at which sex hormones could influence the transduction 
of nerve activity into changes in vascular smooth muscle tone; 1) decreased 
synthesis and release of the main neurotransmitter, noradrenaline by inhibition 
of tyrosinase and tyrosine hydroxylase activity and decreased tyrosine by 17β-
oestradiol, 2) decreased non-neuronal degradation of noradrenaline by 
competitive binding of catecholestrogens to catechol-O-methyltransferase 
(COMT) in vascular smooth muscle thereby increasing noradrenaline in the 
synaptic cleft and the amount available to be removed by capillaries and 3) 
post-junctional activation of adrenergic receptors on the smooth muscle (130). 
The fall in oestrogen levels at menopause, therefore, in addition to the impact 
of NO release, may have its thermoregulatory effect directly by receptor binding 
(245) or indirectly by non-receptor mediated effects. 
  215 
The lack of effect on flush frequency and severity is likely to be as result of 
limited diary data; it is well accepted that HT is effective at reducing flush 
frequency and severity when compared to placebo (199), and GCS data in this 
study, support this.    
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Chapter 7 
Obesity 
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Introduction 
In the past it was thought that overweight women flushed less because androgen 
is converted to oestrogen in adipose tissue (246).  Dubbed the ‘thin hypothesis’, 
thinner women with less adipose tissue should therefore have more hot flushes 
and overweight women should be afforded some protection secondary to higher 
levels of oestrogen.  However, findings from multiple large epidemiological 
studies have challenged this hypothesis.  Evidence now suggests that overweight 
women have 1.5 to 2.0 times increased odds of reporting hot flushes and this risk 
increases with severity of obesity (247).   
Women tend to progressively gain weight over much of their adult lives.  
According to the Study of Women’s Health across the Nation (SWAN), the 
Healthy Women Study, women on average can expect to gain 1.5 pounds (680g) 
a year in their 40s and 50s.  In 2006, 24 per cent of adults (aged 16 or over) in 
England were classified as obese. This represents an overall increase from 15 per 
cent in 1994.   
Women are more likely to be morbidly obese than men (3 per cent compared to 
1 per cent) and to have a raised waist circumference (41 per cent and 32 per 
cent respectively).  Using both BMI and waist circumference to assess risk of 
health problems, particularly cardiovascular disease and diabetes, 14, 16, and 23 
per cent of the women are at increased risk, at high risk and at very high risk 
respectively (248). 
Despite the magnitude of this health problem, it is still unclear why obesity is 
linked to an increased risk of hot flushes.   
Body fat is, amongst other things, an insulator.  In response to heat stress, 
individuals with higher body fat show greater elevations in core body 
temperature.  In response to cold challenge, they show slower reductions in core 
body temperature than do their leaner counterparts.  Subcutaneous adiposity 
(the fat between skin and the abdominal muscle wall) rather than visceral 
abdominal adiposity (the fat behind the muscle wall and in the peritoneal space 
around the organs) is probably most related to hot flushes according to one 
study (54).  Thurston suggests that this subcutaneous adiposity, which is 
  218 
especially insulating, may prevent the heat dissipation action of flushes and 
heavier women may require to have more dissipation events to dissipate a given 
amount of heat (247). 
In early menopausal transition, obesity has been linked to lower levels of E2 
(249) and inhibin B (250), chronic menstrual dysfunction (251), and anovulatory 
cycles (252).  It has also been suggested, however, that women who developed 
hot flushes entered the menopausal transition with high oestrogen levels which 
dropped over time, but that women with low to average oestrogen levels did not 
develop hot flushes (253).   
In addition to low levels of E2, postmenopausal women with high body mass 
index (BMI) have also been shown to have significantly higher levels of 
testosterone and lower total oestrone, progesterone and sex hormone binding 
globulin (SHBG) (124).  This is surprising because adipose tissue produces and 
stores oestradiol.  Circulating oestrogen in blood is lower even if adipose tissue 
levels are elevated and it is this that enters the brain and the thermoregulatory 
centres, which govern hot flushes (254).  When we consider that the leading 
model of hot flushes is thermoregulatory dysfunction governed by the 
hypothalamus, circulating oestrogen that is capable of breaching the blood-brain 
barrier is certainly likely to be of more interest than adipose tissue production 
and storage.   
Obesity also significantly increases the risk of cardiovascular disease (CVD), 
which is linked to impaired endothelial function.  Adipose tissue excess is 
associated with a continuous production of mediators that impair insulin action 
(insulin resistance), which in turn is associated with type 2 diabetes, 
hypertension, dyslipidaemia, and altered coagulation/fibrinolysis, all of which 
create a state of constant and progressive damage to the vascular wall leading 
to endothelial dysfunction (129). 
The endothelium plays a vital role in vascular homeostasis, including vascular 
tone regulation.  Obesity associated with endothelial dysfunction is 
characterised by decreased availability of NO.  Tesauro et al found that patients 
with metabolic syndrome secondary to obesity have impaired forearm 
vasodilator response to acetylcholine (255).  Flow mediated dilation (FMD) of the 
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brachial artery has also been used to demonstrate that weight loss in extremely 
obese patients leads to an improvement of endothelial function.  
It has already been shown that there is an increase in perfusion responses in 
those postmenopausal women who flush when compared to their matched 
contemporaries, but these were all lean women (see Chapter 3).  A group of 
women with BMI>30 were examined to determine whether the increased 
incidence of flushing in obese postmenopausal women might be due to altered 
endothelial function.  
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Hypothesis 
Vasomotor symptoms in obese postmenopausal women are due to altered 
endothelial function as assessed by peripheral microvascular reactivity. 
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Methods 
This chapter describes a sub-analysis comparison of women with a BMI greater 
than or equal to 30 to women with a BMI of less than 30.  These women were all 
recruited to either group 1 (see Chapter five; treated with venlafaxine) or group 
2 (see Chapter six; treated with HRT) of the study. 
Participants 
15 women with a BMI greater than or equal to 30 were included in this sub-
analysis.  9 of these women were in Group 1 and 6 were in Group 2.  The results 
presented in this chapter will compare those women with a BMI≥30 to those 
women with a BMI<30.  See Figure 63.  
  
Figure 63: Participants 
Purple circle represents total number of women seen at visit 2 in group 1 (venlafaxine), blue 
circle within represents those women with a BMI≥30 in the same group.  Orange circle 
represents total number of women seen at visit 2 in group 2 (HRT), green circle within 
represents those women with a BMI≥30 in the same group.  Total participants with BMI≥30 is 
15.  36 women at visit 2 have a BMI<30. 
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Study Design 
Study participants were all seen at baseline when skin blood flow was assessed 
using LASER Doppler imaging (LDI) with iontophoresis (ION) of vasoactive 
compounds.  Qualitative measures were obtained at the same time points. 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 09/MRE00/40).  All patients 
gave written informed consent. 
Body composition 
Measurements of body mass, height, and blood pressure were made as described 
in Chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made using LASER Doppler 
imaging with iontophoresis.  This technique is described in detail in Chapter 2. 
Hot flush diary 
Each participant was asked to keep a ‘Hot Flush’ diary for 4 weeks prior to 
assessment, as described in detail in Chapter 2. 
Qualitative Measurements 
Greene Climacteric Scale 
Each participant completed this questionnaire as described in Chapter 2. 
Becks Depression Inventory 
Each participant completed this questionnaire as described in Chapter 2. 
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Hospital Anxiety and Depression Scale 
Each participant who participated in the study after 16 August 2010 completed 
this questionnaire as described in Chapter 2. 
Plasma analysis 
A fasting blood sample was taken from each participant using 21G Vacuette® 
SAFETY blood collection set + luer adapter from an anticubital vein.  Three 
samples were collected in Vacuette® gel tubes, one 9ml ethylenediamine tetra-
acetic acid (EDTA – lilac top), one 6ml lithium heparin (LiHep – green top) and 
one 4ml citrate (blue top). 
A small volume was removed from the 6ml lithium heparin sample before 
centrifuge and storage as described in Chapter 2.   
ICAM, VCAM, TNF –α, IL-6, Insulin and Adiponectin were measured by ELISA 
technique as described in Chapter 2. 
CRP, Cholesterol, Glucose, HDL, LDL, and Trig were measured by standardised 
methods at The Institute of Cardiovascular and Medical Sciences at Glasgow 
University, as described in Chapter 2. 
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Statistical analysis 
Measurement of vascular responses was performed using raw values.  
Comparisons were by General Linear Model.  Because of the marked differences 
in variances between basal perfusion values and the maximal responses to the 
drugs, but the similar coefficients of variation, log10 transformation of the data 
was performed to equalise the variances and thereby permit parametric data 
analysis 
Demographic data were compared using Student’s t-test to compare blood 
pressure and Mann Whitney U test for non-parametric data. 
Diary data, HFRDIS and qualitative data were compared using Wilcoxon Signed 
Rank test of paired non-parametric data.  Diary data included analysis of mean 
number of flushes per day, hot flush score and night time awakening. 
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Results 
Demographic Characteristics 
There were 36 women with a BMI<30 and 15 women with a BMI≥30. 
 BMI<30 BMI>30 P 
n 36 15  
Age (years) 56 (53-63) 
[46-66] 
54 (51-58) 
[45-63] 
0.14 
Years since LMP 7 (1-11) 
[0.08-20] 
4.5 (1-7.5) 
[0.42-20] 
0.50 
BMI 25.3 (23.5-26.7) 
[19.4-29.8] 
33.8 (31.2-35.9) 
[30.1-38.7] 
<0.001 
WHR 0.79 (0.75-0.82) 
[0.70-0.91] 
0.84 (0.81-0.89) 
[0.75-0.96] 
0.001 
Parity 2 (1-3) 
[0-4] 
1 (0-2) 
[0-3] 
0.23 
*SBP 129.6 ± 16.86 134.9 ± 16.27 0.32 
*DBP 79.81 ± 9.35 88.86 ± 11.49 0.03 
Table 17: Demographic characteristics Group 1 + Group 2 
Data are median (interquartile range)[range].  Statistical analysis was performed using the 
Mann-Whitney U test.  All women are non-smokers.  *Data are mean ± SD, analysis by 
unpaired T-test. 
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 BMI<30 BMI>30 P 
n 31 9  
Age (years) 58 (54-63) 
[46-66] 
57 (53-61) 
[51-63] 
0.39 
Years since LMP 8 (0.33-20) 
 
6 (1-15) 
 
0.48 
BMI 25.2 (23.4-26.9) 
[20.7-29.8] 
33.8 (31.3-35.1) 
[30.3-37.1] 
<0.001 
Parity 2 (0-4) 
 
2 (0-3) 
 
0.44 
SBP 128.4 ± 17.28 128.89 ± 11.97 0.94 
DBP 79.29 ± 9.45 82.67 ± 6.89 0.34 
Table 18: Demographic characteristics of Group 1 (venlafaxine treatment) 
Data are median (interquartile range)[range].  Statistical analysis was performed using the 
Mann-Whitney U test.  All women are non-smokers.  *Data are mean ± SD, analysis by 
unpaired T-test. 
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 BMI<30 BMI>30 P 
n 5 6  
Age (years) 52 (50-53) 
[49-54] 
52 (47-55) 
[45-58] 
1.0 
Years since LMP 6 (0.08-19) 2 (0.42-20) 0.73 
BMI 25.8 (22.0-27.8) 
[19.4-29.8] 
33.7 (30.5-37.1) 
[30.1-38.7] 
0.008 
Parity 2 (1-2) 
[0-3] 
1 (1-2) 
[0-3] 
0.45 
SBP 137 ± 12.92 145.8 ± 18.55 0.41 
DBP 83 ± 8.94 94.40 ± 14.94 0.18 
Table 19: Demographic characteristics of Group 2 (HRT) 
Data are median (interquartile range)[range].  Statistical analysis was performed using the 
Mann-Whitney U test.  All women are non-smokers.  *Data are mean ± SD, analysis by 
unpaired T-test. 
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Responses to iontophoresis of acetylcholine (ACh) and sodium 
nitroprusside (SNP) 
There was no difference in the endothelium dependent (ACh) baseline response, 
however there was a significantly lower endothelium independent (SNP) 
response when comparing participants with BMI<30 (n=36) to participants with 
BMI>30 (n=15) (ACh, p=0.962 and SNP, p=0.025).  See Figure 64. 
 
 
Figure 64: Dose Response Curve Group 1 + 2 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in women with BMI<30 (normal) compared with 
women with BMI≥30 (high).  Data are mean ± SEM.  General Linear Model. 
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It was already shown in chapter five that treatment with venlafaxine decreases 
the increased cutaneous perfusion responses seen in flushing women.  This group 
was subdivided into those women with BMI<30 and those with a BMI>30 to 
determine whether their treatment responses varied. 
Participants in group 1 as a whole experienced a reduction in peripheral 
perfusion responses following eight weeks of treatment with venlafaxine (see 
Chapter five).  This response is maintained in those participants with a BMI<30 
(n=31), and is present for both endothelium dependent and independent 
measurements.  (P=0.001 and 0.04 respectively).  See Figure 65. 
 
Figure 65: Dose Response Curve Group 1 BMI <30 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in women with BMI<30, prior to treatment (base) 
and following 8 weeks venlafaxine treatment (treat).  Data are mean ± SEM.  General Linear 
Model. 
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However, in those participants with a BMI>30 in Group 1 (n=9), this reduction in 
perfusion response is lost in endothelium dependent measurements and reversed 
in endothelium independent measurements, that is, following eight weeks of 
treatment with venlafaxine, endothelium independent cutaneous microvascular 
perfusion appears to be increased.  (ACh, P=0.468 and SNP, P=0.001).  See 
Figure 66.   
 
 
Figure 66: Dose Response Curve Group 1 BMI>30 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in women with BMI>30, no treatment (base) 
compared with 8 weeks venlafaxine (treat).  Data are mean ± SEM.  General Linear Model. 
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It was already shown in Chapter six that treatment with HRT increases cutaneous 
perfusion responses seen in flushing women.  This group was subdivided into 
those women with BMI<30 and those with a BMI>30 to determine whether their 
treatment responses varied. 
Again, in keeping with the group as a whole (see Chapter six), participants with 
a BMI<30 (n=5) who were treated with HRT for eight weeks demonstrated an 
increase in perfusion responses to iontophoresis of both ACh and SNP (P<0.001 
and P<0.001 respectively).  See Figure 67. 
 
Figure 67: Dose Response Curve Group 2 BMI<30 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in women with BMI<30, no treatment (base) 
compared with 8 weeks HRT (treat).  Data are mean ± SEM.  General Linear Model. 
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And again, in Group 2 (HRT) when participants with BMI≥30 (n=6) were 
examined, there was no significant change to endothelium dependent (ACh) 
responses (P=0.63) following eight weeks of treatment with HRT, but a reversal 
in the response seen to SNP.  That is, there was a decrease in endothelium 
independent responses (SNP, P=0.04).  See Figure 68. 
 
Figure 68: Dose Response Curve Group 2 BMI>30 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in women with BMI>30, no treatment (base) 
compared with 8 weeks HRT (treat).  Data are mean ± SEM.  General Linear Model. 
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Hot flush diaries 
Unfortunately, despite recruiting a total of 15 (9 from group 1 and 6 from group 
2) women with a body mass index (BMI) of 30 or more, only 10 women recorded 
pre-treatment (baseline) hot flush diaries.  8 from group 1 and 2 from group 2.  
The overwhelming reason for two thirds of group 2 participants not recording 
pre-treatment diaries was an urgency to begin treatment.  Often these ladies 
had been waiting a considerable length of time already to begin treatment and 
did not wish to delay any longer.  This has had an impact on our results.  The 
participant from group 1 who did not complete diaries refused as it was claimed 
to be impossible to count the number of flushes experienced as they were simply 
too frequent, and long-lasting, that they almost seemed to merge into one flush. 
There were 36 participants with a BMI less than 30.  31 from group 1 and 5 from 
group 2.  Baseline diaries were completed in 35, 31 from group 1 and 3 from 
group 2.  Again the reason for poor compliance with pre-treatment diaries was 
an urgency to begin treatment. 
In table 20; there were no significant differences in the number or severity of 
flushes experienced by participants when comparing two groups; BMI less than 
30 and BMI greater than 30.  This was also true of night time awakening and hot 
flush related daily interference score. 
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 Baseline BMI<30  
(n=35) 
Baseline 
BMI>30      
(n=10) 
P 
Flush frequency 
(mean flush/day) 
7.8 (5.8-9.5) 
[1.0-19.6] 
6.7 (4.0-10.1) 
[2.1-21.2] 
0.97 
Night time awakening (NTA)  2.3 (1.6-3.4) 
[0.5-4.6] 
2.8 (1.0-3.3) 
[0.3-7.6] 
0.57 
Hot flush related daily 
interference score (HFRDIS)  
40.8 (22.0-59.7) 
[5.3-84.7] 
45.4 (25.1-70.3) 
[5.5-83.7] 
0.45 
Hot flush score  17.0 (10.4-20.9) 
[1.8-43.1] 
13.8 (7.8-24.9) 
[1.9-42.4] 
0.95 
Table 20: BMI<30 vs. BMI>30 baseline diary data. 
Group 1 + Group 2.  Data are median (interquartile range)[range].  Statistical analysis was 
performed using Mann Whitney test.  
Flush/day = total number of flushes/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  Hot flush score = mean daily flush frequency 
multiplied by mean score.  A mean was taken of the weeks completed.  NTA (night time 
awakening) = total number of NTA/week divided by the number of diary days completed, and 
a mean taken of the weeks completed.  HFRDIS (hot flush related daily interference scale) 
was completed once per diary week, and a mean was taken of the weeks completed.  
Placebo and Clonidine weeks, diaries were completed for 4 weeks each, and baseline 
diaries were completed for 3 weeks.   
 
  
  235 
Correlation of diary data with demographics 
There was no correlation between BMI or waist hip ratio (WHR) and number or 
severity of flushes (see Figure 69). 
 
 
Figure 69: Correlation of flush frequency and score with BMI and WHR 
Correlation plots and regression lines with 95% confidence intervals. 
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Qualitative Data 
Greene Climacteric Scale 
There was no difference in baseline GCS scores between those participants with 
a BMI<30 (lean) when compared to those with a BMI>30 (obese).   
There was a significant reduction in GCS scores following treatment with 
venlafaxine, in group 1 participants, in both lean and obese subgroups, however 
there was no improvement for either lean or obese participants in group 2 
following treatment with HRT.  Unfortunately, despite improvements in 
compliance with these questionnaires, numbers were still small and this may be 
the reason for lack of significance in this group, as there does appear to be a 
trend towards reduction in scores  (see Figure 70 and Table 21). 
 
Figure 70: Greene Climacteric Scale 
Data are shown as box and whisker plots with median, IQR and range. 
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Lean 
n=36 
Obese 
n=15 
p 
17.0 (13.0-23.8) 
[5.0-37.0] 
22.0 (14.0-27.0) 
[10.0-44.0] 
*0.14 
Group 1 Group 2 
Lean 
N=31 
Obese 
N=9 
Lean 
N=5 
Obese 
N=6 
base treat p base treat p base treat p base treat p 
17.0  
(13.0-24.0) 
[5.0-36.0] 
8.0  
(3.0-11.0) 
[2.0-20.0] 
<0.001 19.0  
(11.0-24.5) 
[10.0-37.0] 
6.5  
(3.5-11.25) 
[0.0-16.0] 
0.03 17.0  
(12.0-28.5) 
[9.0-37.0] 
5.5  
(1.5-8.8) 
[1.0-9.0] 
0.09 26.0  
(22.0-38.8) 
[16.0-44.0] 
15.0  
(9.0-28.0) 
[6.0-39.0] 
0.13 
Table 21: Greene Climacteric Scale 
Data are median (interquartile range)[range].  P values are determined by Wilcoxon Signed Rank analysis of paired data.  *P value is determined by Mann 
Whitney test. 
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Becks Depression Inventory 
Results here are similar to results with GCS scores; there was no significant 
difference in baseline results for lean versus obese participants.  Again, there 
was a significant reduction in BDI scores following treatment with venlafaxine in 
group 1 participants, in both lean and obese subgroups, however no 
improvement for either lean or obese participants in group 2 following 
treatment with HRT (see Figure 71 and Table 22). 
 
Figure 71: Becks Depression Inventory 
Data are shown as box and whisker plots with median, IQR and range. 
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Lean 
n=36 
Obese 
n=15 
p 
8.0 (5.0-12.8) 
[0.0-39.0] 
8.0 (5.0-21.0) 
[4.0-35.0] 
*0.49 
Group 1 Group 2 
Lean 
N=31 
Obese 
N=9 
Lean 
N=5 
Obese 
N=6 
base treat p base treat p base treat p base treat p 
8.0  
(5.0-12.0) 
[0.0-39.0] 
1.0  
(0.0-4.0) 
[0.0-23.0] 
<0.001 8.0  
(5.0-10.5) 
[4.0-20.0] 
2.0 
(0.3-5.0) 
[0.0-8.0] 
0.04 12.0  
(3.0-15.0) 
[0.0-15.0] 
4.0  
(0.5-8.3) 
[0.0-9.0] 
0.20 24.0  
(7.0-30.0) 
[5.0-35.0] 
12.5  
(4.8-27.0) 
[4.0-30.0] 
0.10 
 
Table 22: Becks Depression Inventory 
Data are median (interquartile range)[range].  P values are determined by Wilcoxon Signed Rank analysis of paired data.  *P value is determined by Mann 
Whitney test. 
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Hospital Anxiety and Depression Scale 
As already stated in Chapter 2, this was a questionnaire that was introduced late 
in the study, therefore numbers of participants who completed this were small 
in comparison to the other questionnaires.  The only significant improvement 
seen with this score was in group 1 lean participants following treatment with 
venlafaxine (see Figure 72 and Table 23).  
 
Figure 72: Hospital Anxiety and Depression Score 
Data are shown as box and whisker plots with median, IQR and range. 
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Lean 
n=17 
Obese 
n=8 
p 
9.0 (5.0-14.0) 
[0.0-23.0] 
12.0 (6.8-23.0) 
[5.0-25.0] 
*0.27 
Group 1 Group 2 
Lean 
N=12 
Obese 
N=3 
Lean 
N=5 
Obese 
N=5 
base treat p base treat p base treat p base treat p 
9.0  
(5.5-15.8) 
[0.0-23.0] 
6.0  
(2.0-7.0) 
[0.0-19.0] 
0.03 9.0  
(5.0-12.0) 
[5.0-12.0] 
1.5 
(0.0-3.0) 
[0.0-3.0] 
0.5 11.0  
(1.5-14.0) 
[1.0-15.0] 
3.5  
(0.3-7.5) 
[0.0-8.0] 
0.10 17.0  
(9.0-25.0) 
[6.0-25.0] 
11.5  
(4.0-19.0) 
[3.0-20.0] 
0.10 
 
Table 23: Hospital Anxiety and Depression Score 
Data are median (interquartile range)[range].  P values are determined by Wilcoxon Signed Rank analysis of paired data.  *P value is determined by Mann 
Whitney test. 
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Plasma analysis 
As one might expect obese women had significantly higher total cholesterol 
(p=0.04), triglycerides (p<0.001), apolipoprotein B (p=0.005), and CRP (p=0.01) 
levels.  They also had significantly lower HDL-cholesterol (p=0.002) and 
apolipoprotein A1 (P=0.01). 
These results were not affected by adjustment for age, years since last 
menstrual period (YSLMP) and parity:  total cholesterol (p=0.03), triglycerides 
(p<0.001), apolipoprotein B (p<0.001), CRP (p=0.01), HDL-cholesterol (p=0.001), 
and apolipoprotein A1 (P=0.01).   
Insulin was significantly higher in the obese group (p=0.003), however this was 
not significant when adjusted as above (p=0.17), see Figure 73 and Table 24.  
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Figure 73: Plasma analysis 
Results of plasma analysis, a comparison of obese and lean participants.  Adjusted results; 
Cholesterol, p=0.03; Trig, p<0.001; ApoB, p<0.001; CRP, p=0.01, HDL, p=0.001; ApoA1, 
p=0.01.  Data are shown as box and whisker plots with median, IQR and range. 
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BMI<30 
n=36 
BMI>30 
n=15 
P Adj. P 
R-Sq 
(%) 
Cholesterol 5.3 (4.9-5.7)[3.6-7.4] 6.1 (5.4-6.4)[4.1–6.7] 0.04 0.03 13.7 
Triglyceride 0.9 (0.7-1.1)[0.4-1.8] 1.6 (0.9-2.1)[0.6-4.3] <0.001 <0.001 45.6 
LDL-cholesterol (mmol/l) 3.3 (2.89-3.9)[2.2–5.3] 3.7 (3.2-4.3)[1.8–4.9] 0.11 0.05 12.6 
HDL-cholesterol (mmol/l) 1.6 (1.4-1.8)[0.9–2.5] 1.2 (1.1-1.6)[0.9–1.8] 0.002 0.001 25.9 
Total Cholesterol to HDL-cholesterol ratio 3.2 (2.9-3.9)[2.1-5.1] 1.1 (0.9-1.3)[0.6-1.5] <0.001 <0.001 75.3 
Apolipoprotein A1 (mg/dl) 
141.1 (129.6-157.1) 
[83.9–195.3] 
126.3 (116.3-138.9) 
[100.4–161.3] 
0.01 0.01 17.1 
Apolipoprotein B (mg/dl) 91.8 (82.1-103.0)[71.3-122.9] 114.4 (92.6-118.8)[68.8-134.4] 0.005 <0.001 32.49 
Insulin (mu/l) 4.1 (2.7-6.2)[1.1-25.0] 6.7 (5.4-11.2)[1.7-21.7] 0.003 0.17 12.4 
Glucose (mmol/l) 5.3 (5.0-5.7)[3.8-7.6] 5.4 (5.0-6.4)[4.4-8.0] 0.30 0.07 15.9 
Adiponectin (µg/ml) 92.7 (72.3-113.8)[30.9-241.4] 74.0 (52.3-96.5)[34.1-129.0] 0.05 0.03 11.6 
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C-Reactive Protein (CRP) (mg/l) 0.9 (0.5-1.3)[0.1-5.2] 2.1 (0.7-6.0)[0.4-13.2] 0.01 0.01 21.3 
TNF alpha (pg/ml) 0.8 (0.5-1.3)[0.4-3.1] 0.9 (0.6-1.1)[0.5-6.8] 0.61 0.16 13.2 
IL-6 (pg/ml) 1.2 (0.8-1.7)[0.3-5.8] 1.4 (1.2-2.0)[1.0-7.5] 0.16 0.39 7.2 
ICAM 233.7 (186.9-253.1) 
[149.1-343.0] 
239.7 (204.1-271.0) 
[150.5-422.4] 
0.31 0.33 11.2 
VCAM 604.7 (483.0-703.8) 
[362.9-889.5] 
587.4 (507.1-779.4) 
[448.1-1060.0] 
0.80 0.70 5.6 
Table 24: Plasma analysis 
Results of plasma analysis, a comparison of obese and lean participants.  Data are median (interquartile range)[range].  Statistical analysis was performed 
using Mann-Whitney test.  Adjusted P calculated using general linear model to adjust for Age, Years since last menstrual period (LMP) and Parity. 
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Perfusion response and plasma analysis correlations 
A negative correlation between CRP and endothelium dependent perfusion 
responses was demonstrated in the lean group (p=0.05) (see Figure 73).  A 
negative correlation between endothelium dependent perfusion and TNF alpha 
in the obese group (p=0.03) (see Figure 75) and a negative correlation between 
VCAM and endothelium independent response in the obese group (p=0.05) (see 
Figure 76).  No other associations have been demonstrated.  See Figures 74-77. 
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Figure 74: Lean ACh perfusion response and plasma correlations 
Correlation plots and regression lines with 95% confidence intervals for endothelium 
dependent (ACh) perfusion response and its association with results of plasma analysis. 
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Figure 75: Lean SNP perfusion response and plasma correlations 
Correlation plots and regression lines with 95% confidence intervals for endothelium 
independent (SNP) perfusion response and its association with results of plasma analysis. 
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Figure 76: Obese ACh perfusion response and plasma correlations 
Correlation plots and regression lines with 95% confidence intervals for endothelium 
dependent (ACh) perfusion response and its association with results of plasma analysis. 
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Figure 77: Obese SNP perfusion responses and plasma correlations 
Correlation plots and regression lines with 95% confidence intervals for endothelium 
dependent (ACh) perfusion response and its association with results of plasma analysis. 
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Summary of results 
Perfusion response to iontophoresis of acetylcholine (ACh) and 
sodium nitroprusside (SNP) 
Baseline 
No differences were detected between obese and lean participants, in response 
to vasoactive agents for endothelium dependent perfusion; however there was 
reduced endothelium independent perfusion in the obese group.  
Group 1 perfusion responses following treatment (with venlafaxine) 
Participants with a BMI<30 had results in keeping with whole group responses, 
that is, perfusion responses were reduced following 8 weeks of treatment with 
venlafaxine.  Those participants with a BMI>30 appeared to have an increased 
endothelium independent response following 8 weeks of treatment with 
venlafaxine. 
Group 2 perfusion responses following treatment (with HRT) 
Participants with BMI<30 had results in keeping with whole group responses, in 
that perfusion responses (endothelium dependent and independent) were 
increased following 8 weeks of treatment with HRT.  Those participants with 
BMI>30 appeared to have decreased responses to both acetylcholine and sodium 
nitroprusside following 8 weeks of treatment with HRT. 
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Diary data 
Baseline 
No differences were detected in flush frequency, severity, night time awakening 
or HFRDIS between obese and lean participants.   
Correlation of demographic data with diary data  
There was no correlation between BMI or WHR with flush frequency or score. 
Qualitative Data 
Greene Climacteric Scores 
No differences were detected between obese and lean participants at baseline.   
Group 1 responses to treatment (with venlafaxine) 
There were significant improvements in both obese and lean participants. 
Group 2 responses to treatment (with HRT) 
There was no significant improvement demonstrated in either lean or obese 
participants following treatment. 
Becks Depression Inventory II 
No differences were detected between obese and lean participants at baseline.   
Group 1 responses to treatment (with venlafaxine) 
There were significant improvements in both obese and lean participants. 
Group 2 responses to treatment (with HRT) 
There was no significant improvement demonstrated in either lean or obese 
participants following treatment. 
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Hospital Anxiety and Depression Scores 
No differences were detected between obese and lean participants at baseline.   
Group 1 responses to treatment (with venlafaxine) 
There were significant improvements demonstrated in lean participants, 
however not in obese participants.   
Group 2 responses to treatment (with HRT) 
There was no significant improvement demonstrated in either lean or obese 
participants following treatment.   
Serum analysis 
Total cholesterol, triglycerides, apolipoprotein B, insulin and CRP were 
significantly higher in the obese group.  They also had significantly lower HDL-
cholesterol and apolipoprotein A1. 
Serum analysis and their correlation with perfusion responses  
A negative correlation between CRP and endothelium dependent perfusion 
responses was demonstrated in the lean group.  In the obese group, there was a 
negative correlation between endothelium dependent perfusion and TNF alpha 
and a negative correlation between VCAM and the endothelium independent 
response. 
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Discussion 
Obesity is the result of adipocyte hypertrophy during a positive caloric balance.  
It has been suggested that excessive hypertrophy causes a pathological change in 
the adipose tissue, creating adverse paracrine, endocrine and immune responses 
which may lead to cardiovascular diseases.     
During this hypertrophic process, adipocytes grow out of proportion and 
angiogenesis cannot keep pace, resulting in a relative lack of blood flow leading 
to cellular and adipose tissue hypoxia.  This contributes to pro-inflammatory 
responses, which in turn also lead to regional changes in blood flow.  Local 
hypoxia also increases levels of inflammatory adipokines such as IL6 and TNFα, 
which induce dysfunction of adipose tissue arterioles, leading to further 
microcirculation dysfunction, compounding the hypoxic effects. 
Insulin resistance is also induced by a number of adipokines, as is recruitment 
and infiltration of monocytes, lymphocytes and neutrophils into the blood vessel 
wall, which instigates local inflammation.  Nitric oxide production in endothelial 
cells is also impaired, which further compromises endothelial-dependent 
vasodilatation.  
Unexpectedly then, there was no difference detected, between obese (BMI≥30) 
and lean participants (BMI<30), in endothelium dependent cutaneous 
microvascular perfusion responses.  There was however reduced endothelium 
independent perfusion in the obese participants when compared to the lean 
participants.   
This absence of any difference in the endothelium dependent response is 
particularly surprising when coupled with elevated cholesterol, triglycerides, 
apolipoprotein B and CRP, and significantly lower HDL-cholesterol and 
apolipoprotein A1 in the obese group, all measures which are associated with 
vascular disease in both men and women. 
Insulin was also significantly higher in the obese group, however did not 
withstand adjustment for age, years since last menstrual period or parity.  
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Serum adiponectin levels, however, were lower in obese participants after 
adjusting for age, years since menstrual period and parity.  
Adiponectin is an adipocyte-derived plasma protein of 244 amino acides, and 
differs from the other adipocyte hormones in that its concentration declines 
with increasing obesity.  Besides inhibiting inflammatory pathways, recombinant 
adiponectin increases insulin sensitivity and enhances lipid clearance.  It also 
stimulates NO production in endothelial cells through an AMP-activated protein 
kinase (AMPK) mediated phosphorylation and activation of eNOS.   
Vascular smooth muscle responsiveness to NO has been shown in healthy adults 
to be negatively correlated with total adiposity, but more specifically with 
abdominal adiposity (256).   
Body fat distribution (subcutaneous versus visceral, pericardial, perivascular 
etc.) may be the underlying explanation for distinct metabolic and 
cardiovascular disease risk in individuals with a similar BMI.  Different locations 
of adipose tissue may express different profiles of adipokines (257) and not all 
fat depots may be pathological (“adisopathy”).   
Men often store fat in visceral tissue by the more pathologic hypertrophy of 
adipocytes, whereas women store excess fat in the subcutaneous peripheries by 
hyperplasia (258).  This may explain why, for the same age and weight, men 
have higher rate of cardiovascular disease when compared with women.    
Cardiovascular disease risk in women, however, rises markedly after the 
menopause, and although the aetiology is unclear it may be due to the 
distribution of the fat, which not only becomes more central (259) but increases 
in proportion to total fat mass (260).  There may also be a steeper increase in 
visceral adipose tissue and a steeper decrease in subcutaneous fat (261). 
Perivascular adipose tissue (PVAT) represents an important role in the 
pathophysiology of vascular disease, both smooth muscle and endothelial cell 
dysfunction.  Almost all vessels are surrounded by this fat depot, and it has been 
shown to secrete an as yet unidentified anti-contractile substance, perivascular 
adipose tissue derived relaxing factor (PVADRF), in parallel to the amount of 
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healthy adipose tissue.  Not only does it appear to be abolished in obesity (262), 
but it has been reported to exert pro-contractile effects. 
Perhaps these effects, as a result of increased deposits in PVAT, explain the 
differences seen in endothelium independent responses and not in endothelium 
dependent responses.  However, the anti-contractile effect of PVAT appears to 
be both endothelium dependent via NO, and endothelium independent via 
generation of hydrogen peroxide.  
Changes seen in adipose tissue as a consequence of obesity include infiltration 
and activation of macrophages leading to inflammation characterised by 
upregulation of tumour necrosis factor alpha (TNFα).  It is this that Greenstein 
has suggested has resulted in the impaired ability of PVAT to regulate vascular 
tone (262).  Indeed, there was a negative correlation between TNFα and 
endothelium dependent perfusion in obese participants.   
Thurston suggested obesity resulted in a greater number of hot flushes to 
dissipate a given amount of heat as a result of the insulating effect of 
subcutaneous adiposity (247).  It is possible that the metabolic effects 
associated with increases in visceral fat seen in obesity, and leading to impaired 
endothelial function, result in a diminished ability to peripherally vasodilate, 
thereby compounding the need for more flushes to dissipate the given amount of 
heat.  
There was no correlation between the perfusion response and the flush 
frequency or severity in this study, therefore one cannot speculate that those 
women who are obese may have had greater increased perfusion responses 
compared to lean women, but for the endothelial dysfunction, which has 
inhibited this response.   
There was no difference in flush frequency, severity, night time awakening or 
HFRDIS between obese and lean participants.  Published data suggest that 
women who are overweight are more likely to experience vasomotor symptoms, 
however as the presence of severe flushing was necessary for inclusion in the 
study; it is not possible to discuss the presence or absence of vasomotor 
symptoms in relation to BMI.  What can be stated is that for postmenopausal 
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women who experience severe vasomotor symptoms, there appears to be no 
difference in the frequency or severity when comparing lean with obese.  There 
is also no correlation between number or severity of hot flushes and waist hip 
ratio. 
There was, however a negative correlation identified between CRP and 
endothelium dependent (ACh) perfusion in the lean group and TNFα and ACh 
perfusion in the obese group, as well as VCAM and endothelium independent 
perfusion in the obese group.  These suggest that whilst we have been unable to 
demonstrate an expected difference between lean and obese in peripheral 
perfusion responses, the relationship between the perfusion response and 
biomarkers of chronic inflammation associated with endothelial dysfunction are 
as expected.  Perhaps, thermoregulatory heat loss requirements, in obese 
women with flushing, are able to overcome early endothelial dysfunction.  
Perfusion responses following treatment with venlafaxine in those participants 
with a BMI<30, were in keeping with overall group response.  That is, 
endothelium dependent and independent responses were reduced following 8 
weeks of treatment.  However, in the obese group, there was no change in 
endothelium dependent perfusion responses, but a significant increase in 
endothelium independent (vascular smooth muscle) response.  Yet, diary data 
confirmed an improvement in symptoms.   
Equally, lean participants treated with HRT had similar effects to the HRT group 
as a whole; obese participants again appeared to exhibit an opposite response to 
vascular smooth muscle perfusion, but no apparent differences in endothelium 
dependent perfusion.  There are insufficient diary data to comment on any 
change following HRT administration. 
There certainly appears to be significant differences in the behaviour of the 
cutaneous vessels when treatment responses in obese versus lean are compared, 
despite a beneficial effect of treatment.  It may be easier to explain the HRT 
treatment effect on perfusion in obese women; where the vasodilator effect of 
oestrogen may have been lost in vessels whose PVAT has a diminished ability to 
regulate tone, and in fact, may now be pro-contractile.  Should caution be 
exercised even during the window of opportunity for cardiovascular disease 
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prevention, in women who are obese?  It is more difficult to propose a possible 
mechanism for the vasodilator effect of venlafaxine on obese cutaneous vessels, 
given its strong association with vasoconstriction. 
No differences were detected in measures of GCS, BDI or HADS between lean and 
obese participants.  Again, treatment with venlafaxine resulted in improvements 
in all measures irrespective of BMI.  The exception to this was HADS in Group 1 
obese participants and treatment with HRT where data was most likely 
insufficient.  Further, much larger, studies would be required to identify 
differences in lean and obese responses to treatment and the effect on 
peripheral vasculature, ideally also comparing methods of perfusion assessment. 
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Chapter 8 
Hypogonadal Men 
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Introduction 
Prostate cancer is the most common cancer in men.  Over 40,000 men are 
diagnosed every year, and it is estimated that by 2030, it will be the most 
common cancer (263). 
Before the 1940s, there was no effective treatment for advanced prostate 
cancer, but in 1939 Charles Huggins, aware of the sensitivity of the prostate 
gland, proposed orchidectomy for the control of prostate cancer.  He also 
demonstrated that it reduced pain and produced stabilisation or regression of 
metastatic osseous lesions (134).  In 1941, he discovered that the same results 
could be achieved by the administration of female sex hormones, stilbestrol and 
hexestrol (264). 
Now, 90% of androgen deprivation therapy is achieved chemically, primarily 
luteinising-hormone-releasing hormone (LHRH) agonists, and 5-year survival is 
81% (265) for all prostate cancer.  However, there are side effects associated 
with treatment.  
In 1896, Cabot was the first to report flushes as an effect of castration for 
enlarged prostate (266), even before the association between androgens and the 
prostate, and Huggins and Hodges also reported flushes in 9 out of 21 castrated 
patients 2 to 3 weeks following surgery (267). 
Hot flushes occur in some 44-80% (268) of men, and are usually reported a few 
weeks after initiation of therapy, thought to coincide with achievement of 
castrate levels of testosterone (135).  A proportion of patients (15-27%) describe 
hot flushes as the most significant adverse quality of life (QOL) effect from 
androgen deprivation therapy (ADT) (269, 270), with those experiencing more 
frequent or severe hot flushes reporting greater distress (271, 272).  Hot flushes 
tend to become more frequent 3 months after starting treatment, half will still 
experience them 5 years after starting therapy (147) and in some they may 
persist long term (273), and even after discontinuation of therapy. 
In addition, hot flushes can occur as night sweats, negatively impacting upon 
sleep (274), and are associated with nausea, anxiety and embarrassment.   
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In common with postmenopausal women, hot flushes appear to occur at a time 
of hormone withdrawal and, as with women, alterations in skin blood flow have 
been demonstrated during a flush ‘attack’ (148). 
In addition, improvements seen in symptoms with hormone replacement are 
common to both men (149) and women and suggest a dependence on sex steroid 
levels. 
Despite this and although hormone withdrawal unquestionably plays a major role 
in the development of hot flushes, the physiological mechanism remains 
obscure.  Alterations in the hypothalamic thermoneutral zone have been 
suggested as the mechanism driving the heat loss responses seen in flushing 
postmenopausal women.  We have demonstrated increases in peripheral 
perfusion responses to a vasoactive agent in postmenopausal women, suggesting 
a peripheral involvement.  Is there a similar response seen in men? 
  266 
Hypothesis 
The contribution of altered peripheral vascular function to hot flushes in 
postmenopausal women is also found in hypogonadal men. 
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Methods 
Participants 
A total of 12 men with a diagnosis of prostate cancer who would receive 
androgen ablation therapy were recruited.  Recruitment followed identification 
of suitable participants at the urology oncology multi-disciplinary meeting 
(MDT).  Potential participants were approached with information about the study 
at their clinic appointment, and written information was given to take home.  A 
follow up telephone call was made more than 24 hours later for the decision to 
participate. 
Participating men were all aged 55-75 years, non-smokers, not known to be 
hypertensive, non-diabetic and not taking any drugs which could affect vascular 
function. 
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Study Design 
Study participants were all assessed at visit 1, prior to baseline skin blood flow 
assessment using LASER Doppler imaging (LDI) with iontophoresis (ION) of 
vasoactive compounds (visit 2).  Participants returned for repeat assessment 8 
weeks after initiation of luteinising hormone releasing hormone (LHRH) agonist 
therapy (visit 3) and again at 24 weeks (visit 4) (see Figure 78).  Qualitative 
measures were obtained at the same time points. 
All work was performed according to the Declaration of Helsinki with approval 
granted by the institutional ethics committee (REC 09/MRE00/40).  All patients 
gave written informed consent. 
 
Figure 78: Study design 
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Body composition 
Measurements of body mass, height, and blood pressure were made as described 
in Chapter 2. 
LASER Doppler Imaging with Iontophoresis 
Assessment of cutaneous microvascular perfusion was made at baseline and 8 
weeks after initiation of GnRH agonist therapy.  This technique is described in 
detail in Chapter 2. 
Hot flush diary 
Each participant was asked to keep a ‘Hot Flush’ diary as soon as/if they 
developed flushing during the course of their treatment and for the remainder of 
the study, as described in detail in Chapter 2. 
Plasma analysis 
A fasting blood sample was taken from each participant using 21G Vacuette® 
SAFETY blood collection set + luer adapter from an anticubital vein.  Three 
samples were collected in Vacuette® gel tubes, one 9ml ethylenediamine tetra-
acetic acid (EDTA – lilac top), one 6ml lithium heparin (LiHep – green top) and 
one 4ml citrate (blue top). 
A small volume was removed from the 6ml lithium heparin sample before 
centrifuge and storage as described in Chapter 2.   
ICAM, VCAM, TNF –α, IL-6, Insulin and Adiponectin were measured by ELISA 
technique as described in Chapter 2. 
CRP, Cholesterol, Glucose, HDL, LDL, and Trig were measured by standardised 
methods at The Institute of Cardiovascular and Medical Sciences at Glasgow 
University, as described in Chapter 2. 
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Statistical analysis 
Measurement of vascular responses was performed using raw values.  
Comparisons were by General Linear Model.  Because of the marked differences 
in variances between basal perfusion values and the maximal responses to the 
drugs, but the similar coefficients of variation, log10 transformation of the data 
was performed to equalise the variances and thereby permit parametric data 
analysis 
Comparison of demographic data was by the Mann-Whitney U test, except for 
blood pressure comparisons, which were analysed using unpaired T-test. 
Diary data included analysis of mean number of flushes per day and hot flush 
score.   
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Results 
Demographic Characteristics 
A total of 12 men were recruited.  Recruitment of gentlemen with prostate 
cancer who were to receive androgen ablation therapy, but who had little in the 
way of other co-morbidities, particularly cardiovascular, was challenging. 
n 12 
Age (years) 70 (66-74) 
[54-75] 
Body Mass Index (BMI) 26.8 (24.4-29.6) 
[23.3-40.2] 
Systolic Blood Pressure (SBP)* 147.0 ± 20.1 
Diastolic Blood Pressure (DBP)* 85.4 ± 7.9 
Table 25: Demographic characteristics. 
Data are median (interquartile range)[range].  *Data are mean ± SD 
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Unfortunately there were 2 gentlemen who did not return following 
commencement of androgen ablation therapy, and therefore data are available 
for 10 participants. 
Participants who developed flushing following commencement of androgen-
ablation therapy had higher diastolic blood pressure than those without flushing.   
 
 Non-flush Flush P 
n 6 4  
Age (years) 69 (63-72) 
[54-72] 
74 (70-75) 
[68-75] 
0.07 
Body Mass Index (BMI) 24.9 (23.5-27.1) 
[23.3-29.1] 
30.1 (26.4-38.2) 
[25.9-40.2] 
0.07 
Systolic Blood Pressure (SBP) 137 ± 22.3 155.0 ± 18.8 0.24 
Diastolic Blood Pressure (DBP) 79.4 ± 2.2 90.5 ± 9.6 0.04 
Table 26: Demographic characteristics of Group 3 flush vs. non-flush 
Data are median (interquartile range)[range].  Statistical analysis was performed using the 
Mann-Whitney U test.  All men are non-smokers.  *Data are mean ± SD, analysis by unpaired 
T-test. 
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Responses to iontophoresis of acetylcholine (ACh) and sodium 
nitroprusside (SNP) 
Vascular reactivity for 10 men was measured using LDI + Ion at baseline and 
following 8 weeks of androgen ablation therapy.  4 men developed flushes, and 6 
did not.  Data were analysed as described above. 
There was no difference detected between men who developed flushes and 
those who did not when examining the perfusion responses at baseline, i.e. 
before any treatment had been commenced.  This was true for both the 
endothelium-dependent (ACh) and independent vasodilators (SNP), (ACh, p 
=0.55, SNP, p = 0.62).  See Figure 79. 
 
Figure 79: Dose Response Curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in flushing men compared with non-flushing men 
before commencing treatment.  Data are mean ± SEM.  
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However, after 8 weeks of treatment, the response of subcutaneous vessels was 
greater in the men who developed flushing than in those who did not.  The 
enhanced vascular response occurred following administration of both the 
endothelium-dependent (ACh) and independent vasodilators (SNP), (ACh, 
p<0.001, SNP, p=0.005).  See Figure 80. 
 
 
Figure 80: Dose Response Curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in flushing men compared with non-flushing men 
on androgen ablation therapy.  Data are mean ± SEM. 
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Hot flush diaries 
Of the four participants who developed flushing, only two completed hot flush 
diaries.  One gentleman reported that “every day was the same, so there is no 
point in filling out the diaries” and the other gentleman stated that he had “2 
every day and 2 every night”, and therefore did not feel the need to complete 
the diaries. 
Data are therefore too limited to analyse, however are presented below.  As 
previously described, flushes are most likely to coincide with achievement of 
castrate levels of testosterone a few weeks after commencement of therapy and 
increase in frequency at approximately three months.  For this reason, 
participants were asked to return at 8 weeks following commencement of 
therapy, and again at 24 weeks. 
Table 27 demonstrates the flush frequency and severity in the two participants 
who completed diaries.  Figure 81 demonstrates frequency of flushes with time.  
Both participants appeared to follow the expected pattern, with peak of flushing 
at approximately 8 weeks.  Participant A had complete arrest of flushes at 
around 22 weeks, whilst participant B continued to have a few flushes per day 
following the initial peak.  
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 A. B. 
 8 weeks 24 weeks 8 weeks 24 weeks 
Flush frequency 
(flush/day) 
3.5 ± 3.8 
2.7 (0-6.9) 
[0-10] 
7.7 ± 4.6 
9.3 (3.6-11.0) 
[0-14.1] 
1.3 ± 0.8 
1.1 (0.9-1.8) 
[0.3-2.9] 
0.3 ± 0.3 
0.1 (0.1-0.4) 
[0-1.1] 
Hot flush score  6.8 ± 7.8 
5.0 (0-13.9) 
[0-20] 
15.1 ± 9.6 
18.0 (4.7-22.7) 
[0-28.3] 
1.6 ± 1.3 
1.3 (0.8-2.3) 
[0.2-4.3] 
0.3 ± 0.3 
0.1 (0.1-0.4) 
[0-1.1] 
Table 27: Hot flush diary data. 
Flush/day = total number of flushes/week divided by the number of diary days completed, 
and a mean taken of the weeks completed.  Hot flush score = mean daily flush frequency 
multiplied by mean score.  A mean was taken of the weeks completed.   
 Data are mean ± SD, and median (interquartile range)[range].   
A= first participant. B=second participant. 8 weeks and 24 weeks = time from 
commencement of chemical androgen ablation therapy.   
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Figure 81: mean flush/day 
Graph demonstrates mean number of flushes per day for each week of participation in the 
study. A. = participant A. B. = participant B.  Flush/day = total number of flushes/week 
divided by the number of diary days completed.  
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Four men with flushing returned for assessment at 24 weeks, and whilst there 
appeared to be a reduction in the number of flushes towards the end of the 24 
week study period (see Figure 82), there was no difference in perfusion 
responses at this time point when compared with perfusion responses at 8 
weeks.  Endothelium dependent (ACh) p=0.76. and endothelium independent 
(SNP) p=0.49. 
 
 
Figure 82: Dose response curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in flushing men following commencement of 
androgen deprivation therapy at week 8 (flush 1) and week 24 (flush 2).  Data are mean ± 
SEM. 
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Plasma analysis 
In Chapter 3, it was demonstrated that women with flushing had significantly 
lower HDL-cholesterol levels, lower apolipoprotein A1 and higher I-CAM levels 
than their non-flushing controls. 
As the perfusion responses for flushing hypogonadal men when compared to their 
non-flushing counterparts were similar to that seen with flushing versus non-
flushing postmenopausal women, the same measures were analysed in this group 
of men (see Figure 83 and Table 28). 
Tumour necrosis factor (TNF) alpha was higher in men who developed flushing 
(P=0.03) when compared to those men who did not develop flushing.   
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Figure 83: Plasma analysis 
Data are shown as box and whisker plots with median, IQR and range. 
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 Flush 
n=4 
Non-flush 
n=6 
P 
Cholesterol 
(mmol/l) 
4.3 (3.6-5.7) 
[3.1-6.2] 
3.9 (2.8-6.1) 
[2.8-6.6] 
0.65 
Triglyceride 
(mmol/l) 
0.8 (0.5-1.7) 
[0.5-1.8] 
2.2 (1.2-3.6) 
[1.2-3.8] 
0.90 
Low Density 
Lipoprotein 
(LDL)-cholesterol 
(mmol/l) 
3.1 (1.9-4.0) 
[1.4-4.5] 
1.8 (0.8-4.0) 
[0.6-4.7] 
0.31 
High Density 
Lipoprotein 
(HDL)-cholesterol 
(mmol/l) 
1.3 (0.7-1.5) 
[0.4-1.5] 
1.0 (0.8-1.3) 
[0.7-1.3] 
0.85 
Apolipoprotein 
A1 (mg/dl) 
112.6 (102.5-122.7) 
[97.9-129.8] 
107.5 (89.5-122.2) 
[87.6-122.9] 
0.37 
Apolipoprotein B 
(mg/dl) 
65.0 (45.3-105.6) 
[37.3-113.9] 
59.8 (38.0-95.6) 
[35.5-102.7] 
0.68 
Insulin (mu/l) 4.6 (2.8-8.1) 
[2.6-8.1] 
9.0 (3.8-27.0) 
[3.2-31.8] 
0.24 
Adiponectin 
(µg/ml) 
107.6 (53.3-135.7) 
[43.6-153.6] 
42.3 (24.5-77.9) 
[19.6-88.8] 
0.09 
C-Reactive 
Protein (CRP) 
(mg/l) 
1.3 (0.9-2.2) 
[0.6-2.9] 
1.2 (0.8-1.7) 
[0.7-1.7] 
0.71 
Inter-Cellular 
Adhesion 
Molecule 1 (ICAM-
1) (ng/ml) 
198.3 (188.2-224.7) 
[187.6-230.7] 
251.7 (201.9-280.5) 
[194.8-280.6] 
0.14 
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Vascular Cell 
Adhesion 
Molecule 1 
(VCAM-1) (ng/ml) 
696.1 (661.5-651.7) 
[651.7-713.7] 
831.6 (667.6-960.1) 
[627.1-988.7] 
0.15 
Tumour Necrosis 
Factor alpha 
(TNFα) (pg/ml) 
0.9 (0.7-1.1) 
[0.6-1.1] 
3.1 (1.1-4.4) 
[0.8-4.4] 
*0.03 
Interleukin 6 
(IL6) (pg/ml) 
2.2 (1.2-6.1) 
[0.6-8.9] 
2.4 (1.7-3.6) 
[1.5-3.9] 
0.93 
Haematocrit 
(percent) 
41 (41-43)[41-44] 43 (41-45)[40-46] 0.25 
Table 28: Plasma analysis 
Data are median (interquartile range)[range].  Statistical analysis was performed using 
students t-test on log transformed data.  *statistically significant. 
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analyses of the data have been completed as part of the work that I present in 
this thesis.  
Introduction and aim of project 
Endothelial dysfunction is associated with both acute and chronic inflammation 
(275-277), and it is now thought that cancer, irrespective of its trigger, is 
accompanied by a chronic inflammation, which supports the progression of most, 
if not all, tumours. 
Autoimmune disease (e.g. inflammatory bowel disease) and inflammatory 
conditions of unknown origin (e.g. prostatitis is associated with prostate cancer) 
are recognised as triggers of chronic inflammation associated with cancer 
development (278). 
This project investigated endothelial function, as assessed by cutaneous 
microvascular perfusion, at baseline (i.e. before androgen ablation therapy) in 
men with prostate cancer and compared it to healthy matched controls. 
Hypothesis 
Cutaneous microvascular perfusion responses to vasoactive agents are reduced in 
men with prostate cancer compared to healthy controls.  
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Methods 
Participants 
6 healthy controls without prostate cancer were recruited from within the 
medical faculty.  Participating men are all aged 55-75 years, non-smokers, not 
known to be hypertensive, non-diabetic and not taking any drugs which could 
affect vascular function. 
LASER Doppler Iontophoresis, Plasma analysis, and Statistical analysis 
As described above and in Chapter 2. 
Results 
Demographics 
A total of 12 men with prostate cancer and 6 healthy controls were recruited.  
All had baseline cutaneous perfusion measurements carried out using LASER 
Doppler imaging and iontophoresis. 
 Prostate cancer Healthy controls P 
n 12 6  
Age (years) 70 (66-74) 
[54-75] 
62 (62-71) 
[61-72] 
0.11 
Body Mass Index 
(BMI) 
26.8 (24.4-29.6) 
[23.3-40.2] 
27.8 (23.4-28.7) 
[21.9-29.1] 
0.75 
Systolic Blood 
Pressure (SBP)* 
147.0 ± 20.1 136.0 ± 9.8 0.27 
Diastolic Blood 
Pressure (DBP)* 
85.4 ± 7.9 85.6 ± 2.9 0.95 
Table 29: Demographic characteristics of men with prostate cancer and healthy controls 
Data are median (interquartile range)[range].  Statistical analysis was performed using the 
Mann-Whitney U test.  All men are non-smokers.  *Data are mean ± SD, analysis by unpaired 
T-test. 
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Responses to iontophoresis of acetylcholine (ACh) and sodium 
nitroprusside (SNP) 
Vascular reactivity for 12 men with prostate cancer at baseline (i.e. before 
androgen ablation) and 6 healthy controls was measured using LDI + Ion.  Data 
was analysed as described above.  
The response of the subcutaneous vessels was greater in the healthy control 
group, following administration of both the endothelium-dependent (ACh, 
p<0.001) and independent vasodilators (SNP, p<0.001) (see Figure 84). 
 
Figure 84: Dose Response Curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for 
acetylcholine and sodium nitroprusside in men with prostate cancer before androgen 
ablation therapy (prostate) and in healthy matched controls (control). Data are mean ± SEM. 
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Plasma analysis 
Inflammation with associated release of inflammatory markers is closely linked 
to endothelial dysfunction, and is also thought to play a role in the development 
and progression of tumours. 
In these groups, VCAM-1 (p=0.02) and IL-6 (p=0.048) were both significantly 
higher in the prostate group than in healthy controls, see Figure 85 and Table 
30. 
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Figure 85: Plasma analysis, men with prostate cancer compared with healthy controls 
Data are shown as box and whisker plots with median, IQR and range. 
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 Prostate 
n=12 
Control 
n=6 
P 
Cholesterol 
(mmol/l) 
4.3 (3.1-5.2) 
[2.7-6.6] 
4.2 (3.7-5.7) 
[3.2-6.1] 
0.76 
Triglyceride 
(mmol/l) 
1.6 (0.8-1.8) 
[0.5-3.8] 
1.3 (0.8-1.8) 
[0.6-2.4] 
0.67 
Low Density 
Lipoprotein 
(LDL)-cholesterol 
(mmol/l) 
2.3 (1.5-3.4) 
[0.6-4.7] 
2.9 (1.6-4.3) 
[1.4-5.5] 
0.47 
High Density 
Lipoprotein 
(HDL)-cholesterol 
(mmol/l) 
1.1 (0.9-1.3) 
[0.4-1.5] 
1.1 (0.8-1.7) 
[0.7-1.9] 
0.59 
Apolipoprotein 
A1 (mg/dl) 
112.6 (95.0-122.9) 
[87.6-129.8] 
120.3 (90.1-137.3) 
[82.4-150.4] 
0.58 
Apolipoprotein B 
(mg/dl) 
65.0 (45.4-97.3) 
[35.5-113.9] 
75.3 (52.8-100.5) 
[51.1-105.0] 
0.52 
Insulin (mu/l) 8.1 (3.2-15.9) 
[2.6-31.8] 
8.6 (3.4-16.2) 
[1.8-19.1] 
0.86 
Adiponectin 
(µg/ml) 
71.6 (43.6-117.9) 
[19.6-153.6] 
43.8 (34.5-55.7) 
[28.9-61.7] 
0.11 
C-Reactive 
Protein (CRP) 
(mg/l) 
1.3 (0.7-1.7) 
[0.6-6.3] 
0.3 (0.1-3.3) 
[0.1-5.5] 
0.11 
Inter-Cellular 
Adhesion 
Molecule 1 (ICAM-
1) (ng/ml) 
214.9 (193.2-280.2) 
[187.6-296.3] 
208.1 (188.8-288.5) 
[157.1-314.8] 
0.89 
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Vascular Cell 
Adhesion 
Molecule 1 
(VCAM-1) (ng/ml) 
696.1 (645.6-810.4) 
[584.2-988.7] 
584.8 (540.4-660.7) 
[474.1-720.8] 
*0.02 
Tumour Necrosis 
Factor alpha 
(TNFα) (pg/ml) 
1.0 (0.8-1.9) 
[0.6-4.4] 
0.9 (0.7-1.1) 
[0.5-1.4] 
0.21 
Interleukin 6 
(IL6) (pg/ml) 
2.3 (1.5-3.9) 
[0.6-8.9] 
1.1 (0.8-1.9) 
[0.7-2.9] 
*0.048 
Haematocrit 
(percent) 
42 (41-43)[38-46] 43 (41-45)[40-45] 0.46 
Table 30: Plasma analysis 
Data are median (interquartile range)[range].  Statistical analysis was performed using 
students t-test on log transformed data.  *statistically significant. 
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Summary of Results 
Perfusion response to iontophoresis of acetylcholine (ACh) and 
sodium nitroprusside (SNP) 
• The response of the subcutaneous vessels was greater in men who flushed 
after commencement of androgen ablation therapy than in those who did 
not. 
• There was no difference detected between men who developed flushes 
and those who did not when examining the perfusion responses at 
baseline, i.e. before any treatment had been commenced.  
• In those participants who flushed, there was no difference in perfusion 
responses at week 24 when compared with perfusion responses at week 8. 
• Perfusion responses were greater in the healthy control group than in the 
prostate cancer group at baseline. 
 Diary data 
Data are too limited to analyse. 
Plasma analysis 
Tumour necrosis factor (TNF) alpha was higher in flushing men compared to 
those men who did not develop flushing.   
VCAM-1 and IL-6 were both significantly higher in the prostate group than in 
healthy controls. 
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Discussion 
It would appear that testosterone depleted gentlemen who develop hot flushes, 
do indeed have similar cutaneous microvascular responses to that seen in 
postmenopausal women with severe flushing when compared to their non-
flushing contemporaries.  These results would appear to be consistent with 
flushing as a result of hormone withdrawal, as onset of flushes appear to 
coincide with when one would expect levels of testosterone to reach castrate 
levels. 
Frödin (148) demonstrated that the hot flush is associated with increases in skin 
blood flow and water evaporation at the time of the ‘attack’.  We have 
demonstrated increases in cutaneous microvascular perfusion in response to 
vasoactive substances outwith a flushing episode.  This suggests that following 
withdrawal of testosterone, in this case as a result of androgen ablation therapy, 
cutaneous vessels become more readily vasodilated in some than in others.  
What is the mechanism underlying this change? 
The absence of a demonstrable difference at baseline between those that 
developed hot flushes and those who did suggest that whatever this change is, it 
occurs following the commencement of androgen ablation therapy. 
Steroid hormones may alter vascular reactivity; and several studies have shown 
that short-term administration of testosterone in men with coronary artery 
disease improves endothelial vasomotor function (279, 280).  So too in women; 
higher total testosterone and SHBG have been found to be inversely related to 
carotid atherosclerosis in postmenopausal women (281), and parenteral 
testosterone in women taking oestrogen increased FMD (282).   
Oestrogens and dehydroepiandrosterone (DHEA), an important prohormone of 
oestrogens and androgens, both stimulate nitric oxide (NO) synthesis via 
induction of eNOS (283, 284).  Testosterone has been shown to act as a direct 
vasodilator (285-287), but the precise mechanisms by which it is acting are still 
unknown.  Some suggest the role of nitric oxide (NO) (288, 289), but others have 
denied this (290, 291).  It has also been suggested that the key mechanism 
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underlying testosterone-induced vasodilatation may be modulation of vascular 
smooth muscle ion channel function (292).   
Because 17beta-estradiol causes acute and long-term vasodilatation and 
testosterone and estrogens share the same biosynthetic pathway, it has been 
suggested that testosterone-induced vasodilatation might be an indirect effect 
of the local conversion of testosterone to 17beta-estradiol by vascular P450-
aromatase.  However, this has been excluded, because, inhibition of P450 does 
not inhibit testosterone vasodilatation, estrogen receptor antagonism does not 
inhibit, and non-aromatisable metabolites of testosterone also cause 
vasodilatation. 
Why then, in our group of men, who are all testosterone deplete as a result of 
ADT, do those with flushes have increased perfusion responses compared to 
those without flushes? 
It has been suggested that the pathophysiological mechanism underlying a hot 
flush following hormone withdrawal is well defined (293); an LHRH agonist-
induced noradrenaline flood of the hypothalamus, resulting in poorly regulated 
vasodilation.  This still does not explain the absence of flushing in some 
individuals, when all are hormone-deplete or the improvement in symptoms with 
the passage of time. 
It has been well described in postmenopausal women by Freedman et al, that 
there is a narrowing of the thermoregulatory zone, so that heat loss responses 
are triggered by only small increases in core temperature.  Given the similar 
peripheral responses seen in men with flushing as a result of hormone 
withdrawal to that seen in postmenopausal women, it is possible that this 
mechanism underpins the responses seen here too. 
In chapter 3, we demonstrated that postmenopausal women with flushing had 
decreased levels of HDL-cholesterol and apolipoprotein A1, and increased levels 
of ICAM-1.  Low levels of HDL-cholesterol are associated with an increased risk 
of cardiovascular disease, which is thought to be the end result of 
atherosclerosis.  ICAM-1 is a biomarker, stimulated by inflammatory cytokines, 
associated with the chronic inflammation thought to play a role in 
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atherosclerosis.  Paradoxically, it was the women with flushing who had a worse 
cardiovascular risk profile, with biomarkers for endothelial dysfunction that had 
‘better’ endothelial function than their non-flushing counterparts. 
Whilst we have not demonstrated differences in HDL, apolipoprotein A1 or ICAM-
1, we have demonstrated that levels of TNF-alpha, which plays a role in 
endothelial dysfunction and mediating cardiovascular disease, were higher in 
those men who developed flushing compared to those who did not.  Again in the 
presence of ‘better’ endothelial function.   
While an association between total cholesterol, elevated LDL-C and low HDL-C 
and endothelial dysfunction has not been consistently demonstrated, TNF-alpha 
is a proinflammatory cytokine which induces vascular dysfunction by endothelial 
cell activation, barrier dysfunction and increases in endothelial cell 
permeability.  It also has deleterious effects on endothelium-dependent and 
nitric oxide (NO)-mediated vasodilatation, and it diminishes the production of 
and enhances catabolism of NO.  Like the paradoxical results seen in women 
(described in chapter 3), increased levels of TNF-alpha and ‘better’ endothelial 
function in men who flushed might further support the hypothesis that the 
presence of flushing may signpost underlying cardiovascular disease.   
Certainly, in contrast to the well-established concept that testosterone had 
deleterious effects on the heart and vasculature, carotid intima-media thickness 
has been shown to be inversely correlated with testosterone levels (294), and 
low serum testosterone levels have been associated with an increased risk of 
death from cardiovascular disease (295).  Despite this, a contribution of 
androgen deprivation therapy (ADT) to CVD and diabetes mellitus (DM) is 
uncertain.  An association has been shown for ADT with CVD, fatal myocardial 
infarction and DM (296-298), but an analysis of randomised controlled trials has 
found no dose-response relationship of ADT to CVD (299). 
Mixed information surrounding ADT exists, but even mildly reduced testosterone 
levels have been shown to be associated with type 2 diabetes, obesity and 
dyslipidaemia (300).  Some animal studies (301) have suggested attenuation of 
atherosclerosis development with testosterone treatment, however there is no 
supporting human evidence.  It has been suggested, however, that there may be 
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an “optimal window” of testosterone concentration (302), where adverse effects 
may be expected in concentrations outside of this window.  This might be similar 
to the “window of opportunity” and cardiovascular disease in newly 
postmenopausal women. 
Despite uncertainty surrounding the trigger and pathophysiology of flushing, as a 
result of hormone withdrawal in both men and women, treatments are certainly 
similar.  Both hormonal and non-hormonal treatments are common to both.  
Transdermal oestrogen patches (303), diethylstilbestrol (DES) (304) and synthetic 
progestagens (305) have been used with good effect, and as have gabapentin , 
venlafaxine (306) and other selective serotonin reuptake inhibitors (307), with 
poor results from clonidine (308).   Equivocal results are reported for alternative 
therapies such as acupuncture (309) and vitamin E (149). 
Specific to this group, however, is the likely presence of chronic inflammation, 
widely accepted to play a role in the promotion of cancer cell survival.  We have 
demonstrated that perfusion responses to acetylcholine and sodium nitroprusside 
are decreased in men with prostate cancer when compared to healthy controls.  
Underlying endothelial dysfunction, in the presence of chronic inflammation 
associated with cancer, resulting in reduced vascular responses to vasoactive 
agents may explain this result.  However, whether this difference is specific to 
prostate cancer, or is as a consequence of the presence of cancer-associated 
inflammation, is unknown.  Ethical approval has been granted to study 
peripheral vascular reactivity in a group of men with a non-hormone dependent 
cancer, but work is not yet completed.   
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Discussion and Future Research 
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Final Discussion 
Menopause is a word used by many to describe, not the defined singular time 
point identified in retrospect, but a time period.  The STRAW Working Groups 
have described reproductive ageing as a process, and identified it’s seven stages 
(11), but for women it is ‘the menopause’ and it is often met with dread for the 
symptoms that accompany it.    
Whilst we now know that cessation of menstrual cycles is a result of ovarian 
follicle decline and associated reduction in ovarian follicular hormones, we are 
still somewhat uncertain as to the exact mechanism underlying the most 
commonly reported symptom of this process.  Bloodletting, thankfully, has been 
discontinued as a therapy for the “hysteric fits” associated with the syndrome of 
the menopause, and we now know that oestrogen is effective for vasomotor 
symptoms.   
However, beyond replacing that which we know to be reduced at the same time 
as the symptoms occur, our understanding is somewhat limited.   
We know that flushing bears a resemblance to physiological heat loss 
mechanisms, that is, peripheral vasodilation and sweating, and there has been 
much focus on central thermoregulatory mechanisms.  Freedman’s group has 
described a narrowing of the thermoregulatory zone so that only small increases 
in core temperature are required to trigger heat loss mechanisms.  They also 
found that oestrogen replacement increased the lowered sweating threshold. 
However, this mechanism proposes that central control is primarily/solely 
responsible.  There has been little work demonstrating the role of the effectors 
of this mechanism.  We know that there is increased blood flow to the hand 
during a flushing episode, and we also know that there is diminished 
vasoconstrictor response to cold.  It has further been suggested that the rate of 
temperature change may play a role.  Could there be an independent role of 
cutaneous microvasculature beyond merely acting as an effector? 
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In this thesis I have focused on alterations in cutaneous microvascular perfusion 
in postmenopausal women with severe flushing, factors which may influence 
that vascular function, and the effect of successful treatment of those flushes. 
A peripheral role 
There appears to be increased cutaneous vasodilation in those women with 
severe flushing, suggesting ‘better’ endothelial function, despite a worse 
cardiovascular risk profile.  Evidence exists to support peripheral vascular 
function acting as a prognostic tool for coronary vascular function; however a 
greater vasodilatory response is usually considered a sign of vascular health, 
suggesting that these results are contradictory.  There are also suggestions that 
postmenopausal flushing may be a marker of underlying cardiovascular disease.  
It is possible that on a background of endothelial dysfunction, with associated 
reduced nitric oxide, and therefore increased sensitivity, that the introduction 
of nitric oxide via acetylcholine or sodium nitroprusside may result in an 
increased rebound vasodilatory response in women with flushing.   
Whilst, there are reports of vasomotor symptoms and an association with 
cardiovascular risk, this is not universal. 
A role for neurotransmitters 
Additionally, there could be heat loss mechanisms activating vasodilation via 
alternate pathways despite endothelial function, or an overshadowing of 
peripheral response by the central control.  Noradrenaline is thought to be one 
of the primary neurotransmitters responsible for alterations in this central 
‘thermostat’.  Animal studies show increased levels of noradrenaline after 
castration, and in symptomatic postmenopausal women, hot flushes can be 
provoked by increasing levels of noradrenaline with alpha2 antagonists.  The 
sweating threshold can be increased, and the thermoneutral zone widened, with 
flushes ameliorated with the alpha2 agonist, clonidine. 
In our group, clonidine reduced the number and severity of flushes but this was 
not superior to placebo.  Interestingly, whilst there was no difference in ACh- or 
SNP-stimulated cutaneous microvascular vasodilation following clonidine 
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treatment when compared to placebo treatment, there was an increase in 
perfusion response after clonidine and also after placebo when compared to no 
treatment.   
The placebo effect is well recognised; in flushing related studies, there are 
reports of 25-75% reduction in hot flushes in those receiving placebo (310, 311), 
and as well as long-documented analgesic effects, studies have also shown 
placebo-related reduction in β-adrenergic activity in the heart, and immune 
modulation.  This is clearly an area of particular interest in those women who 
cannot use hormones or other pharmaceutical therapies.  
The effect of successful treatment 
Serotonin, like noradrenaline, is associated with thermoregulation, and again a 
relationship with oestrogen withdrawal has been demonstrated.  Furthermore, 
SSRIs, designed to increase serotonin availability, are known to be effective in 
hot flushing.  We have demonstrated a reduction in flush frequency and severity 
with venlafaxine (SNRI, but SSRI activity at low doses), and a decrease in 
cutaneous microvascular vasodilation after treatment.  No relationship was 
demonstrated between flush reduction and perfusion; however central serotonin 
reuptake transporter binding was correlated with depression score reduction 
following treatment.   
Most studies have failed to show a direct relationship between antidepressant 
occupancy of SERT and treatment response, despite the efficacy of SSRIs being 
reasonably well established and a necessary minimum of 80% occupancy of SERT 
for SSRI treatment of depression stated by most pharmacokinetic studies (231).  
More recently, it has been suggested that SSRI treatment response in major 
depressive disorder can be predicted by pre-treatment binding in the median 
raphe nucleus (232) and the most recent work from Freedman’s group has 
identified a rise in brainstem activity in fMRI preceding a hot flush (71).  
Additional activations were also noted in the forebrain, where projections from 
the raphe nuclei extend.  If, as Freedman suggests, forebrain activity is 
associated with the phenomenological correlates following brainstem activation, 
could there be some dysfunction in the projections, i.e. the experience of the 
flush.  If a hot flush is a dysfunction of the central thermostat as a result of 
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hormone withdrawal, this would be present in all, but if the response or 
experience of that central thermostat dysfunction is mediated by the projections 
to the forebrain and these are altered in some way, that may explain why some 
have flushes and others do not, when the same physiological event has occurred 
in all.  If they can predict the anti-depressant effect, then perhaps we can 
predict, in some way, those who will suffer flushing. 
The absence of correlation between peripheral perfusion and central serotonin 
reuptake transporters may reflect vasoconstriction as a result of direct 5HT 
receptor activation on endothelial cells with discrete central mood effects.  The 
significant reduction in BDI scores following treatment, in the absence of severe 
depression is interesting, and its relationship with SERT binding, novel, 
suggesting the importance of venlafaxine in mood alteration beyond severe 
depression with or without vasomotor symptoms.   
Oestrogen receptors are also present on endothelial cells and as the most 
commonly used, and most effective, treatment for vasomotor symptoms, 
cutaneous microvascular perfusion was assessed following 8 weeks of HRT, and 
demonstrated an increase in both endothelium dependent and independent 
vasodilation.  Improvements in GCS scores were also demonstrated. 
The effect of obesity 
An obvious factor to consider when assessing endothelial function, and 
vasomotor symptoms, is the effect of obesity.  The ‘thin hypothesis’ has all but 
been stamped out, and it is widely accepted that an increase in adiposity is 
associated with an increased risk of flushing.  But, is it as a result of altered 
microvascular perfusion responses, or simply a consequence of excess insulation? 
One might expect that endothelial function would be altered in obese 
participants; metabolic syndrome secondary to obesity has been shown to result 
in impaired vasodilator responses to acetylcholine, however there were no 
differences demonstrated between obese and lean participants at baseline.  This 
may be in part due to the exclusion criteria, meaning that these were basically 
healthy women with no hypertension or diabetes. 
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If women with severe vasomotor symptoms are at increased cardiovascular risk, 
this apparent similarity in perfusion responses of obese and lean women may be 
explained by the underlying cardiovascular risk.  Endothelial dysfunction seen in 
obesity may be similar to that seen in flushing women, thereby negating any 
differences in perfusion responses that we might expect to see at baseline.   
We have, however, not assessed body fat distribution and this, in addition to 
consideration of perivascular fat and its ability to regulate vascular tone, may be 
important.   
What about men? 
Research suggests that hot flushes are common in androgen-deprived men; in 
prostate cancer therapy, flushes are the most significant adverse QoL symptom 
and in some may not resolve even after discontinuation of therapy.  In contrast, 
most men in this group did not experience flushing, and for this reason, numbers 
available for comparison are small.  There are other reasons, including difficulty 
in recruiting men without significant co-morbidities, however, despite this, 
hypogonadal men with flushing demonstrated similar cutaneous microvascular 
perfusion responses to ACh and SNP as postmenopausal flushing women.  That is, 
perfusion responses in men were similar prior to treatment, in those without 
flushing compared to those who went on to develop flushing. 
ACh- and SNP-stimulated vasodilation was, however, reduced when compared to 
healthy controls and this may reflect endothelial dysfunction associated with the 
chronic inflammation known to accompany or even drive malignancy.   
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Limitations 
Sample size 
The power calculation determined that a sample size of 20 would be required to 
determine a 25% change in ACh between groups.  This would suggest that a 
number of groups within the study were too small to generate reliable findings, 
however, this calculation is based on a two sample t-test, and in fact smaller 
groups are required when a paired test is carried out.   
A posthoc power calculation with adjustment for a paired t-test reveals that a 
sample size of 11 would be sufficient to determine a 25% change in ACh at alpha 
= 0.05, with a power of 0.86.  The sample size in the HRT group comparing 
perfusion response following treatment would therefore be sufficient, although a 
larger group would be preferable.  Numbers in the subgroup analysis of obese 
versus lean are too small to generate reliable findings. 
The numbers of men in this study are also small, and further recruitment is 
planned to confirm results. 
Choice of drug 
Venlafaxine 
This drug was chosen as it is has been widely studied in randomised controlled 
trials (RCTs) and is known to be effective in reducing the number and severity of 
flushes.  Furthermore, this dug is used widely as an acceptable and safe 
treatment in women with breast cancer taking tamoxifen.  Whilst it is thought to 
act as a pure serotonin reuptake inhibitor at low doses, we cannot completely 
exclude the role of noradrenaline entirely.  Ideally the results seen here with 
this drug would be compared to a pure selective serotonin reuptake inhibitor 
(SSRI).   
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HRT 
The type of HRT was not standardised for the purpose of this study, as the 
purpose was not to compare the results of varying preparations of HRT on 
vascular function but to assess changes in skin perfusion with improvements in 
flushing with treatment with HRT.  However, I acknowledge that different 
preparations with different progestagens may have influenced the perfusion 
results and certainly may have had an impact on lipids in plasma analysis. 
Diaries 
The diary data for the HRT group are disappointing, and most likely the cause of 
a failure to demonstrate an improvement in flushing with treatment.  HRT is 
widely accepted, and long-proven, to be the most effective treatment for 
vasomotor symptoms.  Ideally those participants who had not completed pre-
treatment diaries would have been excluded from the study. 
Plasma analysis 
Whilst the plasma analysis yielded some interesting results, the nature of this 
work was exploratory rather than strictly hypothesis driven.  The aim was to 
study factors which may influence vessel function and therefore might impact 
upon the changes that we saw in perfusion responses as a result of treatment 
aimed at improving hot flushes.  Therefore, before any definitive conclusions 
could be drawn, hypothesis directed studies would need to be designed. 
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Future Research 
Though the work presented in this thesis has determined some novel concepts, 
confirmation through further exploration of these findings is required.  Areas 
and suggestions for possible future research are outlined below. 
In Chapter 5, the successful treatment of vasomotor symptoms with the 
serotonin and noradrenaline reuptake inhibitor demonstrated significant 
decreases in microvascular vasodilation, although a relationship between these 
was not shown.  The duration of treatment is short relative to the time women 
may experience symptoms and it would be interesting to repeat LDI+ION at a 
other time points to determine whether there is a degree of initial 
vasoconstriction which may resolve with time and which may, as a consequence, 
result in a resurgence of symptoms, as receptor availability is altered. 
There was no placebo group in this study, it may be considered unethical to 
perform SPECT scanning with placebo treatment, however the use of placebo in 
flushing, and its associated physiological responses, certainly warrant further 
exploration. 
The absence of any stimulated vasodilation differences between obese and lean 
women defies what we might expect to see.  Weight loss is known to have a 
beneficial effect on endothelial function and there is some data to suggest that 
it may decrease hot flushes.  What effect would there be on perfusion responses 
and would there be a correlation with flush frequency? 
The HRT group was, admittedly, poor, and should be repeated.  There should 
also be completion of recruitment and further analysis of hypogonadal men with 
prostate cancer; the results have shown some interesting findings which would 
be better demonstrated with a larger cohort, particularly the resolution of flush 
symptoms over time and the relationship with perfusion responses.  Recruitment 
to the group of men with a non-hormone dependent cancer should also be 
completed. 
Calcitonin gene-related peptide (CGRP), and adrenomedullin, have also been of 
interest in flushing as both are potent vasodilators that can cause facial flushing, 
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and have been shown to be increased at times of flushing in both men and 
women, however a link with steroid hormones has yet to be established (312, 
313).  It has been suggested that CGRP and/or substance P may be involved in 
the perception of local skin warming by nociceptive afferent fibres, which have 
been shown to be more closely related to vasodilator response than actual 
temperature (314). 
Breast cancer is the most common cancer in women in the U.K. and up to 85% of 
women treated for breast cancer are affected by hot flushes and night sweats.  
10 years of tamoxifen significantly reduces the risk of recurrence and breast 
cancer mortality (315, 316), however over 50% of women do not adhere to the 5 
years of endocrine treatment with an associated increase in mortality (317), 
perhaps, partly, as a result of ineffective management of vasomotor symptoms 
(318).  SNRIs are commonly used as oestrogen is often contraindicated, cognitive 
behavioural therapy (CBT)(319) has also been shown to be of benefit.  Further 
study of the physiological responses, both peripheral and central, seen after 
successful CBT treatment would be of interest.  Research into other treatments 
for flushing in these women also requires urgent attention. 
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Conclusion 
In this thesis I have explored the role of skin blood flow as a measure of a 
peripheral component in the underlying mechanism of menopausal hot flushes.  I 
have provided evidence that alterations in vasodilation are present and there 
may be a suggestion that cardiovascular risk factors play a part. 
Similarities in cutaneous microvascular perfusion responses are present in men, 
following hormone withdrawal, supporting the role of skin blood flow in the 
pathophysiology, but the effect of obesity does not appear to be modulated 
through alterations in vascular reactivity. 
The role of neurotransmitters in thermoregulation is complex.  Serotonin is 
certainly important and modification of this in the treatment of flushing appears 
to be the best alternative to hormones that we have at present.  It appears to 
alter skin blood flow, and there are certainly positive mood effects, likely as a 
result of central modulation of SERT, however our understanding is still limited, 
and more work is required, both peripherally and centrally. 
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